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A strategy for modulating immunity during vaccination is to target specific professional 
antigen-presenting cells (APCs) and induce their maturation. Professional APCs 
effectively activate antigen-specific T cells, a requirement for induction of strong humoral 
and cellular responses. Mammalian cells, including APCs, possess pattern recognition 
receptors (PRRs) that bind to distinct molecules broadly expressed by different 
microorganisms, collectively known as pathogen associated molecular patterns (PAMPs), 
PAMPs differ in the types of PRRs they engage, the signaling pathways they trigger and 
the types of immune responses they generate. The nature of the immune response is also 
influenced by the stimulated APC subsets, which express different combinations of TLRs 
and other PRRs, resulting in cell and tissue-specific responses to microbes. To design 
combinatorial PRR-targeting adjuvant vaccines, it is essential to understand how different 
APC subsets interact with them and how that leads to specific immune outcomes. It is also 
essential to investigate how delivery vehicles influence cell responses to PAMPs, for 
example biomaterials-based particles. This thesis addresses the effects of combinatorial 
PRR-targeting adjuvant polylactic-co-glycolic acid (PLGA) particle vaccines on APC 
subsets at different stages of the immune response, including recruitment of innate immune 
cells, APC maturation and expression of costimulatory molecules, proinflammatory 





CHAPTER 1: INTRODUCTION AND AIMS 
1.1 Introduction 
Vaccination is one of the earliest and most successful medical interventions in history and 
remains the standard method for global control of infectious diseases in the human 
population. The World Health Organization estimates vaccines save 2-3 million lives each 
year, and in developed countries, many fatal childhood diseases have been fully or nearly 
eradicated.1 However, there is a need for improved understanding of the immunological 
mechanisms underlying vaccination to develop more effective vaccines against life-
threatening infectious diseases. Current vaccine development challenges include targeting 
pathogens that are antigenically variable (e.g., HIV) or immune-evasive (e.g., 
Mycobacterium tuberculosis), tailoring immunogenicity for infants and aging populations 
(e.g., for RSV), designing single-dose vaccines for lifelong immunity (e.g., for influenza), 
and facilitating rapid formulation screening and development for curbing global outbreaks. 
Most recently, the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) has killed more than 3 million people 
worldwide, and the crisis elicited a global scientific effort to develop vaccines and therapies 
for the disease at an unprecedented speed. Phase I trials started as early as March 2020, 
and as of April 2021 there are more than 270 vaccines in various stages of development.2 
Three formulas from Pfizer-BioNTech, Moderna, and Johnson & Johnson (Janssen) have 
been authorized for emergency use in the United States and approved in several countries. 
However, much remains to be determined regarding immune correlates of protection 
against SARS-CoV-2 infection in various patient populations. 
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Vaccines utilize the ability of evolved human immune systems to engage and remember 
pathogenic antigens, components that stimulate the generation of antibodies and 
differentiation of cells that specifically recognize their biological structures. Traditional 
vaccines are composed of live-attenuated or inactivated pathogens, which contain 
endogenous adjuvants and antigens presented on particulate structures. To increase vaccine 
safety and effectiveness, emerging vaccines contain pathogen subunits, including 
recombinant proteins. Nucleic acid vaccines, like Moderna’s mRNA vaccine for COVID-
19, include mRNA or DNA that instructs a patient’s cell to produce antigen on their own. 
Many purified antigens in subunit vaccines are poorly immunogenic, so they are often 
formulated with adjuvants to increase the level and duration of adaptive immune responses 
following vaccination.3 Aluminum-containing adjuvants have been included in vaccines to 
enhance immunogenicity since the 1930s, initially with diphtheria and tetanus vaccines. 
Aluminum salts continue to be added in vaccine formulations due to their historical success 
and low cost, and because the use of established adjuvants accelerates clinical development 
and regulatory approval pathways. However, most of the vaccines we use today were 
develop and tested empirically; as we gain a better understanding of protective immunity, 
the design strategy has shifted to a more rational approach, especially for fighting hard-to-
target pathogens. For almost 60 years, it was accepted by the scientific community that 
aluminum salts were effective because they created a “depot effect,” slowly releasing 
antigen from insoluble particles.4 But research in the mechanisms of action of aluminum 
salts has reignited in the past two decades, and the exact relationship between the 
physiochemistry and immunoreactivity of aluminum salts remains elusive.5 The lack of 
specificity makes them inadequate for a broad range of vaccines, specifically those that 
  
 3 
require a cytotoxic, Th-1 skewed immune response. The goal of next generation vaccines 
is to assemble a structure where each component elicits a specific immunological pathway 
to tailor the resultant immune response. 
A strategy for modulating immunity during vaccination is to target specific professional 
antigen-presenting cells (APCs) and induce their maturation. Professional APCs 
effectively activate antigen-specific T cells, a requirement for induction of strong humoral 
and cellular responses. Mammalian cells, including APCs, possess pattern recognition 
receptors (PRRs) at the cell surface, within endosomes and other intracellular organelles, 
as well as unbound in the cytosol. PRRs bind to distinct molecules broadly expressed by 
different microorganisms, collectively known as pathogen associated molecular patterns 
(PAMPs), including lipids, carbohydrates, peptides, and nucleic acid structures.6 PAMP 
engagement with various PRRs trigger differential innate immune responses and are 
therefore being investigated as adjuvants to guide and strengthen protective immunity. Two 
classes of PRRs include toll-like receptors and RIG-I-like receptors (RLRs). RLRs, 
including RIG-I, MDA5, and LGP2, detect foreign RNA within the cytosol, including 5’ 
triphosphate RNA, long double-stranded RNA, and sequences specific to viral genomes 
such as the poly-uridine region of Hepatitis C virus (i.e., polyU/UC or PUUC).7,8 RLR 
pathways regulate transcription factors NFκB, IRF3, and IRF7, resulting in the production 
of interferons (IFNs) and pro-inflammatory cytokines, and can also limit viral replication 
by initiating cell death.7 
Toll-like receptors (TLRs) are transmembrane glycoproteins that bind PAMPs at the 
plasma membrane, as well as in endosomes. Cell surface TLRs include TLR4, which 
primarily binds to lipopolysaccharides (LPS) in the outer membranes of Gram-negative 
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bacteria. Activation of TLR4 at the cell membrane signals through the MyD88 pathway 
and drives the production of proinflammatory cytokines (e.g., IL-12p70) through NFκB 
activation. A CD14-dependent pathway moves TLR4 from the plasma membrane into 
endosomes, where TLR4 signals via TRIF to induce type I IFN expression.9 
Monophosphoryl lipid A (MPLA) is extracted from LPS through hydrolysis and retains 
TLR4-stimulatory properties with reduced toxicity. It is available in FDA-approved 
clinical adjuvants, including Adjuvant System 04 (AS04), which combines MPLA with 
aluminum salts.10 Nucleic acid-sensing TLRs are intracellular to detect nucleic acids 
liberated from bacteria or viral capsids in endo-lysosomal compartments, including ssRNA 
(TLRs 7/8) and unmethylated CpG DNA (TLR9). Ligand binding to nucleic acid-sensing 
TLRs activate MyD88-dependent pathways triggering the secretion of proinflammatory 
cytokines and type I interferons, particularly by plasmacytoid DCs (pDCs). There is an 
FDA-approved TLR9-targeted adjuvant, CpG 1018, that is used in a Hepatitis B vaccine.11 
During an infection, it is likely that several ligands displayed by a pathogen activate 
multiple different PRRs, leading to increased innate and adaptive immune responses 
(Figure 1). For instance, the live-attenuated yellow fever vaccine activates TLR2, TLR7, 
TLR8, and TLR9 on different dendritic cell (DC) subsets.12 Although pathogens present 
multiple PAMPs and antigens within a particulate structure, most research on PRR-
targeting adjuvants involves delivering soluble antigens with single PRR agonists. 
Researchers have shifted their focus onto particulate vaccine delivery vehicles with 
combination adjuvants to mimic the composition of pathogens better and elicit more 





Figure 1: Pathogens endogenously express multiple PRR ligands. Gram-negative bacteria, 
such as E. coli, express TLR2, TLR4, TLR5, and TLR9 ligands. ssRNA viruses, such as 
Hepatitis C, contain ligands for TLR7/8, RIG-I, and TLR2. The coexpression of different 
PAMPs by pathogens supports the rationale for using combinations of purified PAMPs as 
vaccine adjuvants to stimulate the immune system. Figure created with ©BioRender, 
biorender.com 
Studies have shown that combinations of agonists targeting various TLRs can result in 
synergistic, complementary, and antagonistic effects on innate and adaptive immunity. 
Stimulation of PRRs in different cellular compartments, which researchers have described 
as a “combinatorial security code,” theoretically ensures invading pathogens will cause 
cells to generate robust immune responses.13 In vitro, stimulation of mouse macrophages 
with both TLR3 and TLR9 ligands (poly(I:C) and CpG) upregulated production of TNF, 
IL-6, and IL-12p40, and combining TLR4 with TLR7/8 agonists induced 50-100-fold 
higher levels of IL-12 and IL-23 and more Th1 polarization compared to single agonists in 
human monocyte-derived DC culture.13,14 In vivo, a combination of TL4 and TLR7-
targeting adjuvants and recombinant hemagglutinin induced balanced Th1/Th2-type 
immunity against different influenza strains in mice, while HIV-1 glycoprotein gp140 co-
delivered with TLR7/8 and TLR9 agonists elicited strong humoral immune responses in 
rhesus macaques.15,16 Systemic analyses on the effects of combined TLR ligands have 
indicated the most significant synergies occur between stimuli that trigger different TLR-
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mediated signaling pathways; for example, activation of both MyD88-dependent and 
TRIF-dependent pathways markedly increases IL-12p70 production.17   
There is growing evidence that TLRs cooperate with other types of PRRs in the innate 
immune response to pathogens; however, researchers have not sufficiently investigated the 
immunological events occurring during the combined stimulation of RLRs and TLRs. A 
study revealed that poly(I:C), a synthetic analog of double-stranded RNA, can activate both 
TLR3 and MDA5, resulting in the production of different cytokines.18 Interactions between 
poly(I:C) and TLR3 were primarily responsible for the induction of pro-inflammatory 
cytokines while activating MDA5 stimulated type I IFN responses. Clinical studies have 
shown that suppression of both RIG-I and TLR4-mediated signaling pathways is more 
common in children with an influenza-related critical illness, and increasing stimulation of 
both pathways may ameliorate antiviral and antibacterial responses.19 Research on the 
collaboration of endosomal TLRs and RIG-I in primary human pDCs demonstrated pDCs 
upregulate RIG-I expression in a type I IFN-independent manner upon stimulation by 
TLR7 ligand R848 or TLR9 ligand type A CpG ODN.20 
PAMPs differ in the types of PRRs they engage, the signaling pathways they trigger, and 
the types of immune responses they generate. The nature of the immune response is also 
influenced by the stimulated APC subsets, which express different combinations of TLRs 
and other PRRs, resulting in cell and tissue-specific responses to microbes. To design 
combinatorial PRR-targeting adjuvant vaccines, it is essential to understand how different 
APC subsets interact with them and how that leads to specific immune outcomes. It is also 
essential to investigate how delivery vehicles influence cell responses to PAMPs, for 
example biomaterials-based particles. Incorporating adjuvants into polymeric particles, 
  
 7 
such as polylactic-co-glycolic acid (PLGA) particles, prevents rapid diffusion, which may 
reduce systemic toxicity and enable targeted delivery to immune cells. Another advantage 
of PLGA particles is they facilitate the co-delivery of chemically variable adjuvants, 
especially when combining hydrophobic molecules (e.g., MPLA or imiquimod, R848) with 
a highly hydrophilic molecule (e.g., CpG ODN or PUUC).  
Therefore, this thesis addresses the effects of combinatorial PRR-targeting adjuvant PLGA 
particle vaccines on APC subsets at different stages of the immune response, including 
recruitment of innate immune cells, APC maturation and expression of costimulatory 
molecules, proinflammatory cytokine and interferon secretion, lymphatic migration, and 
activation of T cells. 
1.2 Specific Aims 
1.2.1 Hypothesis 
Pathogens express multiple ligands recognized by various PRRs on APCs that together 
orchestrate APC maturation, migration, and activation of T cells. The central hypothesis of 
this thesis is combinations of two PRR-targeting adjuvants are more effective at stimulating 
APC-mediated innate and adaptive immune responses compared to single PRR-targeting 
adjuvants. The overall objective is to evaluate the immunogenicity of combination 
adjuvants by delivering TLR and RLR ligands on PLGA micro- and nanoparticles, 
otherwise known as pathogen-like-particles (PLPs), to stimulate APCs in vitro and in vivo. 
Aim 1 focuses on the effects of MPLA and CpG on APC migration toward lymphatics and 
particle delivery to lymph nodes, while Aim 2 investigates TLR-RLR adjuvant 
combinations for enhancing antigen-specific T cell responses to SARS-CoV-2.  
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1.2.2 Aim 1: Characterizing Immune Responses to Combined MPLA and CpG 
The goal of this aim is to evaluate how single and combined TLR4 and TLR9 agonists 
MPLA and CpG ODN, both of which are expressed by gram-negative bacteria, regulate 
APC chemotaxis toward lymphatics and PLGA particle delivery to draining lymph nodes. 
The general hypothesis is that co-delivered MPLA and CpG enhance particle transport to 
lymph nodes by targeting migratory APC subsets in the muscle and inducing APC 
chemotaxis toward lymphatic chemokines. Aim 1 is divided into two sub-aims: 
Aim 1.1: Evaluate how single and combined MPLA and CpG, delivered in soluble form or 
together on PLGA particles, modulate murine bone marrow-derived DC (BMDC) 
migration through collagen gel toward lymphatic chemokine gradients using a microfluidic 
platform. Cationic PLGA-polyethylenimine (PEI) microparticles encapsulating MPLA 
were fabricated using a double emulsion, solvent evaporation method and electrostatically 
loaded with Class B CpG ODN 1826. BMDCs were cultured with granulocyte macrophage 
colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) and characterized for CCR7 
expression in response to soluble and PLP-loaded adjuvants. Within a microfluidic device, 
BMDCs were cultured in a 3D collagen matrix channel between two media reservoirs, only 
one of which containing CCL19 or CCL21, establishing a chemokine gradient stable for 
over 24 hours. Adjuvants were either diluted in media reservoirs or PLPs were incubated 
with BMDCs in the collagen matrix, and cell migration was imaged in real time with phase 
contrast microscopy. Finally, cell migration was quantified using high-throughput cell 
tracking software and analyzed using a logistic regression model and directional statistics. 
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Aim 1.2: Determine how single and co-loaded MPLA and CpG on PLGA nanoparticles 
(NPs) affect the recruitment and activation of muscle- and lymph node-resident APC 
subsets, as well as the kinetics of particle-adjuvant partitioning and delivery to different 
muscle-draining lymph nodes in mice. PLGA-PEI nanoparticles encapsulating synthetic 
MPLA (GLA) were functionalized with Alexa Fluor 488 and electrostatically loaded with 
IR700 Dye conjugated-CpG ODN or control ODN (GpC). The dual fluorescent label, dual 
adjuvant (or single adjuvant) PLPs were injected intramuscularly in mice, then anterior 
tibialis muscles and draining lymph nodes (dLN) were isolated after 24 and 48 hours. 
Popliteal, inguinal, and iliac dLN were imaged using near-infrared (NIR) microscopy to 
quantify fluorescence of lymphatically transported IR700-labeled PLPs. Cells from 
muscles and dLNs were analyzed via flow cytometry to characterize cell populations and 
determine which APC subsets internalized AF488-particles and/or IR700-ODN. 
1.2.3 Aim 2: Characterizing Immune Responses to Combined RLR and TLR Agonists 
Positive-strand RNA viruses, such as SARS-CoV-2, have been reported to trigger TLR4, 
TLR7/8, and RIG-I. The objective of this aim is to understand how combined TLR and 
RLR agonists on PLGA NPs with recombinant SARS-CoV-2 spike protein modulate 
innate and adaptive immune responses against SARS-CoV-2. The general hypothesis is 
delivering PUUC with a TLR ligand (MPLA, R848, or CpG) on PLGA NPs increases APC 
production of proinflammatory cytokines and interferons, resulting in enhanced T cell 
proliferation and anti-SARS-CoV-2 humoral and cellular immune responses. Aim 2 is 
divided into two sub-aims: 
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Aim 2.1: Identify PLP adjuvant combinations that enhance murine bone marrow-derived 
DC secretion of proinflammatory cytokines and interferons as well as T cell proliferation 
in an isogeneic mixed lymphocyte reaction (iso-MLR) with SARS-CoV-2 spike protein 
antigen. GM-CSF-dependent BMDCs (including CD11bhi APCs) and FLT3L-dependent 
BMDCs (including pDC and cDCs) were cultured for 24 hours with recombinant SARS-
CoV-2 spike protein and PLPs loaded with one or two of the following ligands: Poly(I:C) 
(TLR3), GLA (TLR4), R848 (TLR7/8), CpG ODN 1826 (TLR9), or PUUC (RIG-I). Cell 
culture media was collected to quantify proinflammatory cytokine (e.g., IL-12p70 and 
TNF-α) and interferon secretion by BMDCs. T cells isolated from spleens and labeled with 
CFSE were mixed with activated BMDCs for 72 hours (iso-MLR culture). Media was 
collected from iso-MLR culture to quantify IFN-γ and IL-4, and T cells were analyzed via 
flow cytometry to quantify CD4+ and CD8+ T cell proliferation and predict which PLP 
formulations would stimulate Th1 and/or Th2 immune responses. Experiments were 
carried out with both female and male BMDCs and T cells to identify sex differences in 
immune responses. 
Aim 2.2: Investigate how intranasally administered PLPs with various dual adjuvant 
formulations modulate innate immune cell populations and gene expression in the lung and 
tailor adaptive immune responses against SARS-CoV-2 in mice. PLGA NPs formulated 
with PUUC or PUUC and one TLR agonist (GLA, R848, CpG) were intranasally 
administered to mice. Lungs were collected at 4 and 24 hours to measure changes in 
inflammatory gene expression in response to PLPs. In a separate experiment, PUUC and 
MPLA-PUUC PLPs were delivered i.n. and lungs were collected again at 4 and 24 hours. 
Lung cell clusters were characterized based on protein and gene expression at the single-
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cell level using CITE-Seq. Finally, mice were vaccinated i.n. with PLP formulations and 
soluble or PLGA NP-conjugated SARS-CoV-2 stabilized spike protein. Sera and 
bronchoalveolar lavage (BAL) fluid was collected before and after booster vaccinations to 
measure anti-spike antibody titers. Lungs were collected one week after booster shots, 
processed for single cell suspensions, and stimulated with SARS-CoV-2 spike peptide 
pools to measure Granzyme B, IFN-γ, and TNF-α responses in CD4+, CD8+, and 







CHAPTER 2: BACKGROUND 
2.1 APCs: Linking Innate and Adaptive Immunity 
As of 2020, the World Health Organization listed communicable diseases as three of the 
top 10 causes of death globally and six of the top ten in low-income countries, including 
neonatal conditions, lower respiratory infections, diarrheal diseases, malaria, tuberculosis, 
and HIV/AIDS.21 Infectious diseases are caused by microorganisms called pathogens, each 
one responsible for a particular disease. The four major classes of pathogens are viruses, 
bacteria, fungi, and parasites. Pathogens must invade and colonize a host to survive and 
multiply. When pathogens breach the first lines of defense of the human immune system, 
including anatomical barriers (skin, mucosal surfaces), antimicrobial enzymes and 
peptides, and the complement system, the immune system’s initial priority is to recognize 
and eliminate the pathogen. Pathogens are broadly and specifically recognized by the 
molecules they express (non-self) distinctly from host cell molecules (self). Innate immune 
cells possess pattern recognition receptors (PRRs) that bind to molecules common to 
most pathogens, known as pathogen-associated molecular patterns (PAMPs). This 
feature of innate immunity enables the host to nonspecifically target and clear pathogens 
immediately upon infection. Adaptive immune cells contain receptors specifically 
generated to recognize fine distinctions between closely related pathogenic molecules, 
called antigens. It takes about four days to generate an antigen-specific response to a new 
pathogen; however, if the host possesses immunological memory of a pathogen, then a 
strong and immediate antigen-specific response is mounted.22 Professional antigen-
presenting cells – mainly dendritic cells, macrophages, and B cells – bridge innate and 
adaptive immunity through their unique ability to recognize PAMPs and induce innate 
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responses, as well as present antigen to T cells and initiate adaptive responses.23 This 
chapter introduces antigen-presenting cells (APCs), outlines APC subsets and their 
functions, reviews APC-targeted vaccine adjuvants, and delineates the roles of APCs and 
the lymphatic system in antigen and/or vaccine delivery to draining lymph nodes. 
 
Figure 2: Innate immune response to infection and vaccination. 1) Bacteria enter tissue 
through a wound leading to inflammation and recruitment of immune cells at the site of 
infection. 2) Innate immune cells, such as neutrophils (light blue) and monocytes (dark 
blue), are recruited from the blood to tissue. 3) Neutrophils phagocytose and degrade 
bacteria, as well as kill bacteria through degranulation (release of anti-microbials) and 
release of neutrophil extracellular traps (NETs). 4) Innate immune cells express pattern 
recognition receptors (PRRs), which recognize and bind to pathogen-associated molecular 
patterns (PAMPs). 5) Immunoglobulins and complement factors specifically and non-
specifically bind to pathogens (opsonization), enabling cells to target and phagocytose 
pathogens. 6) Monocytes express PRRs and secrete pro-inflammatory cytokines and have 
the potential to differentiate into DCs (dark red) and macrophages (light red) under 
inflammatory conditions. 7) Tissue-resident conventional DCs (derived from pre-DCs) 
recognize and endocytose bacteria. 8) Antigen-presenting cells (APCs), especially DCs, 
degrade pathogens and load antigens onto MHC-II molecules in endolysosomal 
compartments. 9) Mature APCs express MHC and costimulatory molecules and follow 
chemokine gradients through lymphatic vessels to lymph nodes where they activate T cells. 
cDC1 (yellow) have the ability to cross-present antigens on MHC-I molecules while cDC2 
(purple) predominantly express MHC-II. 10) Subunit vaccines contain purified adjuvants 
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(e.g., PAMPs) and antigens to stimulate innate and adaptive immunity. 11) Immunization 
simulates infection by inducing inflammation and recruitment of innate immune cells to 
the injection site. APCs internalize soluble and particle-bound antigens and load them onto 
MHC molecules before migrating to lymph nodes. Figure created with ©BioRender, 
biorender.com. 
Antigen-presenting cells are categorized for their proficiency in displaying antigens and 
major histocompatibility complex (MHC) molecules on their surface, which are 
specifically recognized by T cells. In combination with other molecular signals provided 
by APCs, antigen presentation is necessary to activate T cells and initiate effective adaptive 
immune responses. To display antigens, APCs must first recognize, internalize, and 
degrade pathogens to acquire antigens, then further process them into short fragments for 
loading onto MHC molecules. The mechanisms involved in acquiring antigen 
simultaneously trigger the release of molecular signals that control innate immune 
responses. In peripheral tissues, the largest population of APCs with the broadest range of 
combined antigen presentation and innate immune signaling are dendritic cells, followed 
by macrophages; therefore, this section will be primarily referring to these cell types. 
Myeloid APCs develop in the bone marrow and migrate to peripheral tissues or 
continuously circulate through blood and lymphatic vessels to surveil for pathogens (Figure 
2). Tissue-resident APCs engulf invading pathogens through phagocytosis and receptor-
mediated endocytosis, regulated by the binding of microbial PAMPs to membrane-bound 
PRRs on APC surfaces. APCs can also capture pathogens through ingestion of large 
amounts of extracellular fluid, a process known as micropinocytosis. Once internalized, 
pathogens are degraded in endo-lysosomal compartments and release antigens as well as 
other PAMPs that bind to intracellular PRRs. Surface PRRs primarily bind to structural 
components of pathogens, such as bacterial cell wall lipopolysaccharides, viral envelope 
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proteins, and flagellin, while most intracellular PRRs bind to nucleic acids with pathogen-
specific motifs, including single stranded RNA sequences with GU-rich sequences or DNA 
with unmethylated CpG islands.7 Antigens from proteins degraded in endosomes are 
loaded onto MHC class II (MHC-II) molecules, while antigens from proteins degraded by 
the proteosome in the cytosol are loaded onto MHC class I (MHC-I) molecules. Antigen 
from endocytosed proteins require special processing for loading and “cross-presentation” 
to T cells on MHC-I molecules.24 
The key outcome from PRR activation is the production and secretion of specific proteins 
called cytokines, which help promote and maintain inflammation. Cytokines can act in an 
autocrine, paracrine, or endocrine manner, to control behavior of the signaling cell, 
adjacent cells, or distant cells, respectively. The cytokines secreted by APCs are diverse 
and can be grouped into different families based on structure or function. Cytokine families 
include interleukins (IL), tumor necrosis factors (TNF), interferons (IFN), and colony 
stimulating factors (CSF); however, the nomenclature is continuously evolving as new 
cytokines are discovered. For example, the term interleukin was coined because ILs were 
first thought to be exclusively expressed by leukocytes (e.g., neutrophils), but were later 
found to be secreted by a wide range of immune cells.25 The most important cytokines in 
the innate immune response include those in the IL-1 superfamily (IL-1α, IL-1β, and IL-
18), hematopoietin superfamily (IL-6 and GM-CSF), TNF family (TNF-α) and type I 
interferons (IFN-α, IFN-β). Another class of chemoattractant cytokines, known as 
chemokines, are secreted during the innate immune response and direct migration of 
immune cells expressing the matching chemokine receptor. The combination of pro-
inflammatory cytokines and chemokines induce the following events: vasodilation, 
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upregulation of adhesion molecules on endothelial cells, infiltration of immune cells from 
blood circulation into infected tissues, differentiation of myeloid progenitor cells into 
APCs, upregulation of MHC molecules, production of antiviral proteins, amplified fluid 
drainage to lymph nodes, and growth and differentiation of T and B cells. 
 
Figure 3: Adaptive immune response to vaccination. Migratory APCs follow gradients of 
chemokines CCL19 and CCL21 through lymphatic vessels to lymph nodes, where they 
encounter T cells. MHC-antigen complexes expressed by mature APCs engage with T cell 
receptors on CD4+ and CD8+ T cells. Activated CD8+ T cells differentiate into memory 
and effector CD8+ T cells, i.e., cytotoxic T cells. CTLs recognize and kill infected cells. 
Activated CD4+ T cells differentiate into memory and effector CD4+ T cells, i.e., T helper 
cells. T helper 1 cells assist differentiation of CTLs while T helper 2 cells assist 
differentiation of B cells into memory B cells and plasma cells. Plasmacytoid DCs 
primarily reside in lymphoid organs and are specialized in secreting interferons to prevent 
viral replication. Figure created with ©BioRender, biorender.com. 
Many infections are cleared by innate immune responses and cause no disease; however, 
if infections are not quickly resolved, the innate immune system will attempt to contain the 
pathogen while triggering an adaptive immune response. Adaptive immune responses are 
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characterized by the production of antibodies against a particular pathogen-derived antigen. 
Most cases result in immunological memory, which confers protective immunity to 
reinfection with the same pathogens, and helps individuals adapt to their environments. 
The white blood cells that carry out adaptive responses are lymphocytes, mainly B cells 
and T cells, that primarily reside in lymphoid tissues. Lymphocytes that have not been 
activated are naive lymphocytes, and they require activation to differentiate into fully 
functional effector cells (Figure 3). Free antigen can bind to the B cell receptors (BCRs) 
on B cell surfaces, inducing proliferation and differentiation into plasma cells that secrete 
antigen-specific antibodies. Still, B cells require “help” from activated helper T cells for 
optimal immune responses.  
T cells are activated through the binding of T cell receptors to specific peptide-MHC 
complexes on APCs. APCs must migrate from peripheral tissues, through lymphatic 
vessels, to deliver antigen to T cells in secondary lymphoid organs (e.g., lymph nodes, 
spleen). Even in the absence of infection, DCs continuously endocytose self-antigens or 
nonpathogenic environmental antigens and present them to T cells in dLNs to promote a 
tolerogenic response. To induce an optimal immunogenic response, APCs must undergo 
maturation, a process that is triggered by exposure to PAMPs and proinflammatory 
cytokines (Figure 4). During maturation, APCs upregulate MHC molecules and 
costimulatory molecules (CD80, CD86, CD40) and secrete more T cell-polarizing 
cytokines. Without all three signals, 1) antigen recognition, 2) costimulation, and 3) 
cytokine-mediated differentiation, T cells could become anergic or immunosuppressive. 
APCs present peptide-MHCI complexes to CD8+ T cells, which differentiate into cytotoxic 
T cells, and present peptide-MHCII complexes to CD4+ T cells, which differentiate into T 
  
 18 
helper cells. T helper 1 (Th1) cells provide immunity against intracellular pathogens and 
require polarizing cytokine IL-12, while T helper 2 (Th2) cells provide immunity against 
parasites and helminths and require polarizing cytokine IL-4. There is also a third class of 
T helper cells, Th17, which protect against extracellular fungi and bacteria but are 
implicated in autoimmune diseases. APCs can also induce polarization of regulatory T cells 
through secretion of TGF-β and retinoic acid. 
 
Figure 4: Mature dendritic cells express the necessary signals to activate T cells. Dendritic 
cell precursors and immature dendritic cells express CCR2 and CCR6 to enable recruitment 
from bone marrow and blood to peripheral tissues. Immature DCs have a high capacity for 
endocytosing and degrading pathogens, are morphologically round and smooth, and 
express low levels of MHC and costimulatory molecules. After engagement of PRRs and 
internalization of pathogens, DCs transition into a mature state, characterized by increased 
expression of MHC-I/MHC-II molecules, CD40 and CD80/CD86 costimulatory 
molecules, proinflammatory cytokines, and CCL19/CCL21 chemokine receptor CCR7. In 
lymph nodes, mature DCs present three signals to T cells for optimal activation: 1) MHC-
antigen complex, 2) costimulatory molecules, and 3) secretion of T-cell differentiation 
cytokines, e.g., IL-12. Figure created with ©BioRender, biorender.com. 
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2.2 Pathogen Recognition Receptors 
2.2.1 Toll-like Receptors 
Toll-like receptors (TLRs) are a family of type I transmembrane PRRs named after the Toll 
proteins identified in Drosophila melanogaster and known for inducing antimicrobial 
responses when engaged.22 There are ten functional TLRs in humans (TLRs 1-10) and 
twelve in mice (TLRs 1-9, 11-13), and each TLR has evolved to recognize different 
PAMPs and danger-associated molecular patterns (DAMPs). There are various 
combinations of TLRs expressed by immune cells, as well as other cell types including 
endothelial cells, epithelial cells, and fibroblasts; normally, pathogens will express more 
than one PAMP and trigger multiple TLRs on the same cell or different cells, eliciting 
diverse immune responses. TLRs that recognize the structural components of pathogens 
are expressed on the plasma membrane, and these include TLRs 1, 2, 4, 5, 6, and 10. The 
remaining TLRs 3, 7, 8 and 9 are expressed in the membranes of endosomes, and they 
recognize nucleic acids. There are some TLRs, such as TLR4, that can traffic from the 
plasma membrane to endosomes and signal different pathways depending on the location. 
TLRs are comprised of a horseshoe-shaped N-terminal ligand binding domain, a 
transmembrane domain, and a C-terminal cytoplasmic signaling domain. The signaling 
domain of a TLR is known as the Toll IL-1 receptor (TIR) domain because of its similarity 
to the signaling domains of IL-1 cytokine receptors (IL-1Rs).26 Upon ligand binding, TLRs 
form an “m”-shaped homodimer or heterodimer (e.g., TLR1/TLR2, TLR2/TLR6), and the 
TIR domains dimerize to initiate downstream signaling cascades.27 TIR dimers recruit two 
different adaptor protein pairs: MyD88/MAL and TRIF/TRAM. Most TLRs signal through 
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the MyD88 pathway, which activates NFκB and induces the transcription of genes for pro-
inflammatory cytokines including TNF-α, IL-1β, and IL-6. For TLRs 7-9, the MyD88 
pathway also activates IRF7, which results in the production of IFN-α and IFN-β. TLRs 
that signal through the TRIF pathway (TLR3 and TLR4) activate IRF3, which induces 
expression of IFN-β. 
TLR4 is one of the most studied TLRs and is expressed by several types of the immune 
cells including DCs and macrophages. TLR4 recognizes many microbial membrane 
components including mannans (e.g., on C. albicans), glycoinositol phospholipids (e.g., on 
T. cruzi), and viral envelope proteins (e.g., on RSV).28–30 TLR4 also binds endogenous 
antigens released from damaged tissue including fibrinogen, heat shock proteins, and 
minimally modified low-density lipoproteins.31 The most widely recognized ligand of 
TLR4 is lipopolysaccharide (LPS), a cell wall component of Gram-negative bacteria (e.g., 
Salmonella minnesota R595) (Figure 5). The composition of LPS varies between different 
bacteria, but the most conserved component is the lipid A moiety, an amphipathic lipid 
with a variable number of fatty-acid chains per molecule.32 When Gram-negative bacteria 
enter the body they release LPS fragments from the cell wall as they grow or when they 
are destroyed. If LPS fragments enter the bloodstream, they activate cells via TLR4 
throughout the body, causing systemic inflammation and inducing septic shock in humans. 
TLR4-/- mice are resistant to LPS-induced shock; however, they are not able to mount an 
adaptive immune response against bacteria.22 TLR4 activation via LPS requires two 
accessory proteins – CD14, which acquires LPS from LPS-binding protein in the blood 
and extracellular fluid, and MD-2,which associates with the curved N-terminal domain and 
dimerizes TLR4.33 The binding of TLR4 at the plasma membrane activates the MyD88 
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pathway and induces robust IL-12p70 production as well as enhances Th1 cellular and 
humoral responses.34 CD14 mediates endocytosis of TLR4, which results in TRIF-
dependent signaling from the endosome and activation of IRF3/7. CD14-dependent 
internalization of LPS can be bypassed by incorporating LPS into particles, which are taken 
up by phagocytosis.9 
TLR2 recognizes many of the same structural PAMPs as TLR4 but instead forms 
heterodimers with other TLRs. For example, when binding to diacylated lipoproteins, such 
as lipoteichoic acid on Gram-positive bacteria, TLR2 complexes with TLR6.35 When 
binding to triacylated lipoproteins (e.g., on M. penumoniae) TLR2 complexes with TLR1 
which contains a hydrophobic channel capable of binding the third acetylated chain.36 Both 
heterodimers lead to MyD88 and MAL-dependent activation of NFκB/AP-1 and secretion 
of proinflammatory cytokines. It is possible that TLR2 forms a homodimer but may not be 
functional because the TIR domains are too far apart to dimerize and initiate signaling.37 
TLR2 also complexes with CD14. Studies have shown when macrophages lack CD14, 
TLR2 signaling is greatly reduced.38,39 TLR5 is a surface TLR that recognizes bacterial 
flagellin and is constitutively expressed in epithelial cells and immune cells, including 
monocytes and conventional DCs (cDC2 subset). TLR5 expression by intestinal epithelial 
cells is especially important for sensing gut microbiota that have breached mucosal 
barriers.40 TLR10 has been shown to form a heterodimer with TLR2 but negatively 
regulates MyD88-dependent and independent TLR signaling.41 Mouse TLR11 and TLR12 





Figure 5: Toll-like and RIG-I-like receptor signaling. 1) Monophosphoryl lipid A, a moiety 
present in Gram-negative bacterial cell walls, binds to TLR4, which triggers the MyD88 
pathway from the plasma membrane and TRIF pathway from endosomes. 2) TLR9 binds 
to CpG DNA released from bacteria and viruses in endosomes and signals the MyD88 
pathway. 3) TLR7 and TLR8 bind to ssRNA in endosomes and triggers the MyD88 
pathway. 4) RIG-I, a cytosolic receptor, recognizes dsRNA and activates adaptor protein 
MAVS on mitochondria or peroxisomes. 5) MyD88 signals IRAKs and TRAF6 (yellow 
arrows), while MyD88 and TRIF signal TRAF3 (green arrows), to activate transcription 
factors in the nucleus. IRF3/7 and NFκB regulate the transcription of genes associated with 
type I interferons and pro-inflammatory cytokines, respectively. MAVS signaling also 
activates IRF3 and IRF7. Figure created with ©BioRender, biorender.com. 
Nucleic acid-sensing TLRs 3, 7, 8, and 9 strategically localize in endosomes to detect RNA 
and DNA liberated from degraded pathogens, and to limit activation by self-nucleic acids 
that are abundant in extracellular fluid.34 TLR3 recognizes double-stranded RNA (e.g., 
from rotavirus), but may also be activated by messenger RNA released from dying host 
cells.44 Polyinosinic:polycytidylic acid (Poly(I:C)) is a synthetic analog of dsRNA 
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commonly used to study TLR3 function. TLR3 is expressed by human DCs (cDC1) and 
intestinal epithelial cells, but is low or absent in monocytes, neutrophils, and 
lymphocytes.45 TLRs 7 and 8 recognize single-stranded RNA (e.g., from flavivirus), 
particularly with poly-U or GU-rich sequences. They can be activated by synthetic 
imidazoquinolines including imiquimod (R837) and resiquimod (R848) as well as 
guanosine analogues (e.g., loxoribine). TLRs 7 and 8 are highly expressed in intestinal 
tissues, indicating they play a role in host defense against intestinal infections.45 DCs and 
macrophages are the main cell types with TLR7/8, though human airway epithelial cells 
and cardiac cells have been shown to upregulate these receptors during infection.46 TLR9 
recognizes single-stranded DNA, and current dogma suggests that TLR9 discriminates 
self-DNA from non-self-DNA by recognizing unmethylated CpG motifs common to 
bacteria and viruses. However, contradictory results have shown that TLR9 senses natural, 
unmodified ssDNA in the endosome in a CpG-independent manner.47 TLR9 is expressed 
constitutively in human B cells and pDCs, but is low or absent in monocytes/macrophages, 
T cells, NK cells, or cDCs.45 In mice, TLR9 is expressed by myeloid DCs.48 
Nucleic acid-sensing TLRs require interaction with transmembrane chaperone, UNC93B1, 
for exiting the endoplasmic reticulum. TLR9 is transported via UNC93B1 to the cell 
surface, then interacts with AP-2 to trigger endocytosis and trafficking to endosomes, 
where asparagine endopeptidase and cathepsins proteolytically cleave it to an active 
form.49 TLR7 is not trafficked to the cell surface and instead associates with AP-4 in the 
Golgi complex, which delivers TLR7 directly to endosomes. Hijacking these trafficking 
pathways could enable recruitment of TLRs to distinct endosomes with unique signaling 
properties and tailor the immune response. For example, CpG Type A ODN signals TLR9 
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in early endosomes and recruits IRF7, leading to a type I IFN response. In contrast, CpG 
B ODN signals TLR9 in late endosomes and induces activation of NFκB and secretion of 
proinflammatory cytokines.50 A method for tailoring endosomal delivery could be 
delivering TLR agonists on different sized polymeric particles. One study showed delivery 
of CpG ODNs on microparticles, which localize in early endosomes, stimulated IL-6 
secretion, while CpG on nanoparticles, which localize in late endosomes, stimulated 
production of both IL-6 and IFN-α.51 
2.2.2 RIG-I-like Receptors 
Retinoic acid inducible gene (RIG)-I-like receptors (RLRs) are unbound intracellular 
receptors in the cytosol that recognize foreign nucleic acids. They are strategically located 
in the cytosol to survey for intracellular pathogens. RLRs recognize double-stranded RNA, 
a replication intermediate for RNA viruses, that exhibits viral motifs such as an uncapped 
5’ diphosphate or triphosphate end.8 The best characterized RLRs are RIG-I and MDA5, 
which recognize different lengths of dsRNA: RIG-I selectively binds to short dsRNAs 
while MDA5 primarily recognizes long dsRNA.52 The poly-uridine core of Hepatitis C 
Virus, poly-U/UC (PUUC), activates RIG-I and triggers potent anti-HCV responses.53 
Transfected poly(I:C) is also sensed by RIG-I/MDA-5, unlike naked poly(I:C) which is 
recognized by TLR3.54 RIG-I and MDA5 contain N-terminal caspase activation and 
recruitment domains (CARDs) that relay signal to downstream signaling adaptor MAVS 
(mitochondrial antiviral-signaling protein).55 MAVS signaling at the mitochondria 
activates IRF3 and induces type I IFN while signaling at peroxisomes activates IRF1/IRF3 
and induces type III IFN and expression of interferon-stimulated genes (ISGs).56,57 
Signaling at both locations also triggers recruitment of TRAF2/TRAF6 which leads to 
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activation of NFκB.55,58 The RLR signaling pathway can also limit viral replication by 
initiating a form of cell death called pyroptosis.59  
2.3 APC Subsets and their Functions 
In the late 19th century, Ilya Metchnikoff discovered the phagocyte system, comprised of 
cells he termed macrophages (Greek for "large eaters") and microphages ("small eaters"), 
now known as polymorphonuclear leukocytes (i.e., neutrophils, eosinophils, and 
basophils).60 Later, a specialized macrophage with long finger-like membrane protrusions 
(i.e., dendrites) was discovered and thought to be pivotal in the production of antibodies. 
In the 1970s, Ralph Steinman and colleagues performed studies with the “dendritic 
macrophages,” now distinctly classified as dendritic cells, and found they expressed high 
levels of MHC molecules and were potent inducers of T cell activation in mixed leukocyte 
reaction (MLR) assays.61 Currently there are several different subsets of dendritic cells, as 
well as other members of the mononuclear phagocyte system (i.e., monocytes and 
macrophages), that have been defined by their lineage, morphology, surface marker 
expression, and function. 
Dendritic cells originate from hematopoietic stem cells (HSCs) in the bone marrow. The 
downstream progeny of HSCs includes common myeloid progenitors (CMPs) and common 
lymphoid progenitors (CLPs).62 Adoptive transfer of CLPs and CMPs into irradiated mice 
(radiation ablates host bone marrow cells) produces DCs in mice, and similarly human 
CLPs and CMPs differentiate into DCs in vitro.63 However, the contribution of CLPs to 
DC populations remain unclear while CMPs are more widely studied.64 CMPs give rise to 
granulocyte-macrophage progenitors (GMPs), which differentiate into macrophage-
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dendritic progenitors (MDPs), which develop into common monocyte progenitors (CMoP) 
and common dendritic cell progenitors (CDPs). CDPs have lost monocyte and 
macrophage-differentiation potential and give rise only to cells in the DC lineage. It is from 
here that CDP branch into different lineages resulting in two main functional DC types: 
conventional DCs (cDCs) and plasmacytoid DCs (pDCs). In this section we will discuss 
cDCs and pDCs as well as other APCs integral to the adaptive immune response: 
monocyte-derived DCs, macrophages, and B cells. 
2.3.1 Conventional DCs 
In the bone marrow, CSF-1R+ CDPs give rise to pre-DCs, which circulate through the 
blood to reside in lymphoid organs (e.g., spleen, lymph nodes) and non-lymphoid tissues 
(e.g., skin, lung, liver, kidney, intestines).65–67 In these tissues, pre-DCs differentiate further 
into conventional DCs, with the superior potential to process and present antigen, migrate 
to lymph nodes in steady and inflamed states, and prime naïve T cell responses. 
Traditionally, expression of MHCII and integrin alpha X chain (i.e., CD11c) have been 
used to define cDCs. However, with the advent of multiparameter flow cytometry, CyTOF 
technology and RNA sequencing, it has become evident that these markers alone are not 
sufficient for precisely identifying cDCs, as the molecules are shared by multiple 
macrophage subsets.64 Conventional DCs have been grouped into two main subsets, cDC1 
and cDC2, which can be further subdivided based on additional surface markers and the 
tissues in which they reside.  
In all tissues, the cDC1 subset is highly proficient at cross-presenting exogenous peptides 
on MHC-I molecules to activate CD8+ T cells and induce cytotoxic immune responses. 
  
 27 
cDC1 in the spleen and dermis also are a critical source of IL-12, which is required for 
differentiation of CD4+ T cells into Th1 cells.68,69 Transcription factors Batf3, ID2, Nfil3, 
and Irf8 are all involved in cDC1 development and survival. Short-term development of 
cDC1 was observed in the absence of ID2, Nfil3, and Batf3, suggesting that Irf8 is the 
master regulator of cDC1 lineage development.70 Even so, Baft3-/- mice are deficient in 
cDC1 and show no changes in cDC2 populations.71 Due to cDC1 deficiencies in the dermis 
and secondary lymphoid tissues, Baft3-/- mice are unable to mount CD8+ T cell responses 
against influenza virus and West Nile virus, and fail to generate adequate Th1 responses 
against Toxoplasma gondii and Candida albicans.68,69,72,73 In mice, all cDC1 tissue subsets 
express Clec9A, CD24, DEC-205, and XCR1. Several studies have shown that TLR3 is 
preferentially expressed in cDC1 and promotes cross-presentation.74 In the skin, lung, and 
intestine, cDC1 express CD103 and are CD11b-/lo, while lymphoid cDC1 are CD8α+ and 
CD103+/-. CD103+CD8α+ lymphoid cDC1 are not well characterized but have been found 
in the marginal zone of lymph nodes as well as in intestinal draining lymph nodes (i.e., 
mesenteric LNs).75–78 The human homolog to mouse cDC1 are CD141+BDCA-3+ DCs.79 
In contrast with cDC1, cDC2 subsets excel at activating CD4+ T cells and inducing Th2 
and Th17 responses due to increased expression of proteins involved in MHC-II 
processing.79,80 Studies have shown cDC2 were required for Th2 responses against 
Schistosoma mansoni and dust mite allergens as well as Th17 responses against Aspergillus 
fumigatus infection in the lung.81–83 Dermal cDC2 produce the vitamin A metabolite 
retinoic acid, which promotes the generation of Foxp3+ regulatory T cells.84 Activation of 
lymphoid CD4+ cDC2 with TLR7 agonists can induce secretion of type I associated 
cytokines, and antigen targeting via DCIR2 in combination with TLR3 agonist poly(I:C) 
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elicits protective CD8+ T cell responses against tumors.85,86 cDC2 are the most abundant 
type of DC in the skin and share many phenotypical characteristics with macrophages and 
monocyte-derived DCs, especially in a state of inflammation.87 cDC2 are distinguished 
from other APCs based on their expression of IRF4, CD11b, and CD172a (SIRPα). Irf4-
deficient mice completely lack cDC2 in some tissues, while in other tissues cDC2 are short-
lived and cannot migrate to draining lymph nodes.64,88 According to one study, a group of 
migratory cDC2 known as CD301b+ DCs were required for transporting antigen injected 
subcutaneously with Th2-type adjuvants.89 Depletion of CD301b+ DCs led to decreased 
expression of CD69 by CD4+ T cells in lymph nodes, dampened IL-4 production by OVA-
specific OT-II transgenic CD4+ T cells, and impaired Th2 cell development upon infection 
with Nippostrongylus brasiliensis. Surprisingly, depletion of CD301b+ has also enhanced 
the development of T follicular helper (Tfh) cells, germinal center B cells, and antibody 
responses against protein antigens. CD301b+ also express high levels of programmed death 
ligands PD-L1 and PD-L2, and blocking these ligands also suppressed Tfh cells.90 
2.3.2 Monocyte-derived DCs 
Unlike cDCs which arise from pre-DCs, monocyte-derived DCs (mo-DCs) differentiate 
from Ly6Chi monocytes recruited to tissues in response to inflammation; therefore, they 
are also referred to as inflammatory DCs. During differentiation, mo-DCs gradually lose 
Ly6C expression while acquiring MHC-II expression, and are difficult to distinguish from 
macrophages because they share the receptors F4/80, CD64, CD11b, and CD206.91 The 
function of mo-DCs in regulating adaptive immunity is not clear-cut. Research has shown 
that mo-DC are inferior to cDC2 in migrating to lymph nodes and activating T cells after 
stimulation with the hapten dinitrofluorobenzene, yet mo-DCs are required for the 
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activation of CD8+ tissue resident memory (Trm) cells after HSV-1 infection.87,92 One 
study found after subcutaneous immunization with fungal antigens, Ly6C+ Mo-DCs were 
the first antigen-bearing cells to reach lymph nodes, but failed to prime T cells. It was 
proposed that migrating mo-DCs transfer antigen to lymph node-resident cDCs, which 
subsequently induce T cell proliferation.93 In some inflammatory settings, mo-DCs become 
TNF- and iNOS-producing DCs (i.e., Tip-DCs) with potent antimicrobial effector 
functions. Tip-DCs were found to be essential for clearing bacterial infection but not for T 
cell priming.94 A recent work has suggested that Ly6C+ monocytes can enter steady-state 
non-lymphoid tissues, upregulate MHC-II expression, and migrate to lymph nodes without 
differentiation to macrophages or DCs.95   
2.3.3 Plasmacytoid DCs 
Plasmacytoid DCs are a rare, long-lasting population of immune cells that make up 0.3-
0.5% of human PBMCs. They are the primary producers of type I interferon (IFN-α, IFN-
β) during a viral infection and secrete up to 1000x more IFN compared to other cell types. 
pDCs also secrete TNF-α and IL-12. pDCs effectively couple viral recognition by TLRs 
(TLR7, TLR9) and RLRs to the production of interferon, which is generated by infected 
pDCs or uninfected pDCs detecting virus from neighboring cells. IFN-α secretion in 
response to TLR9 ligand CpG is mediated exclusively by pDCs. The most documented 
phenotype of pDCs is a high expression of B220, low to moderate expression of MHC-II, 
and low to negative expression of CD11c. Humans pDCs express ILT7, IL3Rα, BDCA-4, 
and inhibitory receptor BDCA-2. Mouse pDCs express receptors Siglec-H (inhibitory), 
Bst2 (i.e., CD317/PDCA-1), and Ly49Q, as well as signaling protein IRF7 and 
transcription factor Runx2. Receptor Ly49Q was found to be required for optimal IFN 
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production in pDCs, while Bst2 is an IFN-inducible membrane protein that direct inhibits 
viral replication. pDCs are directly recruited from blood to lymph nodes through expression 
of CXCR3, which is a chemokine receptor for T cell-produced chemokines CXCL9, 
CXCL19, and CXCL11.  
pDCs are known to present antigen to T cells and upregulate costimulatory molecules in 
the presence of viral PAMPs and antigens. It is hypothesized that pDC IFN secretion and 
pDC maturation may be separate fates of pDCs, and pDCs differentiate into CD8α+ cDCs 
in the lymph node upon viral activation. During pDC activation, E2-2 expression is 
downregulated, while Id2, a transcription factor of cDC1, is upregulated. Mature pDCs 
prime CD8+ T cells as well as CD4+ T cells and induce Th1 polarization. pDC activity in 
humans has been most studied in cases of HIV and Hepatitis C infection. pDCs respond to 
HCV hepatocytes through TLR7 and RIG-I signaling. In the case of HIV, the virus infects 
pDCs and drives IFN secretion, which may cause T cell hyperactivation and depletion and 
contribute to immunodeficiency. It is also hypothesized that HIV infects and depletes pDCs 
or infected pDCs pass on virus to T cells, leading to poor cellular immune responses. In a 
mouse model of lung RSV, pDC depletion leads to increases in viral titers and exacerbated 
tissue pathology, and while in a model for hepatitis virus, pDC depletion nearly abolishes 
IFN response to MHV, which requires TLR7 signaling and type I interferon for viral 
clearance. 
2.3.4 Macrophages   
Macrophages are highly phagocytic cells that primarily reside in tissues. Different 
inflammatory stimuli cause macrophages to modify their metabolic function and polarize 
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toward a M1 or M2 phenotype.96 M1 macrophages are key effector cells for eliminating 
pathogens, infected cells, and cancer cells. M1 macrophages produce toxic molecules (e.g., 
ROS and NO), proinflammatory cytokines (e.g., IL-1β, TNF-α, and IL-6), as well as 
Th1/Th17-polarizing cytokines (e.g., IL-12, IL-23). M2 macrophages maintain tissue 
integrity by eliminating or repairing damaged cells and tissue matrices. M2 macrophages 
produce ornithine, which promotes cell proliferation and tissue repair through polyamine 
and collagen synthesis, or fibrosis. There are distinct macrophage populations that load 
extracellular antigen onto MHC-II, upregulate costimulatory molecules CD80/CD86, and 
prime CD4+ T cells toward a Th1/Th2 phenotype.97 DCs may be more efficient at activating 
T cells because they have limited lysosomal proteolysis compared to macrophages, 
preventing internalized antigens from being degraded prior to encountering T cells in the 
lymph node.98 
Tissue macrophages have a dual origin involving both embryonic and adult hematopoiesis. 
Some macrophages, including liver Kupffer cells and brain microglia are established prior 
to birth and self-renew without adult hematopoiesis. Other macrophages, particularly those 
in the lamina propria of intestines or red pulp of the spleen, continuously derive from 
circulating Ly6Chi monocytes. Due to their overlapping phenotypes, it is difficult to 
distinguish macrophages from cDC2 and mo-DCs within most tissues and evaluate their 
exact contribution to immune responses. Markers used to differentiate macrophages 
include CD11b, CD14, CD68, CD64, CD115, EMR-1 (human), F4/80 (mice), and CD206 
(M2 Mφ). Macrophages also express low to intermediate levels of CD11c and MHCII.  
There are many tissue-specific macrophage subsets with unique functions. The lymph node 
sinus is lined with CD169+CD11b+CD11clo macrophages that prevent systemic 
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dissemination of pathogens by clearing microbes entering the afferent lymph. They have 
low endocytic potential, and therefore retain antigen on their surface and promote antigen 
presentation of viral antigens to B cells.99 Medullary macrophages efficiently phagocytose 
and degrade opsonized antigens and particulates from the lymph. Alveolar macrophages, 
previously thought to be restricted to the alveoli, have been discovered transporting antigen 
from the lung to draining lymph nodes immediately following exposure to Streptococcus 
pneumonia.100  
2.3.5 B Cells 
B cells develop in the bone marrow and continuously circulate through secondary 
lymphoid organs. They enter lymph nodes through HEVs and localize within the cortical 
region near the subcapsular sinus. Though many antigens do not enter the body as soluble 
molecules during an infection, there are some natural immunogens that do, including: 
insect toxins, anti-coagulants, snake venoms, and many allergens.22 B cells are uniquely 
adapted to bind to specific soluble molecules through their cell-surface immunoglobulin 
(Ig). There is also evidence they can pick up antigen from other APCs in the lymph node, 
including subcapsular sinus macrophages and follicular dendritic cells.99,101 B cells are able 
to internalize molecules and form peptide:MHCII complexes, which they constitutively 
express, allowing them to be targeted by antigen-specific CD4+ T cells. They also can 
upregulate costimulatory molecules in the presence of microbial stimuli. Dendritic cells 
play a larger role than B cells in priming naïve T cells because they have a greater capacity 
for endocytosing, degrading, and processing whole pathogens for acquiring peptide 
antigens. DCs also have a broader range of MHC molecules and antigen specificity and 
therefore are more likely to be recognized by a wide range of T cells. After T cells have 
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been activated and undergone clonal expansion, the chances of encountering a matching 
antigen-specific B cell greatly increase.  
2.3.6 In Vitro Models of APCs 
In 1992, Inaba et al. published a novel method for generating DCs from murine bone 
marrow cultures with GM-CSF.102 Shortly thereafter, Sallusto et al. reported that a 
combination of GM-CSF and IL-4 was most efficient at differentiating human peripheral 
blood monocytes into DCs with high expression of CD1, MHC-II, and costimulatory 
molecules.103 Ever since there has been speculation on whether IL-4 is necessary to induce 
DC maturation in murine bone marrow cultures, and numerous studies on DC behavior in 
vitro have been completed with BMDCs generated with GM-CSF alone or with IL-4.104,105 
There was a recent study demonstrating both GM-CSF and GM-CSF+IL-4 cultures contain 
not only conventional DCs, but monocyte-derived macrophages as well.106 In 2000, Brasel 
et al. developed a FLT3L-dependent bone marrow culture system that generated cells 
sharing morphological characteristics with a more diverse range of DC subsets, including 
pDCs and lymphoid tissue-resident cDCs.107 
2.4 PRR Agonists as Vaccine Adjuvants 
Many pathogens can be eliminated by host immunity but there are some dedicated 
pathogens that have developed highly specialized mechanisms for evading immune 
responses, as well as eliciting host responses that contribute to their survival and 
replication. Therefore, they require help from treatments specially designed to prevent 
infection, primarily vaccines. Today there are several different types of vaccines, including 
those with live-attenuated pathogens, inactivated/killed pathogens, or inactivated toxins. 
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Comprised of recombinant proteins or synthetic peptides, subunit vaccines offer 
advantages over live-attenuated and inactivated vaccines in terms of safety, ease of 
manufacture, and precise immune targeting. However, the purified protein-based antigens 
in subunit vaccines require additional material that trigger the nonspecific innate immune 
signaling pathways that precede antigen-specific immune responses. The immunogenic 
supplement is termed an adjuvant, from the Latin word adjuvare meaning ‘to help,’ 
because it enhances the response to an antigen.  
In the 1920s the first adjuvant included in a human vaccine was aluminum salt (i.e., alum), 
which remains the most popular adjuvant in use today. Alum mainly stimulates Th2 
immune responses, potentiating IgG1 and IgE antibody production, which does not confer 
the best protection for viral infections, including HCV and HIV.55 Other well-established 
adjuvant are AS03 and MF59®, squalene-based oil-in-water emulsions that trigger 
balanced Th1/Th2 responses and are currently used in influenza vaccines.108 The precise 
modes of action of alum and emulsion-based adjuvants remain unclear, but the most widely 
accepted theory is they form a “depot effect” and retain antigen at the injection site to 
prolong immune responses. Another hypothesis is  alum activates the Nalp3 inflammasome 
pathway to promote Th2 immunity.109 The current challenge is to develop adjuvants with 
well-defined mechanisms of action that induce strong Th1 and CTL-mediated immune 
responses, which is important for developing vaccines to protect against cancer and 
infectious diseases such as HIV or dengue.110–112 PRR activation triggers production of 
pro-inflammatory cytokines and type I interferons that coordinate the elimination of 
pathogens and infected cells; therefore, natural and synthetic PRR ligands have the 
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potential to be effective vaccine adjuvants. A number of these agonists are approved for 
use, in clinical trials and in late preclinical stages of development. 
2.4.1 Monophosphoryl Lipid A (TLR4) 
The intact molecule of TLR4 ligand, LPS, is toxic and not suitable for use as a vaccine 
adjuvant.34 MPLA is derived from the bacterial cell wall of Salmonella Minnesota and 
detoxified by mild hydrolytic treatment. It was the first defined TLR ligand to be used in 
licensed vaccines and achieve clinical and regulatory success. It is a component in two 
approved adjuvant systems developed by GlaxoSmithKline: 1) AS01, a liposome-based 
adjuvant containing 3-O-desacyl-4’-MPLA and saponin QS-21, and used in the malaria 
vaccine, RTS,S (Mosquirix) and 2) AS04, an adjuvant combining MPLA with aluminum 
salt, and currently used in vaccines against HPV (Cervarix) and HBV (Fendrix).10,113,114 
Preclinical and clinical studies have shown MPLA improves Th1 immunity and induces 
production of IgG2a antibodies.115 Fendrix with AS04 induced higher seroprotection rates 
and antibody titers compared to licensed, alum-based HBV vaccine Engerix-B® in clinical 
trials and required one less shot; it is now approved in Europe.34 Cervarix with AS04 
induced significantly higher anti-HPV16 and anti-HPV18 L1 antibody responses compared 
to the same vaccine with alum.116 MPLA has also been evaluated in clinical trials as a 
vaccine adjuvant against many types of cancers, including melanoma (Melacine™), 
colorectal carcinoma, and prostate cancer (OncoVax-P).117  
2.4.2 Imiquimod and Resiquimod (TLR7/8) 
Imidazoquinolines imiquimod (R837, TLR7 agonist) and resiquimod (R848, TLR7/8 
agonist) have primarily been investigated for use as topical agents to treat skin conditions 
  
 36 
and cancer. Imiquimod (brand name Aldara™, 3M) is currently licensed for topical use to 
treat anogenital warts, superficial basal cell carcinoma and precancerous growths (actinic 
keratoses).118 Imiquimod has been tested in Phase I/II clinical trials with cancer vaccines 
against chronic myeloid leukemia, vulval cancer, and prostate cancer.119–121  Skin biopsies 
in a clinical trial for an intradermal melanoma NY-ESO-1 subunit vaccine showed 
imiquimod significantly enhanced infiltration of T cells, APCs, and NK cells.34,122 
Resiquimod was also evaluated as topical adjuvant for NY-ESO-1 protein vaccines and 
induced strong CD4+ T cell responses in the majority of patients, as well as CD8+ T cell 
responses in some patients.123 Generally, topical administration of imidazoquinolines is 
well tolerated, but severe side effects arise with oral or systemic use in humans. In a clinical 
study of oral resiquimod for treating chronic HCV infection, subjects receiving 0.2 mg/kg 
of resiquimod reported adverse events including fever, headache, shivering and 
lymphopenia. This was due to the high secretion of IFN-α, which correlated with decreases 
in viral titer as well as lymphocyte counts, and increases in neutrophil counts.124 Repeated 
application of imiquimod can also lead to psoriasis-like skin inflammation, propagated by 
cDC2 and double-negative DCs that secrete IL-23 and γδ T cells secreting IL-17.125 If 
imidazoquinolines are to be administered non-topically, delivery  will have to be optimized 
to prevent systemic toxicity and adverse effects. 
2.4.3 CpG Oligodeoxynucleotides (TLR9) 
CpG ODNs are short synthetic single-stranded DNA molecules containing unmethylated 
CpG motifs. They are composed of phosphorothioate nucleotides, which are more resistant 
to nucleases than natural phosphodiester nucleotides found in genomic bacterial DNA.34 
There are three types of CpG ODN, including Class A (Type D), Class B (Type K) and 
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Class C. CpG-A ODNs possess a mixed phosphodiester/phosphothioate backbone and 
contain a single CpG motif flanked by palindromic sequences and 3’ poly-G string. They 
trigger high production of IFN-α by pDCs but are weak stimulators of TLR9-dependent 
NF-κB signaling and proinflammatory cytokine production. CpG-B ODNs contain one or 
more CpG dinucleotides on a phosphorothioate backbone. They efficiently stimulate B 
cells to produce IgM and IL-6, and trigger pDC to produce TNF-α but weakly stimulate 
IFN-α secretion. CpG-C ODNs also contain a complete phosphorotioate backbone like 
CpG-B ODNs and palindromic CpG motif like CpG-A ODNs. They induce strong IFN-α 
production by pDCs and stimulate B cells. CpG ODN-driven activation of CD8+ T Cells is 
stronger in mice compared to humans, which may be because TLR9 expression in humans 
is restricted to pDCs and B cells while in mice, TLR9 is also expressed on cross-priming 
cDCs.126 Clinical trials examining TLR9-based adjuvants have focused on CpG-B ODN, 
including vaccine trials for malaria, influenza, and anthrax.127–130 In 2017, Heplisav-B, a 
vaccine that contains CpG 1018, was approved by the FDA for the prevention of Hepatitis 
B in people 18 years and older.11 
2.4.4 RIG-I-Like Receptor Ligands 
RLR agonists trigger antiviral immunity and have the potential to be used as pan-antivirals, 
vaccine adjuvants and antitumor agents. SB9200 is a nucleotide-based RLR ligand that has 
been tested in clinical trials for treating chronic Hepatitis B and Hepatitis C. Used in 
combination with Entecavir, SB2900 reduced viremia and delayed recrudenscence of viral 
replication in woodchucks infected with woodchuck hepatitis virus (WHV).131 5’pppRNA 
confers protection again vesicular stomatitis virus, vaccinia virus, and dengue virus in lung 
epithelial cell culture (A549), and treating mice with 5’pppRNA prior to influenza virus 
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challenge reduces incidence of pneumonia.132 5’pppRNA with a uridine-rich sequence and 
99-nucleotide hairpin (M8) specifically activates RIG-I and was used in conjunction with 
virus-like particles expressing H5N1 hemagglutinin and neuraminidase proteins.133  
Vaccination with M8 increased the survival rate of H5N1-challenged mice, simulated Th1 
immunity, and generated higher antibody titers than other adjuvants, including alum, 
AddaVax, and Poly(I:C).134  
2.4.5 Combination Adjuvants 
There are a few FDA-approved combination adjuvants containing PRR ligands - for 
example, AS01 and AS02 contain MPL and QS-21 while AS04 is MPL adsorbed onto 
aluminum salts.135 Live-attenuated tuberculosis vaccines BCG and CADI-05 target 
TLR2/TLR4 and TLR2/NOD2, respectively; however, live-attenuated vaccines have a 
lower safety profile for patients and manufacturers.136,137 To date there are no approved 
combination adjuvants with two or more non-endogenously expressed PRR ligands that 
could be used with subunit or nucleic acid-based vaccines.  
There have been multiple preclinical studies with combinations of PRR agonists. Early in 
vitro studies conducted by Napolitani et al. revealed stimulation of human mo-DCs TLR4 
and TLR7 agonists enhanced proinflammatory cytokine production compared to 
stimulation with single TLR agonists.13 Another study showed IL-12p70 production by 
human PBMCs required combined stimulation of TLR7/8 with TLR4 or TLR3.138 The 
stimulation of GM-CSF/IL-4 BMDCs on TLR3 and TLR7/8 agonists enables induction of 
CTL-mediated responses against colon tumor cells in mice, while stimulation of TLR2 plus 
TLR3 on FLT3L BMDCs enhances CD4+ and CD8+ T cell immunity against tumor 
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challenge.17,139 CD8+ T cell responses are enhanced by targeting DNA-encoded antigen 
HIV-1 Gag to DEC205 on APCs with CpG and Poly(I:C), and simultaneous administration 
of TLR2, TLR3, and TLR9 ligands increased CD8+ T cell responses and conferred 
protection against HIV challenge in mice.140,141 Combination adjuvants also improve 
humoral responses. Carter et al. observed the highest diversity of antibody responses 
against Plasmodium vivax antigen PvRII was observed in animals immunized with 
vaccines containing both TLR4 and TLR7/8 agonists.142 
2.5 Vaccine Delivery to Lymph Nodes 
2.5.1 Particle-Based Vaccine Delivery 
There are major deficiencies associated with using soluble antigens and adjuvants for 
immunization including their vulnerability to extracellular protease degradation, rapid 
lymphatic clearance, and high levels of systemic exposure and toxicity.143,144 Delivering 
soluble adjuvants limits their effective dosages and ratios in formulation, preventing 
optimal stimulation of immune cells at the site of injection.145 To synergize innate immune 
cell activation with antigen uptake, adjuvants and antigens are strategically co-delivered in 
the same vector.  
Poly(lactic-co-glycolic acid) (PLGA) particles are popular vaccine delivery vehicles 
because they allow for both encapsulation and surface loading of antigens and adjuvants. 
PLGA is biodegradable, so contents are slowly released over time at the site of injection to 
sustain immunity over a longer period.146 Scaling the size of particles to mimic pathogens 
is an approach to trigger endocytosis by specific APC subsets and downstream immune 
signaling pathways. For example, Leleux et al. studied how PLGA particle size influenced 
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DC subset migration to dLNs using 250 nm-sized particles to mimic the size of large 
viruses (200-300 nm) and 1 µm-sized particles to mimic bacteria (1-2 µm). They observed 
nanoparticles preferentially activated CD103+ cDC1, a hallmark of viral infection.147  
There is a significant amount of literature on how size affects particle trafficking to dLNs 
through passive drainage or immune cell-mediated transport.148–150 After subcutaneous or 
intradermal injection, particle vaccines in the 20 to 100 nm size range preferentially drain 
to lymph nodes while smaller molecules disseminate to systemic circulation and larger 
particles stay in the tissue.146 Particles 20-50 nm are less hindered by convection through 
the ECM due to its mean mesh size of 50 nm.151 This concept was recently challenged by 
published work showing rapid lymphatic drainage (seconds to minutes) of 1 µm-diameter 
microspheres. They attributed the phenomena to breaches of peripheral skin that occur 
during common microbial infections and are independent of injection-induced 
hydrodynamic fluxes.148 
2.5.2 Dendritic Cell Migration Through Lymphatic Vessels 
Lymphatic endothelial cells (LECs) secrete chemokines CCL19 and CCL21 and express 
adhesion molecules (e.g., ICAM-1 and E-selectin) to guide DC migration from lymphatic 
capillaries to dLNs. CCL19 and CCL21-Ser are secreted by LECs and stromal cells in the 
thymus and secondary lymphoid organs, while CCL21-Leu is secreted by LECs in 
peripheral tissues. CCL19 is also secreted by mature DCs during autocrine signaling.152,153 
These chemokines bind to DCs through receptor CCR7, which has been implicated in a 
diverse set of immune signaling pathways including: the survival of mature DCs, the 
polarization of Th17 cells by splenic DCs, the activation of endocytosis and migration of 
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mature DCs, and the proliferation and increased antigen presentation by BMDCs.154 
Structurally, CCL21 differs from CCL19 because it has an extra 32 amino acid C-terminus 
of basic amino acids and the CCR7 pathway is reported to be differentially regulated by 
the two ligands. For example, CCL19 inducing a higher PIK3R1 and AKT1 activation in 
mature DCs compared to CCL21.155  
A study by Johnson et al. observed that DC migration in steady state is predominantly 
controlled through chemotactic gradients, while in an inflammatory state DC migration is 
β2-integrin dependent. During inflammation, TNF-α is secreted in the periphery and 
stimulates a rapid burst of CCL21 released by LECs, as well as upregulation of ICAM-1 
and VCAM-1. They hypothesize CCR7 signaling enhances the affinity of LFA-1 on DCs 
for ICAM-1, suggesting a synergistic mechanism to facilitate DC homing to dLNs during 
inflammation.156 Vaahtomeri et al. observed physical contact between DCs and the 
lymphatic endothelium is necessary to trigger calcium signaling and release of CCL21 
from intracellular vesicles from LECs. This enriches CCL21 at endothelial cell-cell 
junctions and creates a positive feedback loop recruiting more DCs toward lymphatic 
vessels.157 
2.6 Adjuvants in SARS-CoV-2 Vaccines 
Coronaviruses are enveloped positive-sense single-stranded RNA viruses. SARS-CoV-2 is 
a novel coronavirus that is highly transmissible and causes coronavirus disease 2019 
(COVID-19), which manifests as mild symptoms to severe respiratory illness in humans.158 
The club-like spike (S) protein of SARS-CoV-2 recognizes and binds to host cell receptor 
angiotensin-converting enzyme 2 (ACE-2). The S protein is composed of two subunits, S1 
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and S2. The S1 subunit contains a receptor-binding domain (RBD) that binds to ACE-2 
while S2 mediates membrane fusion and entry into the host cell.159 The S protein is the 
most common antigen included in SARS-CoV-2 vaccine candidates, and most neutralizing 
antibodies developed against the virus react to the RBD of the S protein. The nucleocapsid 
(N) protein is also highly conserved and has been shown to induce cytotoxic T 
lymphocytes; however, the N protein also triggers pro-inflammatory cytokine production 
(cytokine storm) and leads to severe lung pathology.160 
There are currently approved SARS-CoV-2 vaccines that induce potent immunological 
responses without additional adjuvants. For example, the adenovirus vector vaccine by 
Johnson & Johnson endogenously expresses viral proteins that stimulate PRRs, while the 
nucleic acids in the Moderna and Pfizer mRNA vaccines intrinsically engage innate 
immune receptors. A few adjuvants have been formulated for subunit or inactivated 
antigens including aluminum salts, emulsions, and TLR agonists.161 PiCoVacc, an 
inactivated SARS-CoV-2 virus vaccine, was administered with alum in rhesus macaques 
and was successful in producing anti-S protein, anti-RBD, and anti-N protein IgG titers; 
however, CD4+ and CD8+ T cell activation and expansion did not occur up to 29 days 
after vaccination.162 Inactivated vaccine candidate, BBIBP-CorV, delivered with alum was 
successful at producing neutralizing antibody titers and protection against SARS-CoV-2 in 
macaques but also failed to induce T cell responses.163 Alum has also been combined with 
S protein subunit vaccines and plays a role in dose-sparing. In mice, an alum-adjuvanted 
5-µg S protein subunit vaccine produced twice as many neutralizing antibodies as the non-
adjuvanted 50-µg S protein subunit vaccine.164 Emulsion adjuvants, including MF49 and 
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AS03, elicited both humoral and cellular immune responses to MERS-CoV inactivated and 
subunit vaccines.165,166 
Positive-sense single-stranded RNA viruses interact with TLR7 and TLR8, and produce 
dsRNA replication intermediates that are recognized by RIG-I and TLR3.167–170 TLR2 
(dimerized with TLR1 or TLR6) and TLR4 have also exhibited potential to recognize viral 
proteins; in fact, SARS-CoV-2 S protein reportedly induces TLR4 signaling.171–173 Zhao et 
al. evaluated the immune responses of peptide-specific CD8+ T cells induced by HLA-
A*0201-restricted SARS-CoV S epitopes combined with TLR-targeted adjuvants CpG 
ODN, Poly(I:C), and R848 in mice.174 Results showed that the frequency of SARS-CoV S 
peptide-specific IFN-γ+ CD8+ T cells, which showed a memory phenotype 
(CD45RB+CD62L-), was the highest in response to S peptides plus CpG ODN. CpG also 
enhances IgG production in animals immunized with inactivated SARS-CoV vaccine.175 
Langellotto et al. reported single-shot biomaterials-based subunit vaccines consisting of 
GM-CSF, MPLA, and SARS-CoV-2 antigens in mesoporous silica rods rapidly generated 
antibodies against SARS-CoV-2 S1, S2, and N proteins with neutralizing activity.176 
Research on PRR-targeted combination adjuvants with SARS-CoV-2 antigens is limited.  
Liu et al. recently reported lipid nanoparticle-based subunit vaccines co-delivering S1 
protein antigen, MPLA, and CpG elicited stronger CD4+ and CD8+ T cell responses in 
mice than unformulated S1, MPLA, plus CpG, or unformulated S1 plus alum.177 The 
objective of Aim 2 in this thesis is to investigate PRR-targeting combination adjuvants 




CHAPTER 3: AIM 1.1. INVESTIGATING HOW SOLUBLE AND 
PARTICLE-BASED DELIVERY OF MPLA AND CPG 
DIFFERENTIALLY MODULATE 3D CHEMOTAXIS OF BONE 
MARROW-DERIVED DENDRITIC CELLS 
To rationally design a vaccine that enhances DC-mediated delivery to the lymph 
node, there is a need for more research into how adjuvants and other vaccine components 
(e.g., vaccine delivery carriers) influence DC migration. For example, there have been 
reports showing Th2 immunization (OVA with papain) promotes the migration of 
CD301b+ DCs while Th1 immunization (OVA plus LPS and poly(I:C)) promotes the 
migration of CD103+ dermal DCs.178,179 The combination of TLR agonists MPLA (TLR4 
ligand) and CpG DNA (TLR9 ligand), both expressed on gram-negative bacteria, have 
been reported to synergistically enhance DC maturation and humoral 
responses.13,145,180,181 Here we assessed whether MPLA and/or CpG, delivered 
unformulated (herein referred to as “soluble” adjuvant) or on PLGA MPs, stimulates mouse 
BMDC 3D migration toward CCL19 and CCL21 in a device that maintains a stable 
gradient for up to 24 hours. We developed a logistic regression model to filter high volumes 
of cell tracking data and identify migratory cell tracks, and then applied circular statistical 
methods to compare the directionality of cell migration toward CCL19 and CCL21 
gradients under different adjuvant conditions. Ever since the BMDC differentiation method 
with GM-CSF was published, there has been speculation on whether IL-4 is necessary to 
induce DC maturation.102 Therefore, we sought to confirm whether IL-4 is essential for 
induction of CCR7 expression and migration of GM-CSF-cultured cells. Additionally, we 
characterized monocyte, macrophage, and DC populations in BMDC culture and their 
relative CCR7 expression in response to MPLA and CpG.  
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3.1 Materials and Methods 
3.1.1 Bone marrow-derived cells (BMDCs) 
All animal experiments were conducted in accordance with protocols approved by the 
Institutional Animal Care and Use Committee (IACUC) at Georgia Institute of 
Technology (Protocol reference #A100207). Bone marrow was collected from femurs and 
tibiae of female C57BL/6J mice 5 to 10 weeks old (Jackson Laboratory). Red blood cells 
were lysed with RBC Lysis Buffer (Invitrogen), and remaining cells were plated at 1 
million cells/mL in 12 mL RPMI complete medium (Gibco) in a 100-mm tissue culture-
treated petri dish (Corning). RPMI complete medium contained characterized fetal bovine 
serum (10% v/v) (HyClone), penicillin-streptomycin (1% v/v) (HyClone), sodium 
pyruvate (1 mM) (Gibco), MEM non-essential amino acids (1X) (Gibco), 2-
mercaptoethanol (55 µM) (Gibco), GM-CSF (20 ng mL-1) (Peprotech), and IL-4 (10 ng 
mL-1) (Peprotech). GM-CSF-only BMDCs were prepared identically except without IL-4 
in the media. Cells were cultured in a humidified incubator at 37°C with 5% CO2. Half of 
the media (6 mL) was removed and replaced with fresh media on days 2 and 4. Half of the 
media volume (6 mL) was added on day 6 (for total of 18 mL) with cytokine concentrations 
maintained. Loosely adherent cells were collected by vigorous pipetting on days 6-7 for 






3.1.2 Synthesis of PLGA Microparticles 
PLGA microparticles (PLGA – Resomer 502H, Sigma Aldrich) were synthesized using a 
water-oil-water double emulsion, solvent evaporation method previously published.182–184  
MPLA (Lipid A Purified/Detoxified from Salmonella minnesota R595, Avanti) was 
encapsulated in particles (1 µg MPLA per mg PLGA). Particles were modified with 70,000 
MW, 30% w/v branched polyethylenimine (PEI, VWR) to create cationic particles, 
followed by electrostatic adsorption of Class B CpG ODN 1826 (Invivogen) (10 µg CpG 
per mg PLGA MP). To characterize PLGA MPs, size and zeta potential were measured 
with dynamic light scattering (Malvern Zetasizer Nano) (Figure S1).  
3.1.3 Flow Cytometry Experiments 
Loosely adherent BMDCs cultured for 6-7 days as described above were collected from 
petri dishes and replated in 12-well plates with fresh RPMI complete media (1 million cells 
mL-1, 1 to 1.5 million cells per well) containing adjuvants either in soluble form or loaded 
onto PLGA MPs. Soluble (unformulated) MPLA was pre-diluted in DMSO and added to 
media at a final concentration of 50 ng mL-1 and/or soluble CpG DNA was pre-diluted in 
DNAse-free water and added to media at a final concentration of 500 ng mL-1. PLGA MPs 
were concentrated in media (50 μg mL-1) with particulate adjuvant doses equivalent to 
soluble adjuvant doses. BMDCs were incubated with soluble or PLGA MP-loaded 
adjuvant overnight at 37°C and 5% CO2, and then collected for flow cytometry analysis 




Figure 6: Antigen-presenting cell migration toward lymphatic chemokine gradients in vivo 
and in vitro in response to soluble and particulate adjuvants. A) Schematic of antigen-
presenting cells (APCs) endocytosing particulate vaccines, causing them to activate and 
follow a CCL21 gradient toward lymphatic vessels in the dermis. Arrows represent 
differentiation. B) Depiction of lymph node chemokine gradients and antigen presentation 
by APCs in the T cell zone. CCL21 (blue gradient) is secreted by LECs in afferent vessels 
and CCL21 and CCL19 (red gradient) are secreted by LECs and stromal cells in the node. 
APCs follow gradients through the subcapsular sinus to the paracortex (T cell zone), where 
they present antigen to T cells. Monocytes are shown differentiating to inflammatory DCs 
in both the dermis and the lymph node. C) Adjuvant loading scheme on PLGA MPs. MPLA 
is encapsulated during PLGA MP synthesis. PEI is conjugated to the surface through a 
sulfo-NHS plus EDC crosslinking reaction. Positively charged PEI enables electrostatic 
loading of CpG DNA to the particle. D) Setup of microfluidic device for study of BMDC 
migration in response to adjuvant. DCs are loaded in a central collagen matrix channel 
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while chemokine is diluted in media in the left-hand chamber. Soluble adjuvant is diluted 
in media in both chambers and diffuses through the collagen matrix, while adjuvanted 
PLGA MPs are mixed with cells in the collagen matrix. A-D) Created with ©BioRender - 
biorender.com. 
 
Cells were collected in flow tubes or V-well plates (for HTS) and washed with PBS, 
centrifuged at 500xg for 5 minutes, then resuspended in Zombie Green (Biolegend, 20 
minutes RT, 1:1000 dilution in PBS) for labeling of dead cells. Cells were washed with 
FACS buffer (1% BSA, 0.1% sodium azide, 0.5 mM EDTA in PBS) and blocked with 
FcBlock (TruStain FcX anti-mouse anti-CD16/CD32, Biolegend, 1:100 dilution) for 30 
minutes at 4°C prior to adding the fluorescent antibody cocktail: anti-Ly6C (clone HK1.4, 
Brilliant Violet 711, 0.125 µg per 100 µL, Biolegend), anti-CD11c (clone N418, Brilliant 
Violet 421, 0.25 µg per 100 µL, Biolegend), anti-CD11b (clone M1/70, BUV395, 0.25 µg 
per 100 µL, Biolegend), anti-CCR7 (clone 4B12, allophycocyanin, 1 µg per 100 µL, 
Biolegend)  anti-MHCII (clone M5/114.15.2, allophycocyanin-Cy7, 0.125 µg per 100 µL, 
Biolegend or PE, 0.02 µg per 100 µL, eBioscience), anti-CD40 (clone 3/23, 0.25 µg per 
100 µL, PE-CF594, BD), anti-F4/80 (clone BM8, PE/Cy7, 0.125 µg per 100 µL, 
Biolegend). Cells were incubated with antibody cocktail for 30 minutes at 37°C, as 
suggested by Biolegend for labeling with anti-CCR7 antibody. Cells were washed with 
FACS buffer and centrifuged at 500 xg for 5 minutes, and then finally resuspended in 
FACS buffer for flow cytometric analysis with the BD LSRFortessa. Flow cytometry data 
analysis was done with FlowJo (BD). Doublets were excluded by gating singlets on SSC-
A vs. SSC-H. Debris was excluded by gating cells on FSC-A vs. SSC-A. Dead cells 
exhibiting high Zombie Green fluorescence were also excluded (FITC vs. SSC-A). Gating 
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for monocytes, macrophages, and DCs depicted in Figure 7. tSNE plots were created in 
FlowJo.  
3.1.4 Microfluidic Device Setup 
Chemotaxis devices (ibidi GmbH) have a central channel (2 mm L x 1 mm W x 0.07 mm 
H) between two 65-µL reservoirs. The collagen gel mixture was prepared according to 
manufacturer’s instructions (Gibco) by mixing collagen (Rat Tail Collagen I, Gibco) with 
10X PBS (Quality Biological), 1N NaOH (Sigma-Aldrich, sterile filtered and suitable for 
cell culture), and cells suspended in RPMI complete medium (described above). The first 
three ingredients were mixed to obtain a pH of 7 and then cells were added to obtain 
concentrations of 1.5 mg collagen and 3 million cells per mL of gel mixture. If PLGA MPs 
were included, they were first suspended with cells at 50 µg MPs (50 ng MPLA and/or 500 
ng CpG) per 3 million cells prior to adding the rest of the gel mixture. Around 20,000 cells 
(6-7μL gel mixture) were loaded into the central channel, and collagen gel polymerized 30 
to 45 min at 37°C. Soluble adjuvants and chemokines were diluted in RPMI complete 
medium prior to filling reservoirs. Soluble CpG and MPLA were first diluted in DNAse-
free water and DMSO, respectively, and then added to media at concentrations of 50 ng 
mL-1 (MPLA) and/or 500 ng mL-1 (CpG). Chemokines CCL19 (9.4 kDa, R&D Systems) 
and CCL21 (12 kDa, R&D Systems) were concentrated in media at 1 µg mL-1 and added 
to the left reservoir (Figure 6D). The filling ports of the left reservoir were plugged while 
filling the right and vice versa, to avoid disturbances in gradients prior to imaging. 
Gradients were established within 1 hour and maintained over a period of 24 hours, 
validated by measuring the gradient of 10,000 MW FITC Dextran (Sigma Aldrich) at 10-
minute increments over 24 hours and plotting the fluorescence vs. the position over the 
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width of the channel (Figure S2). Chemokine gradients were also validated with AF488-
fluorescent CCL19 and CCL21 (AFA488 NHS ester, Lumiprobe), which were stable with 
and without the presence of MPLA and CpG in media reservoirs for at least 18 hours 
(Figure S7). Twelve devices were imaged simultaneously with phase contrast microscopy 
using a 4X objective in a humidified chamber at 37°C every 3 minutes for 12-24 hours 
(Lionheart, Biotek). The depth of field for the 4X objective is 50 µm, which is about 72% 
the height of the 3D DC culture channel (70 µm). A Z stack of central gel channel was 
imaged with a confocal microscope to confirm 3D culture (Figure S8). 
3.1.5 Cell Tracking 
Phase contrast images of cells within the central channel were combined into stacks and 
corrected for movement due to stage drift with an ImageJ plugin 
(Template_Matching.jar).185,186 Image sequences were uploaded into Volocity 
Quantitation Software (PerkinElmer), a high-throughput automated cell tracking software. 
Cells were identified by an 8-bit intensity threshold (lower limit 70, upper limit 255). The 
model selected in the software to identify the most likely position for each cell at each time 
point is the Trajectory Variation model with the sensitivity of the algorithm set to “Erratic.” 
The measurements derived from each cell track include distance, displacement, velocity, 
meandering index (displacement divided by distance) and bearing angle (the angle of 
displacement from the origin) (Figure 8A).  
3.1.6 Statistical Analysis 
To estimate regression coefficients for Equation 2, distances, velocities, displacements, 
meandering indices, and bearing angles (cosine values) from one thousand cell tracks 
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observationally categorized as migratory and sedentary were input into MATLAB 
(function mnrfit). To include only migratory cells in analyses evaluating the chemotactic 
response to adjuvants (Figures 9-11), the distance, velocity, displacement, MI, and cos(BA) 
values were input into Equation 2. If the odds ratio was less than 1, the cell was predicted 
to be migratory and included in polar plots (Figure 9C-D, Figure 10A-D, Figure 11A-D) 
and violin plots (Figure 10E-F, Figure 10E-F). For each treatment group (e.g., GM-CSF/IL-
4 BMDCs with CpG MP and CCL19), migratory cell track data from three ibidi chemotaxis 
devices (n=3) was combined into a single polar plot or violin plot. Polar plots of bearing 
angle data (function polarhistogram) and violin plots of meandering index data (function 
violin) derived from migratory cell tracks were generated using MATLAB (The 
MathWorks, Inc.).187 Mean directions and resultant lengths (indicative of variance, as 
length approaches 1, the variance of directions approaches 0) in Figures 10C-D and 11C-
D were calculated with equations defined by Mardia & Jupp.188 The Cox test was used to 
assess whether directional data followed a von Mises distribution, comparable to a normal 
distribution of linear data.188–190 For all cases where the data did not fit a von Mises 
distribution, mean directions were compared using the nonparametric multi-sample method 
for circular data, the Mardia-Watson-Wheeler Uniform Scores Test.188 Post-hoc analysis 
was performed according to methods proposed by Tasdan and Yeniay.191 Statistics on 
circular data are explained further in the Supporting Information section. The two-sample 
Kolmogorov Smirnov test estimated equality between meandering index distributions. For 
Figure 9A-B, data was compiled from two separate flow experiments, each with three 
technical replicates (n=6 for each group). Data was confirmed as normally distributed with 
the D’Agostino and Pearson test and analyzed using Two-way repeated measures ANOVA 
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and Tukey’s post-hoc test. For Figure 10G (BMDC subset CCR7 expression in response 
to soluble adjuvants), data was derived from four different trials, with three technical 
samples in each trial (n=12 each group). For normal data, One-way ANOVA with Tukey 
post-hoc test was performed to assess statistical significance (Macrophages, iDCs, cDCs) 
and for non-normal data Kruskal-Wallis with Dunn’s post-hoc test was performed 
(Monocytes). For Figure 11G (CCR7 expression in response to particle adjuvants), data 
was derived from two separate trials (one with 3 and another with 6 technical replicates) 
for a sample size of 9 for each group. Significance was estimated with One-way ANOVA 
and Tukey post-hoc test. Statistical analyses were performed and plotted for cell migration 
data using MATLAB and for BMDC subset and CCR7 expression data using Graphpad 
Prism software. 
3.2 Results 
3.2.1 Synthesis of PLGA Microparticles for Dual Adjuvant Delivery 
The design of MPLA- and CpG-loaded PLGA MPs is outlined in Figure 6C. PLGA MPs 
were synthesized using a water-oil-water double emulsion, solvent evaporation method 
previously published.182–184To encapsulate MPLA into the particles, MPLA was included 
with PLGA in dichloromethane for the first emulsion (1 μg MPLA per mg PLGA). 
Particles were covalently modified with 70,000 MW 30% w/v branched polyethylenimine 
(PEI) to create cationic particles for electrostatic adsorption of Class B CpG ODN 1826 
(10 μg per mg PLGA MP). To characterize PLGA MPs, size and zeta potential were 
measured with dynamic light scattering. The average diameters for Blank and MPLA 
PLGA-PEI MPs are around 1.5 and 1.2 µm, respectively (Figure S1 A-B). The average 
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surface charges for Blank and MPLA PLGA-PEI MPs are 35 and 29 mV, respectively 
(Figure S1 C-D).  
3.2.2 Generation of Heterogenous Cell Populations in BMDC Culture 
To generate BMDCs, bone marrow was collected from femurs and tibiae of female 
C57BL/6J mice 5 to 10 weeks old. Red blood cells were lysed, and cells were plated in 
RPMI complete medium containing fetal bovine serum, penicillin-streptomycin, sodium 
pyruvate, non-essential amino acids, 2-mercaptoethanol, and 20 ng mL-1 granulocyte 
macrophage colony stimulating factor (GM-CSF) with or without 10 ng mL-1 interleukin-
4 (IL-4). Loosely adherent BMDCs were collected by vigorous pipetting after 6-7 days of 
culture for flow cytometric and microfluidic chemotaxis experiments.  
BMDC flow samples (gated for singlets and excluding debris and dead cells) were 
concatenated in FlowJo and gated on relative surface expression of Ly6C and CD11c, and 
CD11b, resulting in four main populations. Figure 7A shows concatenated samples from 
GM-CSF and GM-CSF-IL-4 cultures, as well as inactivated (no adjuvant) to activated cells 
(with adjuvant) to best visualize all possible cell populations. Ly6ChiCD11b+CD11c– cells 
were categorized as classical monocytes,192–194 Ly6ChiCD11bhiCD11cint/hi cells as 
macrophages,106,195,196 Ly6Clo/intCD11bhiCD11chi cells as inflammatory DCs (iDCs), 91,197 
and Ly6Clo/intCD11bintCD11chi cells as conventional DCs (cDCs).65,106,196,197 T-distributed 
stochastic neighbor embedding (tSNE) plots in FlowJo were calculated and displayed to 
visualize relative concentrations of BMDC subpopulations (Figure 7B). Gated populations 
were overlaid on tSNE plots, and heatmaps of CD11b, CD11c, Ly6C, F4/80, MHC-II, and 
CCR7 expression were generated to characterize the tSNE clusters (Figure 7B-C). The 
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monocyte, macrophage and DC populations were further validated by comparing the 
relative median fluorescence intensities (MFI) of F4/80, MHC-II, CD40 and CCR7. DCs 
exhibited high MFI of MHC-II, CD40, and CCR7, macrophages expressed high MFI of 
F4/80 and intermediate MFI of MHC-II, CD40, and CCR7, and monocytes exhibited low 




Figure 7: GM-CSF and GM-CSF-IL-4 derived BMDC cultures contain different 
proportions of monocytes, macrophages, and dendritic cells. A) Gating strategy for 
monocyte, macrophage, iDC and cDC subpopulations based on Ly6C, CD11c, CD11b 
surface expression, as well as gating strategy for CCR7+ and CCR7-hi BMDCs. B) 
Combined and separated tSNE plots of GM-CSF-only BMDCs and GM-CSF-IL-4 BMDCs 
with overlaid BMDC monocyte (blue), macrophage (red), iDC (green), and cDC (purple) 
subpopulations. C) Heatmaps of tSNE plots depicting relative fluorescence intensity of 
BMDC markers. D) Comparing relative fluorescence intensity of APC markers on 
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monocytes, macrophages, iDCs, and cDCs. Fluorescence minus one (FMO) controls 
included (grey). Median Fluorescence intensity values displayed by each histogram. 
3.2.3 Logistic Regression Model Filters Data for Migratory Cell Tracks 
The experimental setup of culturing cells with adjuvant in chemotaxis devices (ibidi 
GmbH) is outlined in Figure 6D and detailed in Experimental Methods. Devices are 
composed of a central channel (2 mm L x 1 mm W x 0.07 mm H) for 3D cell culture 
between two reservoirs. To generate a gradient, the left reservoir contains CCL19 or 
CCL21 (1 µg mL-1) in RPMI complete media, while the right reservoir contains media 
without chemokine. Gradients are established within 1 hour and maintained over a period 
of 24 hours, validated by measuring the gradient of 10,000 MW FITC Dextran at 10-minute 
increments over 24 hours and plotting the fluorescence vs. the position over the width of 
the channel (Figure S2). Cells in the central channel are suspended in 1.5 mg mL-1 rat tail 
collagen I gel, to mimic tissue matrix. Soluble adjuvants are added to media in both 
reservoirs at concentrations of 50 ng mL-1 for MPLA and 500 ng mL-1 for CpG DNA and 
diffuse through the collagen matrix. PLGA MPs are included in the collagen matrix, and 
concentration of particles is adjusted to maintain adjuvant concentrations of 50 ng mL-1 for 
MPLA and 500 ng mL-1 for CpG (50 μg PLGA MPs mL-1). Twelve devices were imaged 
simultaneously with phase contrast microscopy using a 4X objective in a humidified 




Figure 8: Multinomial Logistic Regression Model-Informed Separation of Sedentary and 
Migratory Cell Tracks. Example data set with cell tracks categorized as migratory and 
sedentary using the logistic regression model includes all cell tracks from the soluble 
adjuvant chemotaxis experiments. A) Visualization of displacement, bearing angle, and 
distance derived from tracked cells. Meandering index (MI) is the ratio between 
displacement and distance, and the migration follows a straighter line as MI approaches 1. 
B) Polar histograms of cell track bearing angles (BA) for migratory and sedentary cells, 
categorized based on odds ratio (OR) calculation from logistic regression model (OR>1 
sedentary, OR<1 migratory). Chemokine gradient directs cells toward the left (BA ~180°). 
C) Displacement distributions and D) meandering index distributions of migratory and 
sedentary cells. Any cell track with a displacement of 0 was removed from distributions in 
B-D. 
Image sequences were uploaded into Volocity Quantitation Software (PerkinElmer), a 
high-throughput automated cell tracking software. The measurements derived from each 
cell track include distance, displacement, velocity, meandering index (displacement 
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divided by distance) and bearing angle (the angle of displacement from the origin) (Figure 
8A). To prevent mistakenly tracked cells in Volocity from adding noise to data analysis of 
cell chemotaxis, and avoid individually reviewing thousands of cell tracks, a logistic 
regression model was calculated to separate migratory cells from sedentary cells. These 
sedentary cells included dead or immobile cells that were tracked due to stage drift that 
could not be entirely corrected with the ImageJ algorithm and DCs with appendages that 
were mistakenly tracked as objects moving separately from the cell body. To estimate the 
regression coefficients, the model (Equation 1) was fit to a data set containing 1,000 cell 
tracks observationally categorized as sedentary or migratory (dist is distance, vel is 
velocity, disp is displacement, MI is meandering index, BA is bearing angle). 
ln(Y) = ln (
𝑃(𝑂𝑢𝑡𝑐𝑜𝑚𝑒 1)
𝑃(𝑂𝑢𝑡𝑐𝑜𝑚𝑒 2)




) =0.87 + 0.0013𝑋𝑑𝑖𝑠𝑡 + 6.7𝑋𝑣𝑒𝑙 − 0.033𝑋𝑑𝑖𝑠𝑝 + 0.84𝑋𝑀𝐼 + 0.21𝑋cos(𝐵𝐴)  (𝟐)  
When any distance, velocity, displacement, meandering index, and cosine of bearing angle 
values from a cell track were input into Equation 2, if the odds ratio (Y, Equation 1) was 
greater than 1, the cell was estimated to be sedentary. If less than 1, the cell was estimated 
to be migratory. Polar histograms of bearing angles confirmed that chemotactic cells, 
moving toward the gradient in the left chamber, were predicted as migratory and immobile 
cells that were mistakenly tracked in the direction of the stage drift (toward 270°) were 
predicted as sedentary (Figure 8B).  
The distributions of displacement values (Figure 8C) confirmed most migratory cells were 
moving at least 40 µm away from the point of origin, while most sedentary cells were 
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barely moving above 0 µm. The distributions of meandering indices (Figure 8D) showed 
migratory cells had a MI peak of about 0.21, while sedentary cells peaked around 0.04 and 
then around 1. Because sedentary cells could be DCs with appendages counted as separate 
objects migrating around a center of origin (the cell body), the distance will appear large 
while the displacement is very small, explaining the peak around 0.04. Also, sometimes 
two immobile cells were accidentally connected as a single cell directly moving from point 
A to point B, explaining the MI peak of 1 (displacement equaling distance). For each 
adjuvant and chemokine condition, three devices with cells were imaged, three separate 
experiments. The cell tracks were pooled together, and migratory cell tracks were identified 
using the logistic regression model for subsequent data analysis. 
3.2.4 Addition of IL-4 to BMDC Culture Increases CCR7 Expression and Chemotaxis 
There is speculation on whether IL-4 is necessary to stimulate DC maturation in murine 
bone marrow cultures,106 and numerous studies on DC behavior in vitro have been 
completed using BMDCs generated with GM-CSF alone or combined with IL-4.104,105 
CCR7 expression and migration data were obtained for cells cultured under both conditions 
to confirm whether IL-4 is essential to enable chemotaxis of BMDCs. BMDCs treated with 
only GM-CSF prominently contains monocytes, macrophages and CD11bhi DCs (iDCs) 
while monocyte concentration decreases and CD11bint DC (cDC) concentration increases 
drastically with addition of IL-4 (Figure 9A). CCR7 expression is significantly increased 
across all populations in GM-CSF/IL-4 BMDC culture compared to GM-CSF BMDCs 
(Figure 9B), with GM-CSF/IL-4 DCs expressing the highest CCR7 mean fluorescence 
intensity (Figure 7C-D). 
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For all polar plots in this study, migratory cells exhibiting chemotaxis toward CCL19 or 
CCL21 have a mean bearing angle (MBA) to the left between 150° and 210° (exhibited in 
Figure 9C toward CCL21) and the variance of cell directions decreases as the resultant 
length (RL) of the MBA approaches 1 on a unit circle (exhibited in Figure 9D toward 
CCL21). Without adjuvant, GM-CSF/IL-4 BMDCs exhibited a baseline level of 
chemotaxis while inactivated GM-CSF BMDCs did not exhibit any chemotaxis toward 
CCL21. The addition of MPLA and CpG did stimulate some chemotaxis of GM-CSF 
BMDCs but more significantly induced GM-CSF/IL-4 BMDC chemotaxis (Figure 9C). 
BMDCs generated with only GM-CSF did not exhibit any chemotaxis when activated with 
adjuvant-loaded PLGA MP (Figure S3). Because IL-4 induced expression of CCR7 (Figure 
9B) and exhibited baseline chemotaxis (similar to steady state in vivo),198 as well as 
increased chemotaxis with addition of adjuvant in solution or on particles, GM-CSF/IL-4 




Figure 9: IL-4 increases CCR7 expression and BMDC chemotaxis toward CCL21. A-B) 
Percentage (out of total BMDC population) of monocyte, macrophage, inflammatory DC 
(iDC), and conventional DC (cDC) subpopulations in GM-CSF BMDC versus GM-CSF-
IL-4 BMDC culture with and without adjuvant (soluble MPLA+CpG). Percentage of each  
subpopulation expressing CCR7 in response to soluble MPLA+CpG in GM-CSF-only or 
GM-CSF-IL-4 BMDC culture. *p<0.05, **p<0.01, ***p<0.001 ****p<0.0001 Two-way 
repeated measures ANOVA and Tukey’s post-hoc test. Data combined from two separate 
flow experiments, each with 3 technical replicates, therefore n=6 for each group. C) Polar 
histograms of cell track mean bearing angles (BA) normalized to cell number. Cells from 
three devices (each device from a separate experiment) combined into each polar plot. 
Yellow triangle indicates direction of CCL21 gradient (from left-hand chamber, toward 
180° on polar plot). D) Mean directions and resultant lengths of each polar histogram, 
where length of line is inversely proportional to directional variance (as length approaches 
1, more cells moving in the same direction). All mean directions significant (p<0.01) 






3.2.5 Soluble MPLA Increases While Soluble CpG Decreases Chemotaxis 
As seen with CCL21, GM-CSF-IL-4 BMDCs also exhibited a baseline level of chemotaxis 
toward CCL19 without stimulation by an adjuvant (Figure 10A). Compared to the control 
(no adjuvant), soluble CpG DNA did not increase chemotaxis toward CCL19 or CCL21. 
Conversely, MPLA induced the most directed migration toward CCL19 and CCL21 
(Figure 10C-D). Increasing the CpG DNA concentration from 50 to 5000 ng mL-1 did not 
affect chemotaxis, while increasing the MPLA concentration steadily increased chemotaxis 
toward CCL21 (Figure S4). There was no benefit of combining soluble CpG with MPLA 
to induce chemotaxis toward either chemokine. Cells exhibited no significant difference in 
chemotaxis toward either chemokine when exposed to soluble MPLA-CpG compared to 
MPLA alone (Figure 10C-D). MPLA-induced chemotaxis toward CCL19 and CCL21 and 
CpG-driven decrease in chemotaxis toward CCL19 was also evident by the significant 
differences in meandering index distributions (Figure 10E). A MI distribution skewed 
toward 1 indicates more cells move along a straight path whereas a MI toward 0 indicates 
more cells deviate from a straight path. There was an opposite effect on velocity of cells 
exposed to CCL19 gradients – CpG DNA increased while MPLA decreased cell velocity 
(Figure 10F). CCR7 expression on GM-CSF-IL-4 monocyte and macrophage 
subpopulations (Figure 10G) followed a similar trend to soluble adjuvant-stimulated cell 
chemotaxis, but not on DC subpopulations. MPLA was the strongest inducer of CCR7 
expression on monocytes and macrophages, while CpG most effectively stimulated CCR7 
expression on iDC and cDC subpopulations. Because ~100% of DCs expressed an 
intermediate to high level of CCR7, CCR7hi expression was compared between adjuvant 




Figure 10: Soluble MPLA increases BMDC chemotaxis while soluble CpG does not induce 
BMDC chemotaxis toward CCL19 and CCL21. A-B) Normalized polar histograms 
depicting cell orientation bias toward CCL19 and CCL21 when cultured with adjuvants. 
Control is no adjuvant. Yellow triangles indicate direction of CCL19 and CCL21 gradients 
(from left-hand chamber, toward 180° on polar plot). C-D) Mean directions and resultant 
lengths for each group. Black lines under legend indicate statistical significance (p<0.01) 
between mean directions according to Mardia Watson Wheeler Uniform Scores Test and 
  
 64 
Tasdan-Yeniay post hoc test. Red lines indicate p<0.05. Migratory cell track data from 
three devices (ranges from 432 to 1000 cell tracks for adjuvant and control groups, data 
normalized to cell number) combined into each polar histogram. E--F) Violin plots of 
meandering index and velocity distributions with mean (black solid) and median (black 
dashed). Black lines at the top of the graph indicate significance according to Kolmogorov 
Smirnov two sample test (p<0.01) and red lines indicate p<0.05. G) CCR7 expression on 
various BMDC subpopulations in response to soluble adjuvants, normalized to control 
mean from each experimental run. Data from four different trials combined, three technical 
samples each. ~100% of iDCs and cDCs expressed CCR7, so CCR7-hi expression was 
compared. *p<0.05, **p<0.01 ***p<0.001 ****p<0.0001 One Way ANOVA with Tukey 
Test for Macrophages, iDCs, and cDCs; Kruskal-Wallis with Dunn’s test for Monocytes. 
M+C is MPLA and CpG combined. 
3.2.6 CpG Delivered on PLGA MP Increases Cell Chemotaxis 
CpG delivered on PLGA MP (CpG MP) induced more directed migration toward CCL19 
and CCL21 compared to particles without adjuvant (Blank MP) and MPLA encapsulated 
in MP (MPLA MP) (Figure 11C-D). MPLA and CpG co-delivered on PLGA MP did not 
significantly increase BMDC chemotaxis compared to CpG MP (Figure 11C-D). The 
meandering index distribution of cells migrating toward CCL21 was skewed more toward 
1 with MPLA-CpG MP compared to Blank MP, whereas MPLA MP significantly 
decreased meandering index of cells migrating toward CCL19 (Figure 11E). Like cells 
stimulated with soluble CpG, cells mixed with MPLA MP migrated faster in the presence 
of CCL19 than when mixed with other particles (Figure 11F). Single and dual adjuvant 
PLGA MP did not change CCR7 expression on monocyte, macrophage and cDC subsets, 





Figure 11: CpG delivered on PLGA MP increases BMDC chemotaxis toward CCL19 and 
CCL21. A-B) Normalized polar histograms depicting cell orientation bias toward CCL19 
and CCL21 when cultured with particle-loaded adjuvants. Blank PLGA MP have no 
adjuvant. M+C is MPLA and CpG combined. Yellow triangles indicate direction of CCL19 
and CCL21 gradients (from left-hand chamber, toward 180° on polar plot).  C-D) Mean 
directions and resultant lengths for each group. Black lines under legend indicate statistical 
significance (p<0.01) between mean directions according to Mardia Watson Wheeler 
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Uniform Scores Test and Tasdan-Yeniay post hoc test. Migratory cell track data from three 
devices for CCL21 and four devices for CCL19 combined into each polar histogram. E-F) 
Violin plots of meandering index and velocity distributions with mean (black solid) and 
median (black dashed). Black lines at the top of the graph indicate significance according 
to Kolmogorov Smirnov two sample test (p<0.01) and red lines p<0.05. G) CCR7 
expression on various BMDC subsets in response to PLGA NP groups, normalized to 
control mean from each experimental run. Data from two different experiments combined, 
one with n=3 technical replicates and one with n=6, for a total of n=9 shown here for each 
group. ~100% of iDCs and cDCs expressed CCR7, so CCR7-hi expression was compared. 
*p<0.05, **p<0.01 ***p<0.001 ****p<0.0001 One Way ANOVA with Tukey Test. M+C 
is MPLA and CpG combined on PLGA MP. 
3.3 Discussion 
We investigated the singular and combinatorial effects of adjuvants MPLA and CpG, 
delivered in soluble form or on synthetic biomaterial-based particulate carriers (PLGA 
MPs), on the chemotaxis of GM-CSF/IL-4 BMDCs toward lymphatic chemokines CCL19 
and CCL21. Our data suggests the BMDC chemotactic response to MPLA and CpG is 
context dependent on the method of delivery (soluble vs. PLGA MP). Soluble MPLA and 
CpG PLGA MP were most effective at inducing BMDC chemotaxis, possibly due to the 
bioavailability of these agonists to their respective TLRs. TLR4 signaling recruits MyD88 
at the plasma membrane where it most likely to encounter lipopolysaccharide (LPS), a 
component of Gram-negative bacterial membranes from which MPLA is derived.199 TLR4 
also translocates to endosomes and activates TRIF-dependent signaling, and it has been 
reported that signaling both TRIF and MyD88 pathways optimizes DC maturation.200,201 
Encapsulating MPLA in PLGA particles as a slow-release formulation reduces its 
bioavailability to surface-bound TLR4 compared to soluble MPLA of the same dose. TLR9 
is localized on the endoplasmic reticulum and trafficked to lysosomes containing CpG 
DNA from disintegrated bacteria.202,203 Soluble CpG DNA is taken up by cells through 
fluid phase and receptor-mediated endocytosis.204 When soluble CpG enters a cell via 
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receptor-mediated endocytosis it is contained in early and late endosomes and lysosomes 
that bud off the plasma membrane or Golgi apparatus. Particle-loaded CpG DNA enters 
into phagosomes that directly fuse with the ER,204 which could provide more direct access 
to TLR9. The direct exposure to surface TLR4 by soluble MPLA and ER-localized TLR9 
by particle-loaded CpG DNA could explain the enhanced chemotactic response to those 
adjuvants. Surface-bound TLR4 and TLR9 both signal MyD88, which has been reported 
to be required for migration of DCs to dLNs.205–207 
Interestingly, we did not observe a synergistic chemotactic response to MPLA and CpG in 
our devices. Previous work has shown combinations of TLR agonists delivered in soluble 
form and on biomaterials have elicited inflammatory cytokine responses in vitro and 
enhanced vaccine responses in vivo.13,145,180,181,208 For example, co-delivered MPLA and 
CpG stimulate stronger IFN-β and IL-12p70 responses from GM-CSF BMDCs.13,145,180 
Though this does not correlate with an enhanced migratory response in vitro, there is still 
strong potential for combination adjuvants to induce strong immune responses in vivo. 
Additionally, other biophysical parameters with PLGA particles can be adjusted in future 
experiments to enhance the synergistic chemotactic response, including adjuvant density, 
particle size, and surface charge. 
A common divergence in BMDC culture method is the inclusion or exclusion of IL-4. We 
demonstrated that supplementing GM-CSF with IL-4 enhances BMDC chemotaxis and 
expression of CCR7. GM-CSF/IL-4 BMDC culture is a heterogeneous mixture of cells, 
majority of which phenotypically resemble monocytes, macrophages, or dendritic 
cells.105,106 Purifying subpopulations would help identify which cells are migrating in 
response to adjuvants and chemokines. However, studies have shown that fluorescence-
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activated cell sorting potentially activates stress pathways, including p38 MAPK which is 
also involved in chemotaxis regulation.209–211 Antibody binding may activate signaling 
pathways that alter functional changes of the purified cell population, and high pressures 
during cell sorting may stimulate aberrant dendritic cell maturation.212–215 In addition to 
GM-CSF and IL-4, there are cytokines differentially secreted by subpopulations that 
contribute to the overall phenotype and function of BMDCs. For example, in GM-CSF 
BMDC culture, macrophages secrete higher levels of TNF-α while DCs secrete more IL-
12.180,216  
It is generally accepted that while undergoing maturation, DCs downregulate chemokine 
receptors that facilitate DC entry to inflamed peripheral tissues (e.g., CCR2 and CCR6) 
while upregulating CCR7, which increases responsiveness to CCL19 and CCL21 and 
migration to dLNs.217,218 There are a few atypical chemokine receptors reported to interact 
with CCL19 and CCL21, including ACKR5 (CCRL2), which is upregulated by LPS, TNF-
α, and other inflammatory stimuli; however, whether stimulation of CCRL2 induces cell 
migration is under debate.219,220 Though we observed upregulation of CCR7 on DCs in 
response to soluble CpG, there was no increase in BMDC chemotaxis (Figure 10). 
Scandella et al. concluded upregulation of CCR7 was not sufficient for migration, and lipid 
mediator prostaglandin E2 (PGE2) is required to facilitate chemokine receptor signaling in 
human monocyte derived DCs.221 It has been shown in mice that DC chemotaxis toward 
CCL19 is regulated by cysteinyl leukotrienes LTC4 and LTD4 and ADP-ribosyl cyclase 
CD38 controls migration of DCs from peripheral sites to lymph nodes.222,223 A preliminary 
study has shown soluble CpG decreases genetic expression of CD38, prostaglandin E 
synthase (which catalyzes conversion of PGH2 to PGE2), CCR7, CCL19, and other 
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migration signaling proteins while soluble MPLA maintains and combined MPLA-CpG 
increases their expression (Figure S5). Therefore, it is likely the delivery of soluble CpG 
to BMDCs must be supplemented with other molecular signals to sensitize CCR7 to 
CCL19 and CCL21. For example, Tayalia et al. included PGE2 with delivery of soluble 
CpG to induce DC chemotaxis out of a 3D photopolymerized scaffold toward chemokine 
in collagen gel.224 
The phenotype and function of DCs is reportedly influenced by 2D versus 3D culture 
conditions and substrate stiffness.225,226 A study by Mennens et al. demonstrated culturing 
human PBMCs on low (2 kPa) and high (50 kPa) stiffness substrates increased CCR7 
expression and cell migration toward CCL21 compared to medium (12 kPa) stiffness 
substrates.226 Sapudom et al. reported culturing human monocytic THP-1 cells in 2D and 
transferring to 3D 1 mg mL-1 collagen gels (~47 Pa) slightly increased CCR7 and CD11c 
expression. Our data reveals culturing GM-CSF/IL-4 BMDCs (removed from 2D culture 
after 6 days) in 1.5 mg mL-1 collagen gel for 24 hours does not affect CCR7 expression 
and increases CD11c expression on live cells while lowering CD11b and Ly6C expression 
(Figure S6). Collagen gels were digested using Collagenase D (2 mg mL-1 media), which 
does have effects on cell viability and could downregulate the density of surface markers 
cells express in 3D.227 
Surprisingly, there were minimal differences in cell orientation bias (Fig 5A-B, Fig 6A-B) 
between CCL19 and CCL21 gradients in response to adjuvants. Haessler et al. reported 
when BMDCs were exposed to two opposing gradients off CCL19 and CCL21 in a 
microfluidic device, BMDCs migrated preferentially toward CCL21.228 However, we 
examined the gradients separately, and future work would be to investigate if adjuvants 
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change the preference of chemokines when exposed to opposing gradients. CCL21 is 
capable of binding to sulfated proteoglycans (e.g., heparan sulfate) and forming a fixed 
gradient. There were no proteoglycans directly added to the collagen gel mixture; however, 
a component of the growth medium, fetal bovine serum, does contain glycosaminoglycans 
(GAGs) that could have bound to type I collagen and CCL21.229,230 Schumann et al. 
demonstrated matrix bound CCL21 triggered integrin-mediated adhesion of DCs and 
random movement along CCL21-presenting surfaces. DCs would truncate anchoring 
residues when directly engaging with CCL21, creating soluble CCL21 gradients. Once 
soluble, CCL21 along with CCL19, which lacks the C-terminus mediating 
glycosaminoclycan binding,231 stimulated directed migration toward chemokines but did 
not induce adhesion.232 Furthermore, our results show that where CCL19 did not induce 
directed migration of BMDCs with soluble CpG and MPLA MP, there was an increase in 
cell velocity (Fig 5D, Fig 6D). It has been reported that there are independent signaling 
pathways controlling CCR7-dependent chemotaxis and migratory speed.211 The MAPK 
pathway involving ERK1/2, JNK, and p38 regulates chemotaxis, while the 
Rho/Pyk2/cofilin pathway regulates speed; therefore, different combinations of adjuvants 
with CCL19 and CCL21 could selectively tune the directionality and motility of DCs. 
In summary, we built a framework to measure and analyze BMDC chemotaxis in 3D to 
screen for soluble and particulate adjuvants that enhance CCL19/21 mediated chemotaxis, 
and with our analyses discovered soluble MPLA and particulate CpG were the most 
effective in this regard. Our framework included a logistic regression model to isolate 
migratory cells based on cell track measurements (e.g., MI, displacement), and there is 
potential for the model to differentiate BMDC subpopulations based on parameters such as 
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morphology or migration dynamics (e.g., extension-retraction cycles). Isolation of cells 
based on sorting or fluorescent labeling methods (e.g., using reporter mice) would need to 
be optimized to assign a subpopulation category to each cell and inform the model. We 
observed CCR7 expression and chemotaxis of BMDCs are enhanced by supplementing 
culture media with IL-4, which gives rise to a heterogeneous population of monocytes, 
macrophages, and dendritic cells that collectively, differentially respond to MPLA and 
CpG DNA. The delivery method of MPLA and CpG were important to induce chemotaxis, 
most likely due to the bioavailability of the adjuvants and the cellular location of the TLRs. 
While soluble CpG did increase CCR7 expression on DCs, there was no increase in 
chemotaxis, possibly due to the absence of essential CCR7-signaling mediators such as 
PGE2 and CD38. Most prominently under CCL19 gradients, formulations that increased 
directed migration also decreased cell velocity, aspects of migration controlled by different 
signaling pathways. The delivery of MPLA and CpG together in soluble form or on 
particles did not significantly increase BMDC chemotaxis over delivery of each adjuvant 
alone. It is possible there are synergistic migratory responses to alternative adjuvant 
combinations, such as such as R848 (TLR7/8) and PolyU/UC (RIG-I), which could be 
investigated.233 Along with synergy of combination adjuvants, biophysical parameters of 
adjuvant delivery vehicles such as particle size, charge, and adjuvant density could impact 
DC chemotaxis.234 Furthermore, the effects of particulate adjuvant formulations on DC 
chemotaxis should be studied in vivo using intravital imaging methods demonstrated by 
Halin et al. and Sixt et al.235,236  
Our results show that 3D migration of DCs toward lymphatic chemokines CCL19 and 
CCL21 can be influenced by both adjuvant type and the delivery method. These findings 
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uncover new directions for rationally designing formulations that drive DC migration and 
cell-mediated antigen delivery to the lymph node and tailor the immune response, a major 
















CHAPTER 4: AIM 1.2. ASSESSING HOW MPLA AND CPG 
REGULATE IMMUNE CELL POPULATIONS AND PARTICLE 
TRANSPORT TO DRAINING LYMPH NODES IN VIVO 
4.1 Materials and Methods 
4.1.1 Synthesis of Fluorescent Nanoparticles 
Polylactic-co-glycolic acid (PLGA) nanoparticles were synthesized using a water-oil-water 
double emulsion, solvent evaporation method as described in previous protocols.147,180,233 
200 mg of PLGA (Resomer® RG 502H, Sigma Aldrich) was dissolved in 4 mL of 
dichloromethane and 1 mL of endotoxin-free water in a 50 mL polypropylene centrifuge 
tube. For MPLA particles, 1.2 mg of MPLA-PHAD® (Avanti) was added to this solution. 
The primary emulsion was sonicated over ice for 2 minutes using a 130W Ultrasonic 
Processor with titanium probe at 65% power. The primary emulsion was added to 16 mL 
of 5% w/v polyvinyl alcohol solution and sonicated for 5 minutes over ice to form a 
secondary emulsion. To remove dichloromethane by evaporation, the secondary emulsion 
was added to a beaker with magnetic stirring in the fume hood for three hours. The PLGA-
PVA solution was transferred to a 50 mL centrifuge tube and centrifuged at 3,500 x g for 
20 minutes to remove PLGA microparticles. The nanoparticles were subsequently pelleted 
using ultracentrifugation at 22,000 x g for 20 minutes at 4°C and washed with di H2O. The 
washed particles were resuspended in 5 mL di H2O and left to dry on a lyophilizer for 2 
days. Polyethylenimine (PEI) was added to nanoparticles with an EDC/NHS reaction. 168 
mg EDC (Pierce, Thermo Fisher) and 104 mg Sulfo-NHS (Pierce, Thermo Fisher) were 
added to 160 mg PLGA NPs in 5 mL 0.1M MES buffer (pH 5.5). The solution was vortexed 
and rotated for 2 hours at room temperature. After 2 hours, the PLGA/EDC/NHS solution 
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was added to 24 mL branched PEI (MW 70,000 30% w/v aq. soln., Polysciences), 48 mL 
of 0.2 M MES buffer (pH 6.5), and 3 mL HCl in a beaker on magnetic stirrer for 2 hours 
at room temperature. PLGA-PEI nanoparticles were pelleted using ultracentrifugation 
(80,000 x g for 20 minutes), washed with NaCl solution, washed with di H2O, and 
resuspended in 5 mL RNase/DNase free water (Boston BioProducts). PLGA-PEI 
nanoparticles were lyophilized for 2 days and stored at -20°C.  
To fluorescently label particles (Figure 12A), 50 μg of AlexaFluor 488 NHS ester 
(Lumiprobe) was added to 10 mg of PLGA-PEI nanoparticles in 1 mL sodium bicarbonate 
(pH 8) and rotated overnight at 4°C. AF488 PLGA PEI NPs were centrifuged at 10,000 x 
g for 20 minutes, washed with di H2O, resuspended in 200 μL RNase/DNase free water, 
and lyophilized overnight. The zeta potential of AF488-conjugated particles was quantified 
as 19 mV using a Malvern Zetasizer. IRDye700-conjugated oligodeoxynucleotides 
(ODNs) were custom-made from Integrated DNA Technologies (IA). IRDye700-CpG 
ODN sequence is /5IRD700/TC CAT GAC GTT CCT GAC GTT. The control ODN, 
IRDye700-GpC ODN Is /5IRD700/TC CAT GAT ATT CCT GAT ATT. For 
electrostatically loading ODN, 36 μg IR700-CpG ODN or IR700-control ODN was added 
to 1 mg AF488-PLGA-PEI nanoparticles in 400 μL sodium phosphate buffer (pH 6.5) and 
rotated overnight at 4°C. IR700-ODN-AF488-PLGA PEI nanoparticles were washed with 
RNAse/DNAse free H2O prior to resuspension in saline and intramuscular injections. To 
calculate CpG or control ODN loading, ssDNA levels were measured using the Nucleic 
Acid Quantification feature on the BioTek plate reader. The maximum IR700-ODN 




4.1.2 Intramuscular Injections 
Female Balb/cJ mice (9-10 wks old) were placed under anesthesia (5% isoflurane). To 
prepare particles for intramuscular injections, 6 mg of IR700-AF488 PLGA NP were 
resuspended in 225 μL of physiological saline solution (0.9% NaCl). A dose of 30 μg ODN 
(CpG or control) with or without 5 μg MPLA in 0.8 mg of PLGA NP (30 μL total) was 
injected into the right anterior tibialis muscle of each anesthetized mouse with a 29G 0.3 
mL insulin syringe. Mice were euthanized 24 or 48 hours post-injection. Right anterior 
tibialis muscles, as well as popliteal, inguinal, and iliac lymph nodes (Figure 12B) were 
collected from each mouse and placed in 1X phosphate buffered saline (PBS) without 
calcium or magnesium (Corning).  
4.1.3 NIR Imaging of Lymph Nodes 
Popliteal, inguinal, and iliac lymph nodes were individually added to each well of a solid 
black 96-well polystyrene microplate, in 200 μL 1X PBS each well. Nodes were imaged 
using a near-infrared system consisting of a cooled EMCCD camera (Evolve eXcelon, 
Photometrics) attached to a stereomicroscope (MVX10, Olympus) with adjustable zoom, 
xenon arc light source (Lambda LS, Sutter Instrument Company), and manual filter wheel 
with standard Cy5.5 filter cube (Chroma Technology). Images were acquired with a 200 
ms exposure time, executed using Micro-Manager microscopy software. Node images 
were uploaded into ImageJ, “regions of interest” (ROIs) were drawn around the perimeter 
of the nodes using the Wand Tool, and the raw integrated density of the ROI (summation 




4.1.4 Tissue Preparation and Staining for Flow Cytometry 
Muscles were enzymatically and mechanically dissociated into viable single cell 
suspensions with the Skeletal Muscle Dissociation Kit and gentleMACS Octo Dissociator 
(Miltenyi Biotec). Dissociated tissue was strained through a 40 μm cell strainer into a 50 
mL polypropylene tube. Cells were pelleted through centrifugation at 500 x g for 5 minutes. 
Red blood cells were lysed using 1X RBS Lysis buffer with ammonium chloride 
(eBioscience™). Cells from each muscle were resuspended in 5 mL RBC lysis buffer and 
incubated for 10 minutes at room temperature. The reaction was stopped by adding 20-30 
mL of fluorescence activated-cell sorting (FACS) buffer, which consists of 0.1% sodium 
azide, 1 mM EDTA, and 5% v/v FBS in PBS. Lymph nodes were dissociated in 40 μg/mL 
DNAse I and 1 mg/mL Collagenase D in RPMI 1640 medium through a 40 μm cell strainer 
using a 1mL-syringe plunger. The strainer was the top of a 5 mL Falcon™ Round-Bottom 
Polystyrene test tube. 
Muscle and lymph node cell suspensions were centrifuged at 500 x g for 5 minutes. Each 
muscle and lymph node sample were resuspended in 200 μL FACS buffer and transferred 
to a well of a V-bottom 96 well plate. Plates were centrifuged at 500 x g for 5 minutes, 
samples were washed with PBS, and resuspended in 1:1000 Zombie Aqua™ Fixable 
Viability dye in PBS (Biolegend). Cells were incubated in Zombie Aqua for 30 minutes at 
room temperature, and then washed with FACS buffer. Cells were subsequently stained 
with fluorophore-conjugated antibodies in FACS buffer (200 µL antibody cocktail per 
muscle and 100 µL antibody cocktail per lymph node, estimated about 1 million cells/mL). 
The dendritic cell marker panel consisted of the following (for muscles and lymph nodes): 
BUV395 Rat anti-mouse CD11b (clone M1/70, BD), Brilliant Violet 421™ hamster anti-
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mouse CD11c (clone N418, Biolegend), Brilliant Violet 785™ rat anti-mouse CD86 (clone 
GL-1, Biolegend), PE rat anti-mouse MHC class II (I-A/I-E, clone M5/114.15.2, Thermo 
Fisher), PE/Dazzle™ 594 hamster anti-mouse CD103 (clone 2E7, Biolegend), 
PE/Cyanine7 rat anti-mouse CD301b (clone URA-1, Biolegend), and allophycocyanin 
anti-mouse/human CD45R/B220 (clone RA3-6B2, Biolegend). For muscles, PE/Cyanine5 
rat anti-mouse CD40 (clone 3/23, Biolegend) was added and for lymph nodes, 
PE/Cyanine5 rat anti-mouse CD8a (clone 53-6.7, Biolegend) was added. The macrophage 
and monocyte marker panel consisted of the following (for muscles only): BUV395 anti-
CD11b, Brilliant Violet 421™ anti-CD11c, Brilliant Violet 785™ rat anti-mouse Ly-6G, 
PE mouse anti-mouse CD64 (FcγRI, clone X54-5/7.1, Biolegend), PE/Dazzle™ 594 rat 
anti-mouse Ly-6C (clone HK1.4, Biolegend), PE/Cyanine5 rat anti-mouse F4/80 (clone 
BM8, Biolegend), PE/Cyanine7 rat anti-mouse CD206 (MMR, clone C068C2, Biolegend), 
and allophycocyanin rat anti-mouse CD197 (CCR7, clone 4B12, Biolegend). 
Fluorescence-minus one (FMO) and single-stain controls for each laser/filter channel were 
included to optimize flow gating and compensation. Cells were washed with PBS and fixed 
with FluoroFix™ buffer (Biolegend) containing paraformaldehyde, optimized to stabilize 
tandem dyes. Cells were kept at 4°C overnight and imaged via multicolor flow cytometry 
(BD LSRFortessa™). Flow Cytometry Standard (FCS) files were uploaded into FlowJo 
(FlowJo, LLC, BD) for analysis. Prior to gating for APC markers, singlets were isolated 
using FSC-A vs. FSC-H and SSC-A vs. SSC-H scatter plots, debris removed from FSC-A 
vs. SSC-A scatter plots, and live cells gated on low BV510 (Zombie Aqua) fluorescence, 
optimized with the BV510 FMO. Cells were confirmed positive for APC markers using 
FMO controls. tSNE plots were generated by concatenating 5,625 of live cells from all 
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Blank NP, CpG NP, MPLA NP, and MPLA-CpG NP flow samples (total 180,000 cells) 
and running the tSNE feature.  
4.1.5 Statistical Analysis 
Cell percentages and median fluorescence intensity (CD86, BV786 channel) were 
calculated using FlowJo and exported as tables, which were uploaded into GraphPad for 
creating bar graphs and conducting statistical analysis. Statistical significance was 
calculated between treatment (adjuvant/particle) groups and time points using Two-Way 
ANOVA and Sidak’s or Tukey’s multiple comparisons test. 
4.2 Results 
4.2.1 Fluorescence of IR700-Conjugated CpG and Control ODN Loaded on PLGA PEI 
NP Peaks at 24 Hours and Decreases at 48 Hours in Muscle-Draining Lymph 
Nodes 
Fluorescent images of lymph nodes using a standard Cy5.5 filter on a near-infrared 
microscope system were acquired with a 200 ms exposure time (example Figure 12C). The 
mean fluorescence intensity (sum of pixel gray values normalized by the area of the ROI) 
was plotted for each popliteal, iliac, and inguinal lymph node collected at 24- and 48-hours 
post-injection from mice injected with IR700-Control (GpC) ODN PLGA-PEI NP (Blank 
NP), IR700-CpG ODN PLGA-PEI NP (CpG NP), IR700-Control (GpC) ODN PLGA-PEI 
MPLA NP (MPLA NP), and IR700-CpG ODN PLGA-PEI MPLA NP (MPLA-CpG NP). 
The mean fluorescence intensity of averaged lymph nodes was calculated by averaging the 
means of the iliac, inguinal, and popliteal nodes from each mouse subject. Two separate 
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studies were conducted each with a sample size of 4 mice for each treatment 
(adjuvant/particle) group at 24 and 48 hours; therefore, for each treatment group at each 
time point the sample size was 8 mice (except for MPLA NP at 48 hours, which had 7 
mice). Background (autofluorescent) signal was calculated by averaging the mean 
fluorescence intensity of 17 nodes from saline mice. The background signal was subtracted 
from combined-node and single-node mean fluorescence intensities from each mouse 
subject within each treatment group (Figure 12D-G). It is important to note that the ODNs 
were covalently labeled with NIR dye IR700 while the particles were covalently labeled 
with AF488, which is not detectable with NIR microscopy. For simplicity, the treatment 
groups herein are referred to as Blank NP, CpG NP, MPLA NP, and MPLA-CpG NP while 
understanding that the NIR signal could be from CpG and GpC ODNs separated from or 
electrostatically loaded on PLGA NPs. 
NIR imaging data reveals IR700-GpC and IR700-CpG ODNs drained to lymph nodes 
within 24 hours of intramuscular injection on PLGA NPs (Figure 12D). For each treatment 
group, the mean fluorescence intensity (averaged between iliac, inguinal, and popliteal 
nodes for each mouse subject) significantly decreased by 48 hours (Figure 12D). When 24- 
and 48-hour data is combined for each treatment group, the mean fluorescence intensity of 
CpG NPs for averaged nodes is significantly higher than the mean fluorescence intensity 
of Blank NPs (Figure 12D). The differences between treatment groups when analyzing the 
fluorescence between single draining lymph nodes were not as apparent. For example, 
there were no statistical differences in fluorescence of iliac lymph nodes between treatment 
groups and time points (Figure 12E). The fluorescence of inguinal nodes was significantly 
higher for MPLA-CpG NP-injected mice compared to MPLA NP-injected mice, and the 
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inguinal node fluorescence decreased for most treatment groups by 48 hours (Figure 12F). 
The fluorescence of popliteal nodes was significantly higher for CpG NP-injected mice 
compared to Blank NP- and MPLA-CpG-injected mice, and the popliteal node 
fluorescence decreased for the Blank NP and CpG NP groups by 48 hours (Figure 12G). 
 
Figure 12: IR700-ODN Loaded on PLGA NP Appears in Muscle-Draining Lymph Nodes 
by 24 Hours. A) Scheme for loading PEI, AF488, and IR700-ODN on PLGA nanoparticles. 
B) Locations of iliac, inguinal, and popliteal lymph nodes in the mouse. Iliac nodes are 
located at the terminal segment of the abdominal aorta and origin of the common iliac 
artery. Inguinal (i.e., subiliac) nodes are located near the groin in a fat pad accessible by 
pulling away skin from the mouse. Popliteal nodes are in the popliteal fossa between the 
biceps femoris muscle and semitendinosus muscle. C) Near-infrared image of an inguinal 
lymph node 48 hours after injection of mouse with MPLA-CpG NP. D) Mean fluorescence 
intensities (sum of brightness normalized by ROI area) averaged between the iliac, 
inguinal, and popliteal lymph nodes of each mouse subject in each particle and time group. 
Background fluorescence (average mean fluorescence intensity of 17 saline mice nodes) 
subtracted from each data point. E-G) Mean fluorescence intensities of individual nodes 
(iliac, inguinal, and popliteal) of each mouse with background fluorescence subtracted. 
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**p<0.01 *p<0.05 significance between treatment groups within the same time group. 
^^^p<0.001, ^^p<0.01, ^p<0.05 significance between 24 and 48 hours within same 
treatment group. Significance determined with Two-Way ANOVA and Sidak’s multiple 
comparisons test. †p<0.05 between treatment groups when 24- and 48-hour data combined 
(main column effect). Significance for † calculated with Tukey’s post-hoc test. 
Data collected via flow cytometry reveals AF488+IR700+ events in the muscle, as well as 
AF488loIR700+ events, indicating the IR700 ODN is dissociating from the AF488 PLGA 
PEI NP (Figure 13A). The AF488loIR700+ signal diminishes between 24 and 48 hours. 
There are also three separate signals, AF488+IR700+, AF488loIR700+, and IR700loAF488+ 
in the draining lymph nodes. The three signals are more apparent at 48 hours (Figure 13B). 
 
Figure 13: Scatter plots of AF488 vs. IR700 events reveal ODN dissociation from PLGA 
NP in the muscle and draining lymph nodes. A) Concatenated events from all muscles 
injected with fluorescent particles collected at 24 (left) and 48 (right) hours after injection. 
X axis is fluorescence in the Alexa Fluor 700 channel and Y axis is fluorescence in FITC 
channel; both axes are on a log-10 scale. Gates are drawn around double positive AF488-
I700 events and IR700-only events. Numbers reveal percentages of events in both gates. 
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B) Concatenated events from draining lymph nodes of mice injected with fluorescent 
particles, collected at 24 (left) and 48 (right) hours post-injection. X and Y axes are the 
same as described in Fig. 2A. Numbers are percentage of total events in each gate. 
4.2.2 Particle-Delivered MPLA and CpG ODN Differentially Regulate Innate Immune 
Cell Populations and Maturation in the Muscle 
Muscle cell suspensions were split into two groups, each group stained with a different 
antibody cocktail: one targeting monocyte, macrophage, and neutrophil (MMN Panel) 
markers and one targeting dendritic cell markers (DC Panel). A tSNE plot based on 
concatenated muscle samples (from Blank, CpG, MPLA, and MPLA-CpG NP groups) was 
generated for each panel (Figure 14A, Figure 15A). There was a clear neutrophil cluster 
(purple) in the MMN Panel tSNE plot that was Ly6GhiLy6CintCD11bhi (Figure 14B). All 
particles induced neutrophil infiltration into the muscle, with dual-adjuvant MPLA-CpG 
NP inducing the most significant increase in neutrophils (Figure 14C). The percentage of 
neutrophils significantly decreased between 24 and 48 hours.  
There were also closely-related clusters co-expressing CD11b, CD64 (FCγRI), and F4/80, 
indicating populations of monocytes, macrophages, and mo-DCs. These clusters 
differentially expressed Ly6C – monocytes are Ly6Chi, while macrophages and mo-DCs 
are Ly6Cint. The percentage of M2 macrophages, characterized by expression of CD206, 
were highest in the saline and Blank NP groups at 48 hours, while the CpG, MPLA, and 
MPLA-CpG NPs significantly decreased or prevented differentiation of this population 
(Figure 14E). The percentage of monocytes increased most significantly with the Blank 
NP and CpG NP groups compared to MPLA and MPLA-CpG NP groups (Figure 14F), 
while the percentage of macrophages and mo-DCs increased with MPLA NP at 24 hours 
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(Figure 14F). The percentage of CD64+F4/80+ cells expressing CCR7 slightly increased in 
the MPLA-CpG NP group at 24 hours (Figure 14G).  
In the DC marker tSNE plot, there was a clear CD11bloCD11chi cluster, most likely the 
neutrophils and monocytes distinguished in the MMN panel (Figure 15A-B). However, the 
CD11c+MHCII+ population, traditionally recognized as DCs, was much smaller compared 
to the population of CD64+F4/80+ cells. The CD11c+MHCII+ population statistically 
increased from 24 to 48 hours post-injection, and most prominently with Blank NP and 
MPLA NP groups (Figure 15C). It could be that CpG ODN prevents the increase of 
CD11c+MHCII+ cells, or the control (GpC) ODN promotes their expansion. This trend 
remained the same for CD11c+MHCII+CD11bhi cells (cDC2) as well as 
CD11c+MHCII+CD103+ cells (cDC1). MPLA NP and MPLA-CpG NP groups most 
significantly increased CD40 expression by cDC2 and cDC1, while simultaneously 
decreasing CD86 expression (Figure 15E-F, 15H-I). CD40 expression increased 
significantly for MPLA and MPLA-CpG NP groups between 24 and 48 hours, while CD86 
expression decreased significantly for CpG NP mice between 24 and 48 hours. Expression 
of CD301b was low but overlapped with CD11c+MHCII+ cells and CD301b+ cells shared 
the same trends as cDC2 (data not shown). B220 expression was barely detectable, 




Figure 14: PLGA PEI NP with MPLA and/or CpG differentially regulate monocyte, 
macrophage, and neutrophil populations in the muscle. A) tSNE clusters overlaid with 
neutrophil, monocyte and macrophage populations and B) corresponding heatmaps of each 
marker included in the panel. C) Percentage of live cells expressing neutrophil phenotype 
(Ly6GhiLy6Cint). D) Percentage of live cells expressing monocyte/macrophage phenotype 
(CD64+F4/80+). E) Percentage of live cells expressing CD64, F4/80, and CD206 (M2 
macrophages). F) Percentage of live cells that are Ly6Chi, CD64+, F4/80+ (circulating 
monocytes) and G) Percentage of live cells that are Ly6Cint, CD64+, F4/80+ (differentiating 
monocytes). H) Percentage of CD64+F4/80+ cells that are expressing CCR7. Saline group 
was dropped from this graph because allophycocyanin and Alexa Fluor 700 channels had 
strong spectral overlap and saline groups did not have any particles. With the high 
fluorescence of particles at the muscle, compensation in the allophycocyanin channel will 
be much different between saline and particle groups. ****p<0.0001, ***p<0.001 
**p<0.01 *p<0.05 significance comparing all groups within the same time point according 
to Two-Way ANOVA and Tukey test.  ^^^^p<0.0001, ^^^p<0.001, ^^p<0.01, ^p<0.05 
significance comparing 24 and 48 hours within same particle group according to Two-Way 
ANOVA and Sidak’s multiple comparison test. †p<0.05 significance between two groups 




Figure 15: PLGA PEI NP with MPLA and/or CpG differentially regulate DC populations 
and their expression of costimulatory molecules, CD40 and CD86, in the muscle. A) tSNE 
clusters overlaid with DC populations and B) corresponding heatmaps of each maker 
included in the panel. C) Percentage of live cells expressing DC phenotype 
(CD11c+MHCII+). D) Percentage of live cells expressing cDC2 phenotype 
(CD11c+MHCII+CD11bhi). E-F) Percentage of cDC2 expressing CD40 and CD86. G) 
Percentage of live cells expressing cDC1 phenotype (CD11c+MHCII+CD103+). H-I) 
Percentage of cDC1 expressing CD40 and CD86. ****p<0.0001, ***p<0.001 **p<0.01 
*p<0.05 significance comparing all groups within the same time point according to Two-
Way ANOVA and Tukey test.  ^^^^p<0.0001, ^^^p<0.001, ^^p<0.01, ^p<0.05 
significance comparing 24 and 48 hours within same particle group according to Two-Way 





4.2.3 MPLA and CpG ODN Loaded on PLGA PEI NP Differentially Regulate APC 
Populations and CD86 Expression in Muscle-Draining Lymph Nodes 
In iliac (IL), inguinal (IG), and popliteal (PO) lymph nodes, CpG NP and MPLA-CpG NP 
groups increased percentages of B cells at 48 hours (Figure 16A), while CpG NP 
significantly increased populations of pDCs at 48 hours (Figure S9B). Increases in CD86 
expression on B cells were more prominent at 24 hours (Figure S9C). At this time point, 
CD86 expression increased with MPLA and MPLA-CpG NP in iliac lymph nodes, Blank 
NP and CpG NP in inguinal lymph nodes, and MPLA-CpG NP in popliteal lymph nodes, 
highlighting how the isolation of different draining lymph nodes can shape conclusions on 
immune response (Figure S9C). CpG NP continued to upregulate CD86 on B cells, 
compared to controls, in the iliac and inguinal nodes at 48 hours (Figure S9C). Higher 
percentages of pDCs expressed CD86, and statistical trends resembled B cells in lymph 
nodes at the 24-hour time point (Figure S9D). CD86 expression did not decrease at 48 
hours (as seen with B cells) and was upregulated by different particle groups at this time 
point depending on the lymph node: all particle groups upregulated pDC-CD86 expression 
in the iliac node, only Blank, CpG, and MPLA-CpG NP did so in the inguinal node, and 
only CpG NP and MPLA NP groups increased pDC-CD86 expression in the popliteal 
nodes (Figure S9D). 
There were no major changes in populations of cDC1 and cDC2 in lymph nodes in response 
to particles, except CpG NP statistically increased all types in the popliteal node at 48 hours 
(Figure S10). cDC1 and cDC2 are expressed in the peripheral and lymphoid tissues, 
although CD103 is only expressed on rare populations of lymphoid cDC1 in the marginal 




Figure 16: CpG and MPLA-CpG NPs increase B cell populations while MPLA NPs 
increase CD86 expression on CD11b+ DCs in muscle-draining lymph nodes 24 to 48 hours 
after intramuscular injection. A) Percentage of B cells (B220+MHCII+CD11c-) out of live 
cells in the iliac, inguinal, and popliteal lymph nodes at 48 hours. B) Median fluorescence 
intensity of CD86 on viable CD11b+CD11c+MHCII+ DCs in the popliteal nodes at 24 
hours, and inguinal and popliteal nodes at 48 hours. *p<0.05, **P<0.01, ****p<0.0001 
from Two Way ANOVA with Tukey multiple comparison test and ++p<0.01 with One Way 
ANOVA (Popliteal-48hr group alone) and Tukey test. 
Adjuvant groups differentially upregulated CD86 expression on cDC subsets in lymph 
nodes (Figure 16B, Figure S10). cDCs in the lymph node express higher percentages of 
CD86 compared to B cells and pDCs, therefore median fluorescence intensity of CD86 
was compared with statistical analysis to detect more nuanced changes in expression. CD86 
on cDC2 was statistically increased by MPLA NP in the popliteal node at 24 hours, and in 
inguinal and popliteal nodes at 48 hours (Figure 16B). Patterns of CD86 expression by 
cDC1 followed B cells and pDCs. cDC1 upregulated CD86 at 24 hours in response to 
MPLA and MPLA-CpG NP in iliac nodes, and Blank NP and CpG NP in inguinal nodes 
(Figure S10).  
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CHAPTER 5: AIM 2.1. EVALUATING HOW RLR- AND TLR-
TARTETING PLGA NANOPARTICLES DIRECT BONE MARROW-
DERIVED DC CYTOKINE SECRETION AND T CELL 
ACTIVATION IN VITRO 
4.3 Motivation 
The goal of this sub-aim is to identify particulate adjuvant combinations that enhance APC 
and T cell responses in isogeneic mixed lymphocyte reaction (iso-MLR) assays in vitro. 
Single and combination adjuvants, including TLR agonists MPLA (TLR4), CpG (TLR9), 
R848 (TLR7), and RIG-I ligand PUUC, on PLGA-PEI NP were screened to elucidate 
which adjuvants have the potential to enhance the immune response to SARS-CoV-2 
subunit vaccines. 
4.4 Materials and Methods 
4.4.1 Synthesis of PUUC RNA 
HCV-mimicking poly-U/UC (PUUC) RNA was transcribed from synthetic DNA ODN 
templates (Integrated DNA Technologies, PAGE-purified Ultramer Oligos) using the 
MEGAshortscript™ T7 Transcription Kit (Ambion, Thermo Fisher). The custom DNA 
templates were as follows: 5'-TAA TAC GAC TCA CTA TAG GCC ATC CTG TTT TTT 
TCC CTT TTT TTT TTT CTT TTT TTT TTT TTT TTT TTT TTT TTT TTT TTT TTC 
TCC TTT TTT TTT CCT CTT TTT TTC CTT TTC TTT CCT TT-3' and 5'-AAA GGA 
AAG AAA AGG AAA AAA AGAG GAA AAA AAA AGG AGA AAA AAA AAA AAA 
AAA AAA AAA AAA AAA AAA AAA GAA AAA AAA AAA GGG AAA AAA ACA 
GGA TGG CCT ATA GTG AGT CGT ATT A-3’. RNA was purified through alcohol 
  
 89 
precipitation and measured using the Nucleic Acid Quantification feature on the plate 
reader (Biotek). PUUC was resuspended in RNAse/DNAse free H2O (Boston BioProducts) 
at 1 mg/mL and frozen at -80°C for long-term storage. 
4.4.2 Preparation of PLGA-PEI Nanoparticles and Loading of Adjuvants 
PLGA-PEI nanoparticles were prepared as described in Chapter 4 (Aim 1.2). For preparing 
high-density MPLA NP, MPLA-PHAD® (Avanti), also known as GLA, was added to the 
primary PLGA emulsion (6 µg MPLA-PHAD per mg of NP).180 For R848 NP, non-water-
soluble R848 (STEMCELL Technologies) was added to the primary emulsion (5 µg per 
mg of NP). R848 encapsulation was quantified by dissolving PLGA PEI NP in DMSO and 
measuring absorbance at 324 nm on a plate reader (BioTek).233 R848 encapsulation 
efficiency ranged from 60% to 96%. PLGA NP concentration was always adjusted to 
match the desired dose of R848. CpG ODN (InvivoGen), Poly(I:C) (InvivoGen) and PUUC 
were loaded onto PLGA-PEI NP in sodium phosphate buffer (pH 6.5, 5 mg NP per mL) in 
RNAse-DNAse free low-adhesion 2 mL polypropylene tubes, vortexed for 30 seconds, and 
rotated overnight at 4°C. PLGA PEI NP were centrifuged at 10,000 x g for 10-20 minutes, 
and ssRNA (PUUC), dsRNA (Poly(I:C), ssDNA (CpG ODN) loading was indirectly 
calculated by measuring the A260/A280 ratio with the Nucleic Acid Quantification feature 
on the BioTek plate reader. Adjuvant-loaded PLGA-PEI nanoparticles will be referred to 





4.4.3 Bone-marrow derived Dendritic Cell (BMDC) Culture 
GM-CSF-BMDC cultures were prepared using similar methods to Aim 1.2. However, the 
BMDC density was altered to match consistency with research conducted by Pradhan et 
al.180 Instead of 12 mL per petri dish, 20 mL of BMDCs in RPMI complete medium was 
added to each dish at 1 million cells/mL. For GM-CSF-BMDCs the medium only contained 
GM-CSF (20 ng/mL) and no IL-4. For FLT3-derived BMDCs, bone marrow cells were 
cultured with human FLT3L (PeproTech) concentrated at 200 ng per mL complete RPMI 
medium. The cells were plated at 2 million cells/mL of medium for 9 days in a 6-well plate, 
10 million cells per well. There was no change in medium. Loosely adherent GM-CSF-
BMDC and FLT3L-BMDCs were harvested at days 7 and 9 of culture, respectively, with 
vigorous pipetting and plated in fresh medium for further experiments. All bone marrow 
cells were collected from 5- to 10-week old female or male Balb/cJ mice tibiae and femurs. 
4.4.4 Characterizing APC Subsets in BMDC Culture with Flow Cytometry 
FLT3L and GM-CSF BMDCs were washed with PBS and stained with 1:1000 Zombie 
Green Fixable Viability Dye (Biolegend). BMDCs were blocked with TruStain™ FcX 
(anti-mouse CD16/CD32, Biolegend) in FACS buffer (0.1% sodium azide, 1 mM EDTA, 
and 5% v/v FBS in PBS) at 4°C for 30 minutes. The fluorescent antibody cocktail included 
anti-mouse CD11b (BUV395, BD), CD11c (BV421, Biolegend), B220 (allophycocyanin, 
Biolegend), Ly6C (BV711, Biolegend), Ly6G (BV786, Biolegend), CD64 (PE, 
Biolegend), F4/80 (PE/Cyanine5, Biolegend), and MHC-II (allophycocyanin/Cyanine7, 




4.4.5 Iso-Mixed Lymphocyte Reaction  
PLPs and the S1 subunit of the SARS-CoV-2 spike protein (Biotechne) (100 ng/500,000 
BMDCs/mL media) were added to GM-CSF or FLT3L-cultured BMDCs in a U-bottom 96 
well plate. Each well contained 100,000 BMDCs and PLP concentrations were adjusted 
according to Table 1. The cells were incubated with PLPs for 24 hours. To isolate T cells, 
spleens from male and female Balb/cJ mice were dissociated in 2 mg/mL Collagenase D 
in OptiMEM (Gibco) and filtered through a 40 µm cell strainer. T cells were magnetically 
separated from other splenocytes using the Mouse Pan-T Cell Isolation Kit II (Miltenyi 
Biotec), labeled with CellTrace™ CFSE (Thermo Fisher), and resuspended in complete 
RPMI medium at 1 million cells/mL. BMDC-PLP U-bottom plates were centrifuged at 500 
x g for 5 minutes, and supernatants were collected to quantify BMDC pro-inflammatory 
cytokine and interferon secretion using ELISA and Luminex kits. 200,000 T cells were 
added to each well containing BMDCs and PLPs. After 72 hours, cells were centrifuged, 
and supernatants collected for future IFN-γ and IL-4 ELISAs. T cells were stained with 
Zombie UV to exclude dead cells, and stained with anti-mouse CD3 (BV786, Biolegend), 
anti-mouse CD4 (allophycocyanin, Biolegend) and anti-mouse CD8a (PE, Biolegend) to 
identify CD4+ and CD8+ T cells. A well containing only CSFE-stained T cells was included 
as a non-proliferative control. Percentages of proliferating T cells were calculated by gating 






Table 1: Single and combination adjuvant loading on PLGA NP and doses for BMDC 
culture. 
 
4.4.6 Analysis of BMDC Cytokine Secretion 
Supernatants from FLT3L and GM-CSF BMDC culture after 24-hr incubation with PLGA 
NP formulations and SARS-CoV-2 S1 Spike-S1 protein were frozen at -20°C. 
Supernatants were analyzed for IFN-β and IFNλ3 using DuoSet ELISA kits from R&D 
Systems. IFN-γ, TNF-α, IL-12p70, IL-1β, IL-6, IL-10, and IL-27 concentrations were 
measured using a customized Luminex® kit (R&D Systems). Supernatants were diluted 4-
fold for all cytokines except for IL-1β and IL-6, in which case they were diluted 8-fold. 
Supernatants were analyzed in triplicate for each experimental condition. All cytokine 
concentration values were calculated from standard curves. Cytokine concentrations were 
averaged for each treatment and BMDC group, and input into JMP Pro 16 (SAS). For 
optimal visualization of all groups, z-scores were calculated for each individual cytokine 
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across all groups, by using the “Standardize” feature in JMP. For example, in Figure 18, z-
scores were calculated across each row to view relative increases and decreases in cytokine 
concentration between PLP treatment groups. Z-scores were displayed in a heatmap with 
3-part colorbar using Graphpad software. 
4.5 Results 
4.5.1 FLT3L and GM-CSF Bone Marrow-Derived Dendritic Cell Cultures are 
Comprised of Different APC Subsets 
FLT3L and GM-CSF differentially express monocyte, macrophage, and dendritic cell 
markers (Figure 17). FLT3L BMDCs are predominantly comprised of plasmacytoid DCs 
(B220+Ly6C+CD11c+MHCIIloLy6Glo) and conventional DCs (CD11c+MHCIIhiCD64lo/-
F4/80lo/-). GM-CSF BMDCs are mainly monocytes (Ly6ChiCD11c-), monocyte-derived 
macrophages (CD64+F4/80+) and monocyte-derived DCs (CD64+F4/80+), which are also 
referred to as inflammatory DCs (see Background and Aim 1.1). There is some macrophage 
survival in FLT3L culture, and neutrophil survival in GM-CSF culture.237,238 
4.5.2 GM-CSF and FLT3L BMDC Secrete Distinct Cytokine Patterns in Response to 
Combination Adjuvants 
PLGA-PEI nanoparticles with different combinations of PRR agonists, including TLR 
ligands CpG, MPLA, and R848, as well as RLR ligand, PUUC, were incubated with GM-
CSF and FLT3L BMDCs for 24 hours. SARS-CoV-2 Spike S1 protein was also included 
at a dose of 100 ng per 100,000 BMDCs. Supernatants were collected to measure 
concentrations of interferons, IFN-β, IFN-λ3, and IFN-γ, as well as cytokines TNF-α, IL-
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12p70, IL-1β, IL-6, IL-10, and IL-27. Overall, GM-CSF BMDCs secreted more IFN-β, 
TNF-α, and IL-6 compared to FLT3L BMDCs (Figure 18). With GM-CSF BMDCs, 
MPLA-CpG NPs increased IL-12p70 and IL-10 secretion (Figure S14), MPLA-PUUC NPs 
increased IL-1β and IL-27 secretion, and R848-PUUC NPs increased IL-12p70 and IL-27 
secretion compared to single-adjuvant particles (Figure 19).  
Overall, FLT3L BMDC secreted more IL-10, IFN-γ, and IFN-λ3 compared to GM-CSF 
BMDCs, and CpG was a strong inducer of innate immune cytokines in FLT3L BMDC 
culture (Figure 18). MPLA-CpG NPs promoted stronger IFN-γ and TNF-α responses in 
FLT3L BMDC culture compared to single adjuvants (Figure S14). CpG-PUUC produced 
synergistic and antagonistic effects depending on the BMDC culture type (Figure 20). With 
GM-CSF BMDCs, CpG-PUUC NPs synergistically increased IFN-β secretion, while in 
FLT3L BMDC culture, CpG-PUUC NPs decreased IFN-λ3 levels compared to single-
adjuvant particles. Across multiple trials, female BMDCs produced more IFN-β and IFN-
λ3 compared to male BMDCs in response to adjuvanted particles, particularly MPLA-





Figure 17: FLT3L and GM-BMDCs are comprised of different APC subsets. A) tSNE plots 
of FLT3L and GM-CSF BMDCs with overlaid clusters of APC subsets. Neutrophils are 
Ly6GhiLy6C+, Monocytes are Ly6ChiCD11c-, Macrophages/Mo-DCs are CD64+F4/80-, 
cDCs are CD11c+MHCII+CD64loF4/80lo, pDCs are B220+Ly6C+CD11c+MHCIIlo. B) 








Figure 18: FLT3L and GM-CSF BMDCs differentially secrete cytokines in response to 
adjuvanted particles. Cytokine concentrations (pg/mL) standardized across each row. Scale 
bar for standardization score, also known as z-score, located to the right of the heatmap. 
Higher z scores depicted with red color while lower z scores depicted with blue. *p<0.05 
between GM-CSF and FLT3L BMDC cytokine secretion calculated with multiple t tests 




Figure 19: MPLA-PUUC and R848-PUUC increase proinflammatory cytokine secretion 
by GM-CSF BMDCs. A-B) IL-1β and IL-27 secretion by GM-CSF BMDCs in response to 
24-hr incubation with MPLA-PUUC NPs. C-D) IL-12p70 and IL-27 secretion by GM-CSF 
BMDCs in response to 24-hr incubation with R848-PUUC NPs. *p<0.05, **p<0.01, 






Figure 20: CpG-PUUC impacts interferon production in GM-CSF and FLT3L BMDCs. A) 
CpG-PUUC NPs synergistically increase IFN-β secretion by GM-CSF BMDCs after 24-
hr incubation. B) CpG-PUUC NPs antagonistically decrease IFN-λ3 secretion by FLT3L 
BMDCs after 24-hr incubation. **p<0.01, ****p<0.0001 calculated with One-way 












Figure 21: Female and male BMDCs differentially secrete IFN-β and IFN-λ3 in response 
to combination adjuvants. A) Heatmap of z-scores (mean cytokine concentration in pg/mL 
standardized across each row) with red color indicating higher relative z-score and blue 
depicting lower relative z-score. Sample size for each square is three replicates. B) MPLA-
PUUC and R848-PUUC NPs induce more IFN-β secretion by female GM-CSF BMDCs 
compared to male GM-CSF BMDCs. **p<0.01 Two-way ANOVA with Tukey multiple 
comparisons test. 
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4.5.3 GM-CSF and FLT3L BMDCs Selectively Respond to PRR-Targeted Adjuvants to 
Induce CD8+ T Cell Proliferation and T Cell Death in Iso-MLR Assay 
After BMDCs were incubated with PLGA NP adjuvant formulations for 24 hours, 
supernatants were removed, and T cells were added in a 2:1 ratio to BMDCs. T cells and 
BMDCs were cultured together for 72 hours, supernatants were collected to measure IFN-
γ and IL-4, while T cells were stained to measure proliferation by flow cytometry. GM-
CSF BMDC statistically increased CD8+ T cell proliferation in the presence of MPLA 
PLGA NP, while other adjuvants, including combination adjuvants significantly decreased 
proliferative CD4+ and CD8+ T cells (Figure 22A-B). All combination adjuvants 
statistically increased T cell death compared to controls and single adjuvant formulations 
(Figure 22C). FLT3L BMDCs strongly induced CD8+ T Cell proliferation when cultured 
with CpG PLGA NP, and even more so with MPLA-CpG NP and CpG-PUUC NP (Figure 
23B). Culturing FLT3L BMDCs with all PLGA NP formulations induced T Cell Death, 




Figure 22: GM-CSF BMDCs Promote CD8+ T Cell Proliferation in Response to MPLA 
PLGA NP and Combination Adjuvants Induce T Cell Death. A) Percentage of live 
CD3+CD4+ T cells proliferating in presence of GM-CSF BMDC, gated on diminished 
CFSE signal (see Supplementary section for example). B) Percentage of live CD3+CD8+ T 
cells proliferating in presence of GM-CSF BMDCs. C) Percentage of CD3+ Cells 
expressing Zombie UV (dead cells). *p<0.05. **p<0.01, **p<0.001, ****p<0.0001 One-
Way ANOVA and Tukey Test for multiple comparison 
 
    
  
  
   
    
        
    
  
      
    





Figure 23: FLT3L BMDCs Promote CD8+ T Cell Proliferation in Response to Single and 
Combination Adjuvants with CpG. A) Percentage of live CD3+CD4+ T cells proliferating 
in presence of FLT3L BMDC, gated on diminished CFSE signal (see Supplementary 
section for example). B) Percentage of live CD3+CD8+ T cells proliferating in presence of 
FLT3L BMDCs. C) Percentage of CD3+ Cells expressing Zombie UV (dead cells). 








CHAPTER 6: AIM 2.2. CHARACTERIZING INNATE AND 
ADAPTIVE IMMUNE RESPONSES TO INTRANASAL 
VACCINATION WITH CO-DELIVERED RLR AND TLR 
AGONISTS ON PLGA NANOPARTICLES 
5.1 Materials and Methods 
5.1.1 Intranasal Administration of PLPs 
PLPs were formulated with adjuvants using methods outlined in Chapters 4 and 5 (Aim 1.2 
and Aim 2.1). Female Balb/cJ mice, 9-10 weeks old, were anesthetized using 5% 
isoflurane. Adjuvant-PLP doses were resuspended in 60 µL (total volume) of physiological 
saline (0.9% NaCl), administered dropwise to both mouse nostrils. IVIS imaging 
confirmed fluorescent PLPs are present in the trachea and all mouse lung lobes 24 hours 
after intranasal administration (Figure 24). 
5.1.2 Lung Gene Expression Analysis with RT-PCR  
For this experiment, three mice were included in each treatment group, at each time point: 
PUUC (20 µg dose), CpG-PUUC (20 µg CpG and 20 µg PUUC), MPLA-PUUC (24 µg 
MPLA and 20 µg PUUC), and R848-PUUC (20 µg R848 and 20 µg PUUC). For each 
mouse ~4 mg of PLGA NP were delivered intranasally. A control group of mice with only 
saline administered was also included. Mice were euthanized at 4 and 24 hours after 
intranasal administration of PLPs. Lungs were collected in 1 mL TRIzol™ Reagent 
(Invitrogen) in a tube with 1.4 mm ceramic beads. Tubes were placed on a tissue 
homogenizer (MP Bio FastPrep-24) for 3 1-minute increments. 200 µL of chloroform was 
added to the tissue homogenate, and the samples were centrifuged for 15 minutes at 12,000 
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x g at 4°C. The mixture separated into a lower red phenol-chloroform phase, interphase, 
and clear upper aqueous phase. The upper aqueous phase was mixed at a 1:1 ratio with 
ethanol and added to RNeasy spin columns (Qiagen) to purify the RNA. The RNA binds 
to the silica membrane of the spin column and contaminants are washed away. DNAse is 
also added to remove residual DNA. Pure RNA is eluted with RNAse/DNAse free water, 
RNA is quantified with Nanodrop spectrophotometer (Thermo Fisher), and frozen at -
80°C. cDNA was synthesized from RNA using the SuperScript® III First-Strand Synthesis 
System (Thermo Fisher) and purified cDNA was kept at -80°C. For each treatment group, 
at each time point, cDNA from three mice was pooled (e.g., pooled cDNA for PUUC 4 hr 
group, pooled cDNA for PUUC 24 hr group). About 8 ng cDNA combined with SYBR 
Green Mastermix (Qiagen) was aliquoted to each well of a 384-well RT2 Profiler PCR 
Array with genes specific to Mouse Inflammatory Response & Autoimmunity (Qiagen). 
One plate was prepared for each treatment group, at each time point (e.g., one plate PUUC 
4 hr group, one plate PUUC 24 hr group). Plates were run in the Applied Biosystems 
QuantStudio Flex 6 rtPCR instrument, and data was analyzed using resources from 
Qiagen’s GeneGlobe Data Analysis Center. Gene expression for the control and treatment 
groups was first normalized to reference genes (Actb, B2m, Gapdh) and then the treatment 
groups were normalized to the control group. All genes with at least one treatment group 







Figure 24: Intranasal administration of fluorescent PLPs and IVIS imaging of mouse lungs. 
A) Schematic of intranasal delivery of PLPs in 60 µL saline. B) Fluorescent image of NIR-
dye labeled PLPs in mouse trachea and lungs taken 24 hours after i.n. administration. Image 
generated with IVIS and 0.75s exposure time. 
5.1.3 Single-Cell Gene and Protein Expression Analysis with CITE-Seq 
For this experiment, three mice were included in each treatment group, at each time point: 
PUUC (20 µg dose) and MPLA-PUUC (24 µg MPLA and 20 µg PUUC). For each mouse 
~4 mg of PLGA NP were delivered intranasally. The control group for this experiment 
included naïve mice. A saline group was not included, as the previous RT-PCR experiment 
revealed there were some genetic differences between the saline groups at 4 and 24 hours, 
and we could only include one control for the CITE-Seq experiment. Mice were euthanized 
at 4 and 24 hours after intranasal administration of PLPs. Lungs were collected in 1X PBS 
in a 6-well plate, transferred to gentleMACS C tubes with enzyme solutions from the Lung 
Dissociation Kit (Miltenyi Biotec), and mechanically dissociated with the gentleMACS™ 
Octo Dissociator. Red blood cells were removed with 1X RBC Lysis Buffer (eBioscience). 
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Lungs cell suspensions from three animals were pooled for each treatment group (and naïve 
group) at each time point. Live cells were enriched using the Dead Cell Removal Kit 
(Miltenyi Biotec). CITE-Seq samples were prepared according to protocols available on 
the Biolegend and 10X Genomics websites, also outlined in published work.239 Cells were 
blocked with TruStain FcX™ Fc Blocking reagent for 5-10 minutes at 4°C and TotalSeq™ 
-A antibody cocktail was added to each cell sample for an additional 30 minutes. Cells 
were washed, resuspended in PBS, and barcoded using the Genomics Single Cell 3’ v3 
Reagent Kit. cDNA was amplified, ADT-derived cDNAs and mRNA-derived cDNAs were 
separated, and libraries were sequenced. CITE-Seq data was analyzed using Seurat 4.0, an 
R toolkit for single cell genomics.240 The CITE-Seq data included in this chapter is lung 
cell clustering based on relative mRNA expression using tSNE. Clustering based on mRNA 
and protein expression is included in future work. 
5.1.4 SARS-CoV-2 Vaccination Groups 
For this experiment, there were six mice per treatment and control group for a total of 78 
mice in thirteen groups: (A) Seven vaccine groups included 1 µg of unformulated SARS-
CoV-2 spike protein delivered with adjuvanted PLPs: MPLA (24 µg), CpG (20 µg), PUUC 
(17 µg), CpG-PUUC (20 µg, 17 µg), MPLA-PUUC (20 µg, 17 µg), R848-PUUC (20 µg, 
20 µg), and MPLA-CpG (24 µg, 20 µg). (B) Two vaccine groups included 1 µg of PLGA 
NP-conjugated SARS-CoV-2 spike protein delivered with adjuvanted PLPs: PUUC (17 
µg) and MPLA-PUUC (20 µg, 17 µg). (C) There were three controls included: saline, 
unformulated SARS-CoV-2 spike only (1 µg) and PLGA NP-conjugated SARS-CoV-2 
spike only (1 µg). (D) One vaccine group included 2 µg of unformulated stabilized SARS-
CoV-2 spike protein delivered with MPLA-PUUC PLPs (20 µg, 17 µg). The following 
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spike protein was delivered unformulated: SARS-CoV-2 Spike (Active Trimer), with C-
terminal Histidine, recombinant from HEK293 cells, obtained from R&D Systems. The 
following spike protein was conjugated to PLGA NP: Spike Glycoprotein (Stabilized) from 
SARS-CoV-2, Wuhan-Hu-1 with C-terminal Histidine and Avi Tags, Recombinant from 
HEK293F cells obtained from BEI Resources, NIAID, NIH.  
5.1.5 Preparation of Spike Protein-Conjugated PLGA PEI NPs 
For conjugation of spike to PLGA-PEI NP, 5 mL of 2 mg/mL PLGA NP in non-amine 
buffer (0.1 M phosphate buffer, pH 8, 0.15 M NaCl, 2 mM EDTA) was mixed with excess 
Traut reagent (150 mM). The mixture was left at room temperature for overnight rotation. 
Thiolated PLGA-PEI-NP (PLGA-PEI-SH) were purified using centrifugation and washing 
two times. Particles were lyophilized overnight. The remaining number of amine groups 
on thiolated particles were determined using a fluorescamine assay with lysine as the 
standard. According to the assay, particles were 60-70% thiolated. Thiolated patricles were 
stored at -20°C prior to loading spike protein.  
A stock solution of PEG-SPDP (100 mg) was prepared by dissolving NHS-PEG-SPDP in 
50 µL of DMSO. 5 mg of PLGA-PEI-SH NP was sonicated in 1 mL of PBS with 2 mM 
EDTA (pH 7.6), and then mixed with excess NHS-PEG-SPDP (200 µg in 0.1 µL) and 50 
µg of Avi Tag- spike protein. The mixture was left at room temperature for six hours on a 
rotator. Particles were centrifuged n at 21,000 x g for 10 minutes, twice, and supernatant 
was pooled. The supernatant was filtered through a 100,000 MW Ultra-4 Amicon filter 
tube to retain unconjugated protein and remove NHS-PEG-SPDP. The remaining spike 
protein concentration was measured using a micro-BCA assay (Boster Bio). The protein 
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conjugation efficiency ranged from 84% to 92%, so the final concentration of spike on 
PLGA PEI NP ranged from 8.4 to 9.2 µg per mg PLGA PEI NP and the particle dose per 
mouse ranged from 119 µg to 108 µg to deliver 1 µg of spike protein (small compared to 
the ~4 mg dose of adjuvanted PLPs). 
5.1.6 Vaccination Timeline and Tissue Collection 
Vaccinations with particle-conjugated or unformulated SARS-CoV-2 spike protein and 
PLPs were administered intranasally in 10-week-old female Balb/cJ mice. Three mice out 
of the six in each treatment and control group were sacrificed at Day 27 to collect blood 
and bronchoalveolar lavage fluid for anti-spike IgG and IgA ELISA assays. A booster 
intranasal vaccination was administered to the remaining mice on Day 28. A week later 
(Day 35), mice were euthanized, and lungs were collected for ex vivo stimulation assays 
with spike protein. Blood and BAL fluid were also collected to assess post-booster 
antibody responses. To collect serum, blood samples were left at room temperature for 1 
hour to clot, and then were centrifuged at 3000 rpm, for 10 minutes at 4°C. Serum 
(supernatants) was transferred to a 2 mL low-adhesion tube and heat-inactivated for 30 
minutes at 56°C. Serum was aliquoted into low adhesion stubes at stored at -80°C until 
use. BAL fluid samples were also centrifuged at 3000 rpm for 10 minutes at 4°C and were 
aliquoted and stored at -80°C. 
5.1.7 IgG and IgA ELISA Assays 
Nunc Maxisorp™ flat-bottom 96-well plates were coated with 1 mg/mL stabilized SARS-
CoV-2 spike protein in carbonate-bicarbonate buffer (pH 9.6), 100 µL per well, and 
incubated overnight at 4°C. Plates were washed three times with PBS-Tween20 buffer 
  
 109 
(0.05% TWEEN®20, pH 7.4, PBST buffer). Plates were blocked with PBST buffer 
containing 1% BSA and 0.02% sodium azide (PBSTBA buffer), 300 µL per well, and 
incubated overnight at 4°C. Serum samples were serially diluted in PBSTBA, 100 µL of 
diluted serum was added per well and incubated at 4°C overnight. Plates were washed three 
times with PBST Buffer, and 100 µL of 1:5,000 biotinylated anti-mouse IgG or IgA 
(Southern Biotech) in PBSTBA was added. After incubating 1 hour at RT, plates were 
washed three times with PBST buffer and 100 µL of 1:2,500 Strep-HRP (Thermo Fisher) 
in PBSTBA was added. After another hour at RT, plates were washed six times and 100 
µL 1-Step Ultra TMB Substrate solution (Thermo Fisher) was added to each well. After 30 
minutes, 2N Sulfuric Acid stop solution was added to each well and within 2 minutes the 
absorbance of plates at 450 and 630 nm was quantified with a plate reader. Final absorbance 
values for serum titers were calculated by subtracting the absorbance at 630 nm from the 
absorbance at 450 nm. Absorbance values were plotted in GraphPad, and statistical 
significance between treatment groups was determined with Two-Way ANOVA and 
Tukey test. 
5.1.8 Ex Vivo Lung Cell Stimulation Assays 
Lungs from vaccinated mice were dissociated into single cell suspensions as previously 
described. After RBC lysis, lung cells were resuspended in RPMI complete medium (10% 
FBS, 1% Penicillin-streptomycin, 1 mM Sodium Pyruvate, and 55 µM beta-
mercaptoethanol) at 10 million cells/mL. 2.4 million cells were added to each well of a U-
bottom cell-culture treated 96-well plate and left overnight in a cell culture incubator at 
37°C and 5% CO2. After 6 hours, cells were centrifuged at 500 x g for 5 minutes, the 
supernatant was discarded, and cells were resuspended in complete RPMI medium with 20 
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µL of PeptTivator® SARS-CoV-2 Prot_S (Miltenyi Biotec) and 5 µg of Brefeldin A 
(Biolegend) per mL of media. The PepTivator® peptide pools contain peptides of 15-mer 
sequences with 11 amino acid overlap, covering the immunodominant sequence domains 
of the surface glycoprotein of SARS-CoV-2. This includes sequence domains aa 304-338, 
421-475, 492-519, 683-707, 741-770, 785-802, and 885-1273. The final concentration of 
each peptide was about 1 µg per mL of medium, therefore about 1 µg of peptide per 10 
million lung cells.  
5.1.9 Intracellular Cytokine Staining 
After 6 hours, lung cells were centrifuged, resuspended in PBS and transferred to a V-
bottom well plate for flow staining. Cells were stained for viability with Zombie Green 
Fixable Viability Dye (Biolegend) (30 min RT) and blocked with TruStain FcX and True-
Stain Monocyte Blocker™ solutions (Biolegend) (30 minutes 4°C). The surface staining 
antibody cocktail contained the following: anti-mouse CD45 (BUV395, BD), CD44 
(BV711, Biolegend), CD69 (BV785, Biolegend), CD103 (PE-Dazzle 594, Biolegend), 
CD8a (PE/Cyanine5, Biolegend), and CD4 (allophycocyanin-fluorophore, Biolegend) (30 
minutes 4°C). Stained cells were fixed and permeabilized with the Foxp3/Transcription 
Factor Staining Buffer Set (eBiosciences), and intracellular staining cocktail included the 
following antibodies: anti-mouse IFN-γ (PE, Biolegend), Granzyme B (Pacific Blue, 
Biolegend), and TNF-α (PE/Cyanine7, Biolegend). Flow cytometry of samples was 
performed on the BD LSRFortessa and analysis done with FlowJo software (BD). Graphs 
were produced and statistical analysis conducted using GraphPad software. Statistical 
significance of T cell population percentages and cytokine expression between treatment 




5.2.1 PUUC-TLR Agonist Combinations Differentially Regulate Inflammatory Gene 
Expression in Mouse Lungs after Intranasal Administration 
High-throughput screening of genes associated with inflammation and autoimmunity was 
performed with mouse lung tissue after intranasal administration of PUUC NP, CpG-
PUUC NP, MPLA-PUUC NP, and R848-PUUC NP (Figure 25). Combination adjuvants 
upregulated inflammatory genes at 4 hours, while PUUC upregulated more genes, 
particularly chemokine-related, at 24 hours. MPLA-PUUC strongly increased expression 
of proinflammatory cytokine-related genes, particularly IL-1β and IL-6, compared to other 
adjuvants (Figure 26A). MPLA-PUUC also strongly upregulated the lymphotoxin alpha 
gene, Lta, which encodes a protein produced by activated Th1 and CD8+ T cells as well as 
NK cells. It is of note that MPLA-PUUC simultaneously increases expression of IL6, 
IL23a, and IL17a, all genes for Th17-associated cytokines. IL17a expression is also 
maintained by MPLA-PUUC at 24 hours. Not surprisingly, MPLA also induced expression 
of CD14 and peptidoglycan protein recognition protein (PGLYRP1). CD14, IL1β, IL6, and 
IL23a are all associated with immune responses to Mycobacterium tuberculosis and 
Bordetella pertussis (Gram-negative bacteria). At 24 hours MPLA-PUUC upregulates the 
gene for Tollip, an adaptor protein that inhibits TLR4 signaling and reduces inflammation, 
and conversely has been implicated in propagating low-grade inflammation.241 
At 4 hours, CpG-PUUC upregulated a cluster of genes associated with the JAK/STAT 
signaling pathways, including: Ifna4, Ifne, IL10, IL13, IL19, Il20ra, and IL24 (Figure 
26B). While MPLA-PUUC and R848-PUUC induced higher expression Ifnb1, CpG-
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PUUC stimulated the highest expression of Ifna and Ifne. Ifne (encoding novel type I IFNε) 
is expressed in mucosal tissues, including the lungs, small intestine, and female 
reproductive tract, particularly by epithelial cells.242,243   
R848-PUUC uniquely induced expression of multiple genes associated with T cells: at 4 
hours, CCL1, CCL8, CXCL11, and IL9, and at 24 hours, IL2. CCL1 and CCL8 are 
produced by monocytes and bind to chemokine receptor CCR8, expressed by monocytes, 
macrophages, CD301b+ DCs, Th2 cells, and regulatory T cells (Figure 26C).178,244 
CXCL11 recruits activated T cells and its gene expression is stimulated by IFN-γ and IFN-
β.245 Therefore, the upregulation of CXCL11 is consistent with R848-PUUC-induced Ifnb1 
expression. IL-9 is secreted by CD4+ T cells, particularly Th9 cells, a subset that is 
associated with allergy and asthma, cancer, helminth infection, and autoimmune diseases; 
however, their exact role is poorly understood.246 IL-2 promotes T cell survival, 
proliferation, and differentiation into effector cells.247 In steady-state conditions, IL-2 is 
mainly produced by CD4+ T cells, and to a lesser extent, CD8+ T cells, NK cells, and NKT 
cells. R848-PUUC also upregulated inflammatory gene MMP25, which is mostly 
expressed by granulocytes and secondarily NK cells, and involved in NF-κB activation.248 
Between 4 and 24 hours R848-PUUC maintained expression of REG3A, CCL8, and Nodal. 
REG3A is an antimicrobial protein homologous to a C-type lectin that controls bacterial 
infection and may influence tissue regeneration.249 Is mostly expressed in the human 
intestine and pancreas, not in human lung, but it has been detected in mouse lung tissue. 





Figure 25: Expression of Inflammatory Genes in the Mouse Lung after Intranasal Injection 
of PUUC with CpG, MPLA, and R848 on PLGA NP. Heatmap correlates with z-scores of 
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expressions of inflammatory genes; z-scores were calculated for each gene type (i.e., 
standardized across rows) to show relative upregulation and downregulation of genes 
between groups. All treatment group fold regulation was first normalized to reference 
genes and control group (saline) before z-scores were calculated. 
 
Figure 26: MPLA-PUUC, CpG-PUUC, R848-PUUC, and PUUC PLPs differentially 
induce inflammatory gene expression in mouse lungs 4 and 24 hours after intranasal 
administration. Heatmaps correlate with z-scores of gene fold regulation, standardized 
across rows. Fold regulation values calculated by normalizing to reference genes and 
control group (saline) prior to standardization. 
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PUUC NPs distinctly upregulate chemokine gene expression in the lung at 24 hours; an 
effect that is diminished with the addition of TLR agonists (Figure 26D). These 
chemokines, including CCL12, CCL17, CCL2, CCL4, and CCL7, are involved in 
neutrophil and monocyte recruitment. PUUC NPs induce the highest genetic expression of 
IRF7, a signaling protein involved in type I interferon production, while also upregulating 
IFN-α genes. PUUC NPs also upregulated TNF expression at 24 hours and Nos2 
expression at 4 hours, which suggests Tip-DCs and macrophages were activated. 
 
Figure 27: UMAP of Cell Subsets in the Mouse Lung Clustered based on mRNA and 
protein expression. CITE-Seq analysis incorporated both the barcoding of cells to measure 
mRNA expression as well as the antibody-tagging of cells to measure protein expression. 
Data was input into SEURAT to compute a UMAP of lung cell clusters based on mRNA 




5.2.2 CITE-Seq Analysis Reveals Changes in Lung Cell Populations and Genetic 
Expression in Response to PUUC and MPLA-PUUC PLGA NPs 
Lung cells were collected from mice intranasally treated with PUUC NP and MPLA-PUUC 
NP, and analyzed with CITE-Seq to elucidate cell-specific immune responses to PAMPs 
and inform vaccine design. MPLA-PUUC NP was selected as the combination adjuvant 
due to its strong induction of proinflammatory and Th17-polarizing cytokines and 
maintenance of immune response- and inflammation-related genes between 4 and 24 hours. 
MPLA-PUUC is also a TLR-RLR combination that is not naturally co-expressed and could 
direct a unique immune response. For cost purposes, the analysis was restricted to five 
samples, and RT-PCR revealed differences in PUUC and MPLA-PUUC signaling at 4 and 
24 hours; therefore, both treatment groups and time points were included in the experiment. 
Naïve mice were selected as a control because saline injections caused variable gene 
expression at 4- and 24-hours post-injection and six samples could not be included in the 
CITE-Seq analysis. Cells were clustered based on mRNA and protein expression. 
By 4 hours post-administration of PLPs, PUUC NP and MPLA-PUUC NP induced 
infiltration and differentiation of CD4+ and CD8+ T cells, NK cells, B cells, monocytes, 
alveolar macrophages, eosinophils, and neutrophils (Figure 27, Figure 28). PUUC NP and 
MPLA-PUUC NP also increased the number of AT2 cells, which often regenerate from 
stem cells during lung injury.250 At 24 hours, there was a clear increase in interstitial 
macrophage and dendritic cell populations, suggesting inflammation-driven monocyte 
differentiation into APCs. Neutrophils and eosinophils continued to be recruited to the lung 
at 24 hours, more so in response to MPLA-PUUC. There is an apparent decrease in 
endothelial cell, epithelial cell (AT1/AT2), fibroblast, and lymphocyte populations by 24 
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hours. Live cells were enriched for CITE-Seq analysis so the reduction in clusters could be 
a result of cell death. There are a few variables in CITE-Seq analysis that influence the 
clustering of cells types, including the proportion of mitochondrial DNA (mtDNA), which 
is used as a threshold to filter out low-quality and dying cells. Changing this threshold 
adjusts the inclusion of cells based on mtDNA expression, which can be misleading; for 
example, activated T cells increase expression of mtDNA. Also, UMAPs show the relative 
differences of cell populations between clusters. Because there is significant infiltration of 
granulocytes in the presence of adjuvant at 24 hours, this could change the proportion of 




Figure 28: Relative distribution of UMAP clusters between naive, PUUC, and MPLA-
PUUC treatment groups. UMAP from Figure 27 is separated by group to see relative 





5.2.3 MPLA-PUUC NP Increase CD4+ and CD103+CD69+ T Cell Responses to 
Restimulation with SARS-CoV-2 Spike Peptide Pools 
Combinations of PUUC and TLR agonists, CpG, R848, and MPLA were screened as 
adjuvants for intranasal subunit vaccines against SARS-CoV-2. The primary formulations 
inducing humoral and cellular immune responses were PUUC NP and MPLA-PUUC NP; 
therefore, for simplicity, only the single and dual adjuvant groups containing MPLA and/or 
PUUC are included in the figures of this section. Aim 2.2 Supplementary Information 
contains graphs with all adjuvant groups. 
Two different methods of antigen delivery were screened with combination adjuvants: 
unformulated (“soluble”) stabilized SARS-CoV-2 spike protein, and PLGA-NP-
conjugated stabilized SARS-CoV-2 spike protein (with Avi Tag for conjugation). The 
reasoning for delivery of antigen on particles is similar to that of adjuvants – the immune 
system has evolved to recognize the particulate state of microbes, and endocytosis of 
particulate microbes stimulates intracellular processing of antigens.146,251 Studies have 
shown that delivering antigens and adjuvants in separate PLGA particles can improve or 
attain the same immune responses compared to co-delivered antigens and adjuvants.252,253 
Therefore, we opted to deliver antigen and adjuvant separately for this study. 
Sera and BAL fluid collected from mice 27 days (without booster) and 35 days (one week 
post-booster) after intranasal vaccination were tested for presence of anti-SARS-CoV-2-
spike IgG and IgA. Only the PUUC NPs with soluble spike protein produced anti-spike 
IgG detectable in serum, without booster (Figure 29). This result was not replicated in 
mouse sera collected one week later, post-booster. Mice immunized with MPLA NP 
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produced moderate levels of anti-spike IgG post-booster, with high variability. One MPLA 
NP-immunized mouse with high serum anti-spike IgG also possessed high BAL fluid anti-
spike IgA. None of the other BAL fluid samples contained detectable levels of anti-spike 
IgA pre- or post-booster. 
 
Figure 29: Serum Anti-Spike IgG Titer in Mice 28 days after intranasal administration of 
adjuvanted PLGA NP and soluble spike protein (no booster). Results from ELISA assay 
measuring anti-spike IgG in serially diluted mouse sera. Groups contain 3 biological 
replicates, each with 2 technical duplicates. Technical duplicates averaged first, and curves 
represented here contain the mean and standard deviation from the 3 biological replicates. 
***p<0.001 with Two-Way ANOVA and Tukey Test. 
Lung cells from mice that received the prime and booster vaccines were restimulated with 
overlapping spike peptide pools for six hours ex vivo and intracellularly stained for flow 
cytometry. Restimulated lung cells from mice immunized with MPLA-PUUC NP and 
particle-conjugated spike protein contained the highest percentages of IFN-γ- and TNF-α-
secreting CD4+CD44+ T cells (Figure 30). CD44 is a cell-surface protein commonly 
expressed by effector and central memory T cells.254  MPLA-PUUC NP with soluble spike 
led to the highest percentages of CD69+CD103+ T cells, known as tissue-resident memory 
cells, in restimulated lungs (Figure 31). These cells exhibit a double negative CD4-CD8- 
phenotype, suggesting these cells are γδ T cells, a subset of T cells enriched in epithelial 
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and mucosal tissues that are activated in an MHC-independent manner (Figure S23).255  
Adjuvants with soluble spike protein, and more so adjuvants with NP-conjugated spike 
protein, decreased percentages of TNF-α-producing CD8+CD44+ and CD69+CD103+ T 
cells. There were no significant changes in overall CD8+ effector and central memory T 
cell percentages, or percentages of Granzyme-B- and IFN-γ-secreting CD8+ T cells. 
 
Figure 30: CD4+ CD44+ T Cell IFN-γ and TNF-α secretion in isolated lung cell culture 
from Vaccinated Mice (prime and booster) after Restimulation with Spike Peptide Pool. 
A) Percent of CD45+ lung cells expressing CD4 and CD44 (effector and central memory 
CD4 T Cells). B) Percent of CD4+CD44+ T cells expressing IFN-γ. C) Percent of 
CD4+CD44+ T cells expressing TNFa. Each group has three biological replicates. 




Figure 31: CD8+ CD44+ T Cell and CD69+CD103+ T Cell Populations and TNF-α 
secretion in isolated lung cell culture from Vaccinated Mice (prime and booster) after 
Restimulation with Spike Peptide Pool. A) Percent of CD45+ lung cells expressing CD8 
and CD44 (effector and central memory CD8 T Cells). B) A) Percent of CD45+ lung cells 
expressing CD69 and CD103 (tissue resident memory T cells). C) Percent of CD8+CD44+ 
T cells expressing TNFa. D) Percent of CD69+ CD103+ cells expressing TNFa. Each 
group has three biological replicates. *p<0.05. **p<0.01, ****p<0.0001 One-Way 






CHAPTER 7: CONCLUSIONS AND FUTURE WORK 
6.1 Conclusions 
6.1.1 APC-Mediated Immune Responses to Combination Adjuvants In Vitro are 
Dependent on the Type of APC Culture 
The three most common in vitro models of antigen-presenting cells are based on 
hematopoietic stem cell culture with GM-CSF, GM-CSF and IL-4, or 
FLT3L.102,106,107,237,256 Consistent with previous studies, this work demonstrates that GM-
CSF BMDCs are a heterogenous mixture of neutrophils, monocytes, macrophages and 
monocyte-derived DCs (also known as inflammatory DCs), and the addition of IL-4 
induces cDC phenotypes characterized by higher expression of CCR7, CD40, and MHC-
II and decreased expression of F4/80 (Figure 7). The differentiation of cDCs in vitro with 
IL-4 is supported by the fact that IL-4 strongly induces IRF4, which is highly expressed by 
cDC2 in vivo.64,88 FLT3L BMDCs are mainly made up of cDCs and pDCs, though FLT3L 
also promotes the survival of some macrophages in culture (Figure 17).237  
Studies in Aim 1.1 and Aim 2.1 showed that APC response to single and combination 
adjuvants were dependent on the cytokines used in BMDC culture. In Aim 1.1, GM-CSF 
BMDCs did not exhibit as strong of CCR7 upregulation and chemotaxis toward CCL21 as 
BMDCs cultured with GM-CSF and IL-4 (Figure 9). Gating on APC subsets within GM-
CSF/IL-4 BMDC culture also revealed differential expression of CCR7 in response to 
MPLA and CpG (Figure 10). In Aim 2.1, GM-CSF BMDCs secreted more IFN-β, TNF-α, 
IL-1β, and IL-6 in response to PUUC and TLR agonists while FLT3L secreted more IFN-
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γ and IFN-λ3. GM-CSF BMDC culture is useful for assessing the proinflammatory 
cytokine response to adjuvants, while experiments with FLT3L BMDC culture may be 
more predictive of IFN response in vivo. Combination adjuvants also differentially 
stimulated both types of BMDC culture. Additive or synergistic cytokine responses to 
combination adjuvants, particularly MPLA-PUUC and R848-PUUC, were induced more 
in GM-CSF culture (Figure 19). This highlights the important role of monocytes, 
macrophages, and mo-DCs in the innate immune response to co-expressed PAMPs on 
pathogens. 
BMDC activation of T cells activation in response to combination adjuvants, specifically 
MPLA-CpG and CpG-PUUC, was more significant with FLT3L culture (Figure 23). 
Strong T cell activation with FLT3L culture is supported by data showing cDCs are more 
present in FLT3L culture, and according to literature cDCs are more proficient at antigen 
presentation compared to mo-DCs, macrophages and monocytes.22,257 The correlation of T 
cell death with T cell activation was also dependent on BMDC culture type. Increased 
CD8+ T cell proliferation with GM-CSF BMDC culture correlated with lower T cell death 
but with FLT3L culture, CD8+ T cell proliferation correlated with higher T cell death, as 
well as reduced IL-4 secretion. FLT3L BMDCs could potentially overstimulate T cells 






6.1.2 APC-mediated Immune Responses to Combination Adjuvants and Antigens are 
Dependent on Vaccine Delivery Systems 
APCs in vitro and in vivo differentially responded to soluble vs. particle-delivered antigens 
and adjuvants. In Aim 1.1, BMDC chemotaxis toward CCL19 and CCL21 was more 
strongly induced by unformulated (“soluble”) MPLA compared to MPLA PLGA MP, and 
by CpG MP compared to soluble CpG. The conclusion was that microparticles limited the 
bioavailability of MPLA to the cell surface, where MPLA triggers the MyD88 pathway. 
CpG delivery on PLGA MP stimulates phagocytosis by APCs, and phagosomes directly 
fuse with the ER, therefore providing more direct access to TLR9, which also signals 
MyD88.202,203 Induction of chemotaxis with soluble MPLA and CpG MP, triggering 
surface TLR4 and endosomal TLR9, respectively, is consistent with studies showing that 
MyD88 signaling regulates migration of DCs to draining lymph nodes.205,207,259 
Induction of Th1 immunity, characterized increased IFN-γ and TNF-α secretion by effector 
CD4+ T cells, was more apparent in SARS-CoV-2 spike peptide-restimulated lung cells 
collected from mice immunized with MPLA-PUUC and spike protein delivered on separate 
PLGA particles (Aim 2.2). Contrarily, increases in CD103+CD69+ T cell percentages, 
which may be γδ T cells due to the lack of CD4 and CD8 expression, were observed with 
lung cells from mice immunized with MPLA-PUUC NP and unformulated spike protein. 
In Aim 1.1, MPLA-PUUC NP induced higher cytokine secretion of IL-1β and IL-27 in 
GM-CSF BMDC culture, which contains high percentages of macrophages, proficient 
phagocytes. Activation of macrophages through MPLA-PUUC and stimulation of IL-1β 
and IL-27 along with phagocytosis of NP-conjugated antigen, may all culminate in 
effective priming of CD4+ T cells and induction of Th1 immunity. IL-1β, shown to be 
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upregulated in vivo by MPLA-PUUC (Figure 25), also enhances the polarization of M1 
macrophages, which are capable of promoting Th1 polarization of CD4+ T cells.260,261 
Activation of monocytes, macrophages, and mo-DC with particle MPLA-PUUC NP and 
unformulated spike protein may be sufficient to stimulate inflammation but not antigen 
presentation; hence, MHC-independent γδ T cells, which function as innate immune cells, 
are activated.262 
In Aim 1.2, IRDye700-conjugated CpG and control (GpC) ODN dissociated from AF488-
conjugated PLGA NP in the muscle by 24 hours, and the IR700+AF488lo/- signal 
diminished from 24 to 48 hours (Figure 13). NIR images of lymph nodes also exhibited 
higher fluorescence at 24 hours compared to 48 hours (Figure 12). Soluble ODN triggered 
CD86 expression by B cells, pDCs, and cDC1 in the lymph node by 24 hours, and while 
CpG ODN specifically triggered B cell proliferation by 48 hours (Figures S9, S10). 
Meanwhile, PLGA NP were retained in the muscle at 48 hours and increased CD40 
expression by DCs (Figure 15) as well as differentiation of macrophages (Figure 14). This 
work suggests that differential timing of delivery by co-administered adjuvants could 
amplify the immune response; in the case of MPLA-CpG NP, dissociated CpG could 
directly target and activate B cells in draining lymph nodes while MPLA NP retained in 
tissues enhances monocyte, macrophage, and cDC activation (Figure S9, Figure 15). 
6.1.3 Route of Administration Determines Success for Combination Adjuvants 
Combination adjuvants including MPLA-CpG, MPLA-PUUC, CpG-PUUC, and R848-
PUUC differentially upregulate expression of profinflammatory cytokines and interferons 
that control immune cell populations at the site of administration (Figure 18, Figure 25). 
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MPLA, co-delivered with either CpG or PUUC, strongly increases infiltration of 
neutrophils within 24 hours after delivery into the muscle and lungs (Figure 14, Figure 28) 
and produces high levels of proinflammatory cytokines (Figure S14, Figures 18-19, Figure 
25).  Cytokine storm and recruitment of polymorphonuclear cells to the lung is observed 
in the immune response to SARS-CoV-2 and neutrophilia has been associated with severe 
respiratory symptoms and poor outcomes for COVID-19 patients.263,264 Neutrophils have 
a short lifespan, and after exhaustion and apoptosis are removed by phagocytes under 
normal conditions. However, if apoptotic neutrophils are not removed in time, they 
progress toward secondary necrosis, which contributes to chronic inflammation and 
development of diseases such as chronic obstructive pulmonary disease.265,266 MPLA-
PUUC, MPLA-CpG, and R848-PUUC also induce more IFN-β production by BMDCs and 
lung cells compared to single adjuvants (Figure 18, Figure 25).267 Patients with severe and 
critical cases of COVID-19 have highly impaired type I interferon responses, characterized 
by the absence of IFN-β and low IFN-α production.268 Inhaled IFN-beta has been identified 
as a potential therapeutic for COVID-19 patients in combination with other treatments such 
as lopinavir, ritonavir, ribavirin, and remdesivir.269–272  
CpG with and without MPLA induces high expression of IFN-λ3 (Figure 18), which has 
intrinsic antiviral effects and signals IFNLR in the airway epithelium and is therefore being 
investigated as another potential IFN-related treatment.273 However, studies have shown 
that IFN-λ produced by mice in response to influenza increases susceptibility to 
pneumonia, and higher amounts of IFN-λ mRNA in BAL fluid and naso-oropharyngeal 
samples from SARS-CoV-2-positive patients correlated with disease morbidity.274,275 In 
response to poly(I:C), which can signal through both TLR3 and MDA5 (an RLR), dendritic 
  
 128 
cells in the lung produced strong levels of IFN-λ that caused damage to the lung epithelium 
(in contrast, R848 caused upregulation of proinflammatory cytokines but did not correlate 
with barrier function decrease).275 Major et al. found that IFN-λ hampered lung repair by 
inducing the p53 pathway and impairing differentiation of alveolar epithelial progenitor 
cells into secretory and multiciliated cell types.276 Overproduction of type III IFN could 
explain the decrease in epithelial cell population 24 hours after intranasal administration of 
PUUC NP and MPLA-PUUC NP in mice (Figure 27, Figure 28); however analysis of 
differentially expressed genes in cell clusters must be completed to confirm this theory. In 
other tissues, inhibition of cell division and death of infected cells would be an appropriate 
antiviral response and more well-tolerated, highlighting the benefits of intramuscular or 
intradermal injections for SARS-CoV-2 immunization.273  
The route of administration also influences which lymph nodes (and how many) receive 
vaccine cargo from migratory APCs and flow of lymph from the injection site. In turn, this 
determines where APCs activate T cells, generating effector, central memory, and tissue-
resident memory T cells, and promote localized antigen-specific immune responses to 
infection. For example, Takamura et al. found that intranasally primed memory CD8+ T 
cells were superior to intraperitoneally primed CD8+ T cells in their ability to be reactivated 
by antigen in the mediastinal lymph nodes in mouse models of influenza and parainfluenza 
virus infection.277 In Aim 1.2, fluorescent particles injected into the muscle draining to 
multiple lymph nodes, including the popliteal, inguinal and iliac nodes, which exhibited 
different APC responses to adjuvants (Figure 12). In addition to intramuscular injections, 
intradermal and footpad injections drain to these lymph nodes, and studies have shown that 
tail injections drain to inguinal nodes and the colon and spine drains to iliac lymph 
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nodes.278–280 More defined lymph node mapping and specific targeting of lymph nodes in 
humans could mediate localized immune responses to sites of infection. 
6.2 Future Work 
There are several more parameters of vaccine design to be investigated in the screening of 
combination adjuvants. In the context of biomaterials-based particle delivery systems, 
factors include particle size, surface charge, surface modifications, and polymer 
composition.281,282 Each of these factors influence the loading capacity, encapsulation 
efficiency, release kinetics, and targeted delivery of antigens and adjuvants to shape 
immune responses.282 There are also non-polymeric particles to evaluate for delivery of 
combination adjuvants, including inorganic particles (e.g., gold nanoparticles/nanorods, 
carbon nanotubes, silica-based particles), liposomes, and virus-like particles.283 The 
SARS-CoV-2 antigen used in the intranasal subunit vaccine formulation was the spike 
protein that is encoded by mRNA in current COVID-19 vaccines.284 There are many other 
types of SARS-CoV-2 antigens, including envelope, membrane, and nucleocapsid 
proteins, as well as other pathogen-derived antigens to be tested with RLR/TLR 
combination adjuvants.285 
More physiologically relevant in vitro models are necessary for high-throughput screening 
of combination adjuvant formulations and predicting immune responses in vivo. Work in 
Aim 1.1 optimized an in vitro model of BMDC chemotaxis in response to adjuvants to 
predict migration of APCs and cell-mediated antigen transport to draining lymph nodes 
during vaccination. There are more biological, chemical, and physical parameters to 
change or add for improvement of this model, including (a) the application of flow and 
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pressure mimicking interstitial fluid dynamics during vaccination, (b) the addition of 
extracellular matrix proteins that regulate cell migration and chemokines (e.g., CCL21) 
gradients, and (c) the inclusion of lymphatic endothelial cells as the source of chemokine. 
There are also new BMDC culture methods effective at generating distinct APC subsets 
that can be utilized to elucidate APC-subset-specific responses to combination adjuvants. 
For example, a BMDC culture method with FLT3L and GM-CSF generates functional 
Baft3-dependent CD103+ cDC1.286 
Studies in Aim 1.2 measured how co-delivery with MPLA influenced lymphatic transport 
of CpG ODN. Presence of IRDye700-conjugated ODN in lymph nodes, as well as changes 
in APC populations in the muscle and draining lymph nodes are indirect measurements of 
APC migration. More complex in vivo models must be utilized to measure direct migration 
of APCs; for example, Kaede transgenic mice. Kaede is a photoconvertible fluorescent 
protein that converts from green to red upon exposure to UV light. When lymph nodes are 
imaged or processed for flow cytometry, the cells fluorescing red are presumably those that 
have migrated from the site of UV exposure.287 To better predict partitioning of cargo from 
PLGA particles using NIR microscopy, particles will be conjugated to IR dye emitting 
around 800 nm and measured in a separate filter from IRDye700-conjugated cargo. Also, 
the colocalization of particles and cells in the lymph node can be quantified based on 
fluorescent immunohistochemistry and confocal microscopy of lymph nodes. 
Vaccines with combination adjuvants for SARS-CoV-2 are still under investigation. A 
second round of vaccinations with PUUC and MPLA-PUUC NP mixed with unformulated 
or particle-conjugated spike protein is underway; for this round, particles were injected 
intramuscularly, and spleen will be collected for restimulation with spike peptide pools. 
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Though priming of T cells in mediastinal lymph nodes has been shown to induce more 
potent cell-mediated immunity upon reinfection in the lungs, particle-based formulations 
must be optimized to ensure efficient delivery into the lungs. The controlled release of 
combination adjuvants and proper dosing is also important to control inflammatory 
responses and prevent cytokine storm. There is more analysis to be done with the CITE-
Seq data, including differential gene expression analysis between different lung cell 
clusters and treatment groups. 
Through the presentation of multiple PAMPs on micro- and nano-sized delivery vehicles, 
particle-based combination adjuvants have the potential to elicit more tailored humoral and 
cell-mediated responses to confer protective immunity against infectious pathogens. This 
work has shown the differential effects of combination adjuvants on a) APC expression of 
CCR7 and migration toward lymphatic chemokines, b) recruitment, differentiation, and 
maturation of immune cell populations at injection sites and draining lymph nodes, c) APC 
cytokine secretome and activation of T cells, and d) adaptive immune responses to SARS-
CoV-2 spike protein. More detailed characterization of immune responses must be carried 
out in vitro and in vivo to better understand specific combination adjuvant-APC subset 







APPENDIX A: SUPPLEMENTARY FIGURES AND METHODS 
8.1 Aim 1.1 Supporting Information 
8.1.1 Supplemental Experimental Methods 
8.1.1.1 Measuring phenotype of BMDCs in 2D vs. 3D culture 
GM-CSF/IL-4 BMDCs were cultured for six days in RPMI complete medium as described 
in the main paper. Loosely adherent cells were removed and cultured in 48-well plates at a 
density of 1.5 million cells mL-1 in media or collagen gels (1.5 mg mL-1 collagen). For 3D 
culture replicates, 100 µL of BMDCs in collagen gel mixture was added to each well and 
polymerized for 1 hour at 37°C. For the 2D replicates, 100 µL of BMDCs in media was 
added per well. After 1 hour, 200 µL of media with unformulated (soluble) MPLA was 
added per well with a final adjuvant concentration of 50 ng mL-1. After 24 hours, cells were 
collected from 2D wells using a cell scraper and 3D wells by digesting gels with 
Collagenase D (2 mg mL-1 media) for 10 minutes. Cells were analyzed by flow cytometry 
as described in the main paper. Results shown in Figure S6. 
8.1.1.2 Validating CCL19 and CCL21 gradient stability and 3D culture in devices 
9-kDa CCL19 and 12-kDa CCL21 were incubated with AF488 NHS ester in sodium 
bicarbonate buffer for 3 hours (Lumiprobe). Buffer was exchanged for PBS and fluorescent 
chemokines were concentrated using Amicon 3 kDa Ultra-2 Centrifugal Filters (Millipore 
Sigma). AF488-fluorescent chemokines diluted in media (1 µg mL-1) were added to the 
left reservoir of microfluidic devices. Media without chemokines was added to the right 
reservoir. Collagen gel channels were imaged with the Lionheart Biotek fluorescent 
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microscope using the 4X objective for 18 hours, with images taken every 10 minutes. The 
fluorescence intensity across the channel was measured using the “Plot Profile” function 
of ImageJ and graphed with MATLAB (Figure S7). To validate 3D culture of BMDCs in 
the collagen gel, live cells were labeled with Biotracker 555 Orange Cytoplasmic 
Membrane Dye (Sigma-Aldrich) and NucBlue™ Live ReadyProbes™ Reagent 
(Invitrogen) before suspended in the collagen gel channel (left to polymerize for 1 hour at 
37°C). Media reservoirs were filled with Live Cell Imaging Solution (Gibco). A 40 µm Z 
stack was taken (20 slices) using a ZEISS confocal microscope. The image was projected 
in 3D using ImageJ. The xy and zy planes are shown in Figure S8. 
8.1.2 Circular Statistical Methods 
8.1.2.1 Calculation of Mean Direction and Resultant Length 
For the analysis in this paper, cell displacements are assumed to be unit vectors (sample 
size=n) with corresponding bearing angles. These vectors are arranged so the beginning of 
the first vector is at the origin. The mean bearing angle of cell migration is the direction of 
the resultant vector and of the center of mass [1].188 The Cartesian coordinates of the center 
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If cell bearing angles are more concentrated toward a single direction, the mean resultant 
length will be closer to 1. If the bearing angles are dispersed, then the mean resultant length 
will be closer to 0. Another measure of dispersion is the circular variance, which is defined 
as: 
 
𝑉 = 1 − ?̅?                                                                                                                                      (𝑺𝟒)                                                                                                                                    
 
Therefore, as the mean resultant length approaches 1, the variance decreases. 
8.1.2.2  Cox Test 
Prior to conducting a multi-sample statistical test, it is important to assess whether the 
distribution of cell directions follows a von Mises distribution. The von Mises distribution 
for points on a circle is comparable to a normal distribution of points on a line.189 The Cox 
test is a goodness-of-fit test where the null hypothesis of a von Mises distribution is rejected 
for large values of S.190 Under the null hypothesis, the sampling distribution of S is a chi-
squared distribution with two degrees of freedom. The function Iν(κ) is the modified Bessel 
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𝑠𝑐 = ∑ cos 2(𝜃𝑖 − ?̅?) − 𝑛
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Assuming the sample size is greater than 15, the value of the concentration parameter of a 
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Further details can be found in Mardia & Jupp (2000) as well as Fisher (1993).188,288 
If each cell migration data set fits a von Mises distribution, next step is a circular statistical 
equivalent to the one-way ANOVA, known as the Watson-Williams High Concentration F 
Test. Given the more likely scenario all the data sets do not fit a von Mises distribution, 
mean directions would be compared using the non-parametric multi-sample method, a 
Mardia-Watson-Wheeler Uniform Scores Test.  
8.1.2.3  Mardia-Watson-Wheeler Uniform Scores Test 
Suppose you have q populations. In this paper, each population is a condition cells are 
tested under (for example, cells activated with a particular adjuvant, migrating toward a 
particular chemokine). The null hypothesis is 
𝐻0: 𝐹1 = ⋯ = 𝐹𝑞  
where Fq is the continuous distribution function of q population. The alternative hypothesis 
is that the distribution functions are not all the same. Each population has a sample size of 
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ni. All  the populations are combined into a single data set with a combined sample size of 
n=n1+…+nq.  
Within the combined data set, the angles are ranked with 0° being the lowest ranking. If 
there are ties between angles, then the rankings are randomly assigned. For example, if 
there are two cells with bearing angles of 20°, instead of both being assigned a ranking of 
15, they will be randomly assigned 15 and 16. The ranking is denoted by symbol r. The 
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The variable Ri is the resultant length of the uniform scores in the ith sample, and according 
to Equation S2 would be 
𝑅𝑖
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If each population has a sample size greater than 10, then the distribution of W is 
comparable to a chi-square distribution with 2(g-1) degrees of freedom.289 
8.1.2.4  Post-Hoc Test 
There are two post-hoc tests proposed by Tasdan and Yeniay to identify means that are 
significantly different from each other after performing the Watson-Williams and Mardia-
Watson-Wheeler tests.191 The first post-hoc test uses the classical Bonferroni procedure 
while the second test uses Holm’s improved Bonferroni procedure for testing pairwise 
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hypotheses. Watson Williams or Mardia-Watson Wheeler tests can be used for pairwise 
comparisons. The p-value from each pairwise comparison is ranked in order from smallest 
(P1) to largest (Pm).  
𝐻0 = {𝐻1, 𝐻2, …𝐻𝑚}                                                                                                            (𝑺𝟏𝟒)  
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8.1.3 Supplemental Figures 
 
 
Figure S1: Size and charge characterization of PLGA MP. The size and charge (zeta 
potential) of Blank and MPLA-encapsulated PLGA-PEI MP were measured using dynamic 
light scattering (Malvern Panalytical Zetasizer Nano ZS). Each colored line represents a 
different batch of Blank or MPLA-PLGA-PEI microparticles. A) Average peak mean 
intensity (d.nm) for Blank PLGA-PEI MP and graph of size distribution by number. 10 
batches represented. B) Average peak mean intensity (d.nm) for MPLA PLGA-PEI MP 
and graph of size distribution by number. 4 batches represented. C) Average surface zeta 
potential of Blank PLGA-PEI and graph of zeta potential distribution. 11 batches 
represented. D) Average surface zeta potential of MPLA-PLGA-PEI and graph of zeta 






Figure S2: FITC dextran gradient through collagen matrix is stable for 24 hours in 
microfluidic device. The fluorescence intensity of 10,000 MW FITC-Dextran plotted 
across the width of the collagen matrix channel (µm). At 0 μm is the left reservoir with 
chemokine media, and at 1000 μm is the right reservoir without chemokine. After 1 hour, 




Figure S3: GM-CSF-only BMDCs do not exhibit chemotaxis in response to MPLA-CpG 
MP. Polar histograms of GM-CSF and GM-CSF+IL-4 cell orientation toward CCL21 
gradients (yellow triangles represent gradient direction toward left reservoir, 180° on polar 
plot) after activation with MPLA-CpG MP (No Adjuvant indicates no MP present). Far 
right: polar plot comparing mean directions and resultant lengths (inversely proportional 
to directional variance). Black brackets next to legend indicates statistical significance 
between mean directions (p<0.01) with Mardia-Watson-Williams Uniform Scores Test and 






Figure S4: Increasing concentrations of soluble MPLA correlates with increased BMDC 
chemotactic response, while increasing concentrations of soluble CpG do not stimulate 
chemotaxis. Normalized histograms of BMDC orientation toward CCL21 gradients (250 
ng/mL, different from rest of experiments with 1 ug/mL chemokine) in response to A) 
increasing concentrations of CpG DNA or B) increasing concentrations of MPLA. Yellow 
triangles represent gradient direction toward left reservoir, 180° on polar plot. Control is 
no adjuvant. Far right polar plots compare mean directions and resultant lengths (inversely 
proportional to directional variance). Black brackets next to legend indicates statistical 
significance between mean directions (p<0.01) with Mardia-Watson-Williams Uniform 












Figure S5: Soluble CpG decreases expression of CCR7 signaling mediators while MPLA 
maintains and MPLA-CpG increases expression. BMDCs were cultured with soluble 
MPLA and CpG as described in Methods section for 12 hours, then homogenized to collect 
RNA for PCR analysis. Blue on the color scale depicts decreased expression (negative fold 
change) of genetic markers compared to the control (BMDCs without adjuvant) while red 
depicts increased expression (positive fold change) compared to the control. Data 
normalized to Hprt housekeeping gene. Markers were selected for the following reasons: 
(1) Arrb2, internalization of CCR7;290 (2) CCL19, autocrine chemotaxis signaling;153,217,291 
(3) CCR7, chemokine receptor; (4) CD38, reported mediator of CCR7 signaling;223 (5) 
Cdc42, controls CCR7-dependent endocytosis and change in cytoarchitecture;155 (6) 
PTGES2, catalyzes conversion of PGH2 to PGE2 to enhance CCR7 signaling;221,292 (7) 
Rac1, controls CCR7-dependent endocytosis and change in cytoarchitecture;155 (8) Rhoa, 
controls CCR7-dependent migratory speed;155 (9) Runx3, reportedly regulates TGFβ-







Figure S6. Phenotype of GMCSF/IL-4 BMDCs activated by MPLA in 2D vs. 3D. 
Representative histograms of cells cultured for 24 hours in 2D (suspended in media) or 3D 
(suspended in collagen gel with media above the gel) and activated by MPLA. Top panel 
shows histograms of marker fluorescence for all cells and the bottom panel shows marker 
fluorescence for live cells, which have a low Zombie Green (ZG, fixable viability dye) 
signal. 
 
Figure S7: Stability of AF488-fluorescent CCL19 and CCL21 gradients with addition of 
soluble adjuvants. Top panel: CCL19 fluorescence intensity across collagen gel (width 1 
mm) with and without MPLA and CpG in media. Bottom panel: CCL21 fluorescence 
intensity across collagen gel with and without MPLA and CpG in media reservoirs. Blue 




Figure S8: 3D BMDC culture in collagen gel channel of microfluidic device. A) Center of 
collagen gel channel in x-y plane imaged with a 20X objective. Cytoplasm was labeled 
with Biotracker 555 and nucleus labeled with DAPI. B) Collagen channel in z-y plane. Z 






8.2 Aim 1.2 Supporting Information 
 
Figure S9: PLGA PEI NP with MPLA and/or CpG differentially regulate B cell and pDC 
populations and their expression of CD86 in draining lymph nodes. A) Percentages of B 
cells out of live cells (B220+MHCII+CD11c-) in iliac (IL), inguinal (IG), and popliteal (PO) 
at 24 and 48 hours. B) Percentages of pDCs (B220+MHCII+CD11c+) out of live cells. C) 
Percentages of B cells expressing CD86. D) Percentages of B cells expressing CD86. 
****p<0.0001, ***p<0.001, **p<0.01, *p<0.05 significance for particle groups compared 
to saline within each lymph node group according to Two-Way ANOVA and Tukey test 








Figure S10: PLGA PEI NP with MPLA and/or CpG differentially regulate cDC 
populations and their expression of CD86 in draining lymph nodes. All cDC populations 
are negative for B220 to exclude B cells and pDCs. A-B) Changes in cDC2 
(CD11c+MHCII+CD11b+) percentages out of live cells and CD86 expression (BV786 
median fluorescence intensity). C-D) Changes in CD103+ cDC1 
(CD11c+MHCII+CD11blo/-CD103+) percentages out of live cells and CD86 expression 
(BV786 MFI). E-F) Changes in CD8a+ cDC1 (CD11c+MHCII+CD8a+) percentages out of 
live cells and CD86 expression. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05 
significance for particle groups compared to saline within each lymph node group 
according to Two-Way ANOVA and Tukey test for multiple comparison. ++p<0.01 
according to One-Way ANOVA and Tukey test, but not Two-Way ANOVA. 
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8.3 Aim 2.1 Supporting Information 
 
Figure S11: Flow gating scheme for measuring T cell proliferation in iso-MLR assay. 
 
Figure S12: Heatmap of cytokine levels produced by GM-CSF and FLT3L BMDCs after 
24 hours of incubation with PLPs from iso-MLR Trial #3 with female BALB/cJ mice. 
Color scale corresponds with z-scores, calculated by standardizing mean cytokine 
concentration values (pg/mL) across rows. Each square is a z-score calculated from a 




Figure S13: Heatmap of cytokine levels produced by GM-CSF BMDCs after 24 hours of 
incubation with PLPs from iso-MLR Trial #6 with female BALB/cJ mice. Color scale 
corresponds with z-scores, calculated by standardizing mean cytokine concentration values 
(pg/mL) across rows. Each square is a z-score calculated from a cytokine concentration 












Figure S14: MPLA-CpG NPs enhance pro-inflammatory cytokine and interferon 
production by GM-CSF and FLT3L BMDCs after 24 hours of incubation. A) IL-12 and 
IL-10 secretion by GM-CSF BMDCs after 24-hr incubation with MPLA NPs, CpG NPs, 
and MPLA-CpG NPs. Sample size is 6, with 3 technical replicates from two separate trials. 
For IL-12 data set, all BMDCs were from female BALB/cJ mice. For IL-10 data set, one 
trial was with female BMDCs and one with male BMDCs. *p<0.05, ***p<0.001, 
















8.4 Aim 2.2 Supporting Information 
 
Figure S15: Heatmap depicting fold changes in expression of inflammatory and 
autoimmunity-related genes 4 and 24 hours after intranasal delivery of PLPs to mouse 




Figure S16: Serum IgG and BAL fluid IgA levels in mouse sera post-booster intranasal 
vaccination with PLPs. 
 
 
Figure S17: Serological assays measuring mouse serum IgG and BAL fluid IgA before and 





Figure S18: CD4+ T cell populations and cytokine secretion in mouse lung cell culture after 





Figure S19: CD8+ T cell populations and cytokine secretion in mouse lung cell culture after 





Figure S20: CD103+CD69+ T cell populations and cytokine secretion in mouse lung cell 












Figure S21: CD8+ T cell populations and cytokine secretion in mouse lung cell culture after 
restimulation with SARS-CoV-2 spike peptide pool. MPLA-PUUC and PUUC NP groups. 
  
Figure S22: CD103+CD69+ T cell populations and cytokine secretion in mouse lung cell 
culture after restimulation with SARS-CoV-2 spike peptide pool. MPLA-PUUC and 





Figure S23: CD103+CD69+ T cell populations and cytokine secretion in mouse lung cell 
culture after restimulation with SARS-CoV-2 spike peptide pool. MPLA-PUUC and 
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